avgr20200930

0001437749-20-023413.txt : 20201110 0001437749-20-023413.hdr.sgml : 20201110 20201110172619 ACCESSION NUMBER: 0001437749-20-023413 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201110 DATE AS OF CHANGE: 20201110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avinger Inc CENTRAL INDEX KEY: 0001506928 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 208873453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36817 FILM NUMBER: 201302271 BUSINESS ADDRESS: STREET 1: 400 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-363-2400 MAIL ADDRESS: STREET 1: 400 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 10-Q 1 avgr20200930_10q.htm FORM 10-Q avgr20200930_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-36817

AVINGER, INC.
(Exact name of registrant as specified in its charter)


Delaware		20-8873453
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

400 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices and zip code)

(650) 241-7900

(Telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s):		Name of each exchange on which registered:
Common Stock, par value $0.001 per share		AVGR		The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐

Non-accelerated filer ☒		Smaller reporting company ☒

		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of November 6, 2020, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 84,922,079.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

●

the outcome of and expectations regarding our current clinical studies and any additional clinical studies we initiate;

●

our plans to modify our current products, or develop new products, to address additional indications;

●

our ability to obtain additional financing through future equity or debt financings;

●

the expected timing of 510(k) clearances by the FDA for enhanced versions of Pantheris, Ocelot and Lightbox;

●

the expected timing of 510(k) submission to the FDA, and associated marketing clearances by the FDA, for additional versions of Pantheris, Ocelot and Lightbox;

●

the expected growth in our business and our organization;

●

our expectations regarding government and third-party payor coverage and reimbursement, including the ability of Pantheris and Ocelot to qualify for reimbursement codes used by other atherectomy products;

	●	our ability to continue as a going concern;

	●	our ability to remain in compliance with the listing requirements of the Nasdaq Capital Market;

●

our ability to retain and recruit key personnel, including the continued development of our sales and marketing infrastructure;

●

our ability to obtain and maintain intellectual property protection for our products;

●

our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional financing;

●

our expectations regarding revenue, cost of revenue, gross margins, and expenses, including research and development and selling, general and administrative expenses;

●

our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act;

●

our ability to identify and develop new and planned products and acquire new products;

	●	our financial performance;

	●	the effects of the COVID-19 pandemic on our business and results of operations;

●

our ability to remain in compliance with laws and regulations that currently apply or become applicable to our business, both in the United States and internationally;

	●	developments and projections relating to our competitors or our industry; and

	●	our expectations of qualitative and quantitative effects of COVID-19 to the extent discussed, as well as any expectations of recovery from or forward looking short-term or long-term implications thereof.

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the “Risk Factors” section and elsewhere in this Quarterly Report on Form 10-Q, our Quarterly Report on Form 10-Q filed with the SEC on May 13, 2020, our Quarterly Report on Form 10-Q filed with the SEC on July 31, 2020, and our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2020. We urge you to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the United States Securities and Exchange Commission (“SEC”) as exhibits to the Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

AVINGER, INC.

AS OF AND FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020

TABLE OF CONTENTS

		Page
Part I	Financial Information
Item 1.	Unaudited Financial Statements	1
	Condensed Balance Sheets	1
	Condensed Statements of Operations and Comprehensive Loss	2
	Condensed Statements of Stockholders’ Equity	3
	Condensed Statements of Cash Flows	5
	Notes to Condensed Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33
Item 4.	Controls and Procedures	33

Part II	Other Information
Item 1.	Legal Proceedings	33
Item 1A.	Risk Factors	34
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 3.	Defaults Upon Senior Securities	38
Item 4.	Mine Safety Disclosures	38
Item 5.	Other Information	38
Item 6.	Exhibits	39

Signatures		40

“Avinger,” “Pantheris,” “Lumivascular,” and “Tigereye” are trademarks of our company. Our logo and our other trade names, trademarks and service marks appearing in this Quarterly Report on Form 10-Q are our property. Other trade names, trademarks and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, our trademarks and trade names referred to in this Quarterly Report on Form 10-Q appear without the ™ symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and trade names.

PART I. FINANCIAL INFORMATION

ITEM 1. UNAUDITED FINANCIAL STATEMENTS

AVINGER, INC.

CONDENSED BALANCE SHEETS

(unaudited)

(In thousands, except share and per share data)

	September 30,			December 31,
	2020			2019
Assets
Current assets:
Cash and cash equivalents	$	25,326		$	10,943
Accounts receivable, net of allowance for doubtful accounts of $19 at both September 30, 2020 and December 31, 2019		1,341			1,458
Inventories		3,994			3,912
Prepaid expenses and other current assets		524			311
Total current assets		31,185			16,624

Right of use asset		4,269			4,856
Property and equipment, net		942			1,661
Other assets		550			684
Total assets	$	36,946		$	23,825

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	632		$	663
Accrued compensation		1,455			1,782
Series A preferred stock dividends payable		2,900			—
Accrued expenses and other current liabilities		683			654
Leasehold liability, current portion		787			722
Borrowings, current portion		11,632			8,967
Total current liabilities		18,089			12,788

Leasehold liability, long-term portion		3,483			4,135
Borrowings, long-term portion		911			—
Other long-term liabilities		9			7
Total liabilities		22,492			16,930

Commitments and contingencies (Note 6)

Stockholders’ equity:
Convertible preferred stock issuable in series, par value of $0.001;
Shares authorized: 5,000,000 at September 30, 2020 and December 31, 2019;
Shares issued and outstanding: 48,503 at September 30, 2020 and December 31, 2019; aggregate liquidation preference of $48,503 at September 30, 2020 and December 31, 2019		—			—
Common stock, par value of $0.001;
Shares authorized: 100,000,000 at September 30, 2020 and December 31, 2019;
Shares issued and outstanding: 84,921,079 and 10,364,663 at September 30, 2020 and December 31, 2019, respectively		85			10
Additional paid-in capital		377,080			355,220
Accumulated deficit		(362,711	)		(348,335	)
Total stockholders’ equity		14,454			6,895
Total liabilities and stockholders’ equity	$	36,946		$	23,825

See accompanying notes.

AVINGER, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(In thousands, except per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenues	$	2,302		$	2,410		$	6,029		$	6,569
Cost of revenues		1,525			1,563			4,392			4,629
Gross profit		777			847			1,637			1,940

Operating expenses:
Research and development		1,417			1,371			4,308			4,120
Selling, general and administrative		3,461			4,091			10,501			12,168
Total operating expenses		4,878			5,462			14,809			16,288
Loss from operations		(4,101	)		(4,615	)		(13,172	)		(14,348	)

Interest income		1			70			33			242
Interest expense		(433	)		(377	)		(1,245	)		(1,091	)
Other income, net		8			299			8			868
Net loss and comprehensive loss		(4,525	)		(4,623	)		(14,376	)		(14,329	)
Accretion of preferred stock dividends		(967	)		(895	)		(2,901	)		(2,685	)
Net loss attributable to common stockholders	$	(5,492	)	$	(5,518	)	$	(17,277	)	$	(17,014	)

Net loss per share attributable to common stockholders, basic and diluted	$	(0.08	)	$	(0.70	)	$	(0.46	)	$	(2.75	)
Weighted average common shares used to compute net loss per share, basic and diluted		69,459			7,900			37,246			6,189

See accompanying notes.

AVINGER, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(In thousands, except share data)

	Convertible Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance at June 30, 2020		48,503	$	—		51,339,024	$	51	$	365,684		$	(358,186	)	$	7,549
Issuance of common stock in public offerings, net of commissions and issuance costs		—		—		33,221,725		33		11,979			—			12,012
Vesting of restricted stock units		—		—		360,330		1		—			—			1
Employee stock-based compensation		—		—		—		—		384			—			384
Accretion of Series A preferred stock dividends		—		—		—		—		(967	)		—			(967	)
Net and comprehensive loss		—		—		—		—		—			(4,525	)		(4,525	)
Balance at September 30, 2020		48,503	$	—		84,921,079	$	85	$	377,080		$	(362,711	)	$	14,454

	Convertible Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance at June 30, 2019		44,923	$	—		6,421,317	$	6	$	348,505		$	(338,591	)	$	9,920
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units		—		—		107,303		—		18			—			18
Employee stock-based compensation		—		—		—		—		523			—			523
Issuance of common stock in public offering, net of commissions and issuance costs		—		—		3,813,559		4		3,807			—			3,811
Accretion of Series A preferred stock dividends		—		—		—		—		(895	)		—			(895	)
Net and comprehensive loss		—		—		—		—		—			(4,623	)		(4,623	)
Balance at September 30, 2019		44,923	$	—		10,342,179	$	10	$	351,958		$	(343,214	)	$	8,754

See accompanying notes.

AVINGER, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (CONTINUED)

(unaudited)

(In thousands, except share data)

	Convertible Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance at December 31, 2019		48,503	$	—		10,364,663	$	10	$	355,220		$	(348,335	)	$	6,895
Issuance of common stock in public offerings, net of commissions and issuance costs		—		—		74,140,297		74		23,574			—			23,648
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units		—		—		416,119		1		27			—			28
Employee stock-based compensation		—		—		—		—		1,160			—			1,160
Accretion of Series A preferred stock dividends		—		—		—		—		(2,901	)		—			(2,901	)
Net and comprehensive loss		—		—		—		—		—			(14,376	)		(14,376	)
Balance at September 30, 2020		48,503	$	—		84,921,079	$	85	$	377,080		$	(362,711	)	$	14,454

	Convertible Preferred Stock					Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares			Amount		Shares		Amount		Capital			Deficit			Equity
Balance at December 31, 2018		45,671		$	—		3,492,200	$	3	$	338,342		$	(328,885	)	$	9,460
Conversion of Series B preferred stock into common stock		(1,523	)		—		380,750		—		—			—			—
Conversion of Series C preferred stock into common stock		(2,170	)		—		542,500		1		(1	)		—			—
Exercises of warrants for common stock		—			—		1,998,079		2		7,991			—			7,993
Issuance of common stock in public offering, net of commissions and issuance costs		—			—		3,813,559		4		3,807			—			3,811
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock unites		—			—		115,091		—		54			—			54
Employee stock-based compensation		—			—		—		—		1,532			—			1,532
Issuance of Series A preferred stock to pay dividends		2,945			—		—		—		2,918			—			2,918
Accretion of Series A preferred stock dividends		—			—		—		—		(2,685	)		—			(2,685	)
Net and comprehensive loss		—			—		—		—		—			(14,329	)		(14,329	)
Balance at September 30, 2019		44,923		$	—		10,342,179	$	10	$	351,958		$	(343,214	)	$	8,754

See accompanying notes.

AVINGER, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)

	Nine Months Ended September 30,
	2020			2019
Cash flows from operating activities
Net loss	$	(14,376	)	$	(14,329	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		676			654
Amortization of debt issuance costs and debt discount		126			129
Stock-based compensation		1,160			1,532
Noncash interest expense		1,119			962
Change in right of use asset		129			(357	)
Provision for excess and obsolete inventories		390			80
Other non-cash (gains) losses, net		(52	)		—
Changes in operating assets and liabilities:
Accounts receivable		142			(147	)
Inventories		(464	)		(1,149	)
Prepaid expenses and other current assets		(197	)		(59	)
Other assets		5			(16	)
Accounts payable		(31	)		(229	)
Accrued compensation		(327	)		(8	)
Accrued expenses and other current liabilities		29			(768	)
Other long-term liabilities		—			(32	)
Net cash used in operating activities		(11,671	)		(13,737	)

Cash flows from investing activities
Purchases of property and equipment		—			(88	)
Proceeds from sale of property and equipment		40			18
Net cash provided by (used in) investing activities		40			(70	)

Cash flows from financing activities
Proceeds from borrowings		2,330			—
Proceeds from the issuance of common stock related to warrant exercises		—			7,993
Proceeds from the issuance of common stock in public offerings, net		23,648			3,811
Proceeds from the issuance of common stock under officers and directors purchase plan		36			54
Net cash provided by financing activities		26,014			11,858

Net change in cash and cash equivalents		14,383			(1,949	)
Cash and cash equivalents, beginning of period		10,943			16,410
Cash and cash equivalents, end of period	$	25,326		$	14,461

Supplemental disclosure of cash flow information

Noncash investing and financing activities:
Accretion of Series A preferred stock dividends	$	2,901		$	2,685
Issuance of Series A preferred stock to pay dividends	$	—		$	2,918
Reclassification of right of use asset to prepaid rent	$	(129	)	$	358
Increase to right of use asset and leasehold liability arising from lease amendment	$	—			4,680
Transfers between inventory and property and equipment	$	(7	)	$	380

See accompanying notes.

AVINGER, INC.

Notes to Condensed Financial Statements

1. Organization

Organization, Nature of Business

Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (“OCT”) visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox, as well as a variety of disposable catheter products. The Company’s current products include its non-imaging catheters, Wildcat and Kittycat, as well as its Lumivascular platform products, Ocelot, Ocelot PIXL, Ocelot MVRX and Ocelaris (“Tigereye”), all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy systems under its suite of Lumivascular products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is located in Redwood City, California.

Liquidity Matters

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within one year from the date of the issuance of these financial statements.

In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of September 30, 2020, the Company had an accumulated deficit of $362.7 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $25.3 million at September 30, 2020 and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through at least the fourth quarter of 2021. Even though we received net proceeds of approximately $8 million from the issuance of common stock upon the exercise of warrants during April and May of 2019, net proceeds of $3.8 million from the sales of our common stock in our August 2019 offering, $3.9 million from the sale of our common stock in our January 2020 offering, $2.3 million of loan proceeds in April 2020 pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act, $3.0 million from the sale of our common stock in April and May 2020, $5.5 million from the sale of our common stock in June and July 2020 and $11.3 million from the sale of our common stock in August and September 2020, the Company will need to raise additional funds through future equity or debt financings within the next twelve months to meet its operational needs and capital requirements for product development, clinical trials and commercialization and may subsequently require additional fundraising.

The Company can provide no assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for our existing stockholders. Given the recent decline in the Company’s stock price, any financing that we undertake in the next twelve months could cause substantial dilution to our existing stockholders, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. In addition, the COVID-19 pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company. During the second quarter of 2020 we took certain actions to manage available cash and other resources to mitigate the effects of COVID-19 on our business, which included reduction of discretionary costs, reduction of base salaries for all of our non-manufacturing employees by 20% and reduction of hours worked by our manufacturing workers by 20%. While salaries and hours worked largely returned to prior levels in July 2020, we will continue to employ certain actions to manage our resources in the foreseeable future. There can be no assurance that such strategies will be successful in mitigating the negative impacts of the COVID-19 pandemic on our business. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development of one or more of its products. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.

Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of borrowings at September 30, 2020 and December 31, 2019 has been classified as current in these financial statements. CRG has not invoked the material adverse change clause.

Public Offerings

On August 26, 2019, we completed a public offering of 3,813,559 shares of common stock at an offering price of $1.18 per share. As a result, we received net proceeds of approximately $3.8 million after underwriting discounts, commissions, legal and accounting fees and the conversion price of the outstanding shares of Series B preferred stock, issued in our February 2018 offering, was reduced to $1.18 per share as a result.

On January 31, 2020, we completed a public offering of 6,428,572 shares of common stock at an offering price of $0.70 per share. As a result, we received net proceeds of approximately $3.9 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our February 2018 offering, was reduced to $0.70 per share.

On April 30, 2020, we completed a public offering of 12,600,000 shares of common stock at an offering price of $0.25 per share. On May 6, 2020 we issued an additional 1,890,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter’s over-allotment option in connection with the aforementioned offering. As a result, we received aggregate net proceeds of approximately $3.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our February 2018 offering, was reduced to $0.25 per share.

On June 26, 2020, we completed a public offering of 20,000,000 shares of common stock at an offering price of $0.27 per share. On July 9, 2020 we issued an additional 3,000,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter’s over-allotment option in connection with the aforementioned offering resulting in $0.7 million of additional net proceeds. As a result, we received aggregate net proceeds of approximately $5.5 million including the overallotment option and after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

On August 6, 2020, under the Shelf Registration Statement, we completed a public offering of 15,789,474 shares of common stock at an offering price of $0.38 per share. On August 11, 2020 we issued an additional 2,368,421 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter’s over-allotment option in connection with the aforementioned offering. As a result, we received aggregate net proceeds of approximately $6.2 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

On August 25, 2020, under the Shelf Registration Statement, we completed a public offering of 11,063,830 shares of common stock at an offering price of $0.47 per share. On September 1, 2020 we issued an additional 1,000,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter’s over-allotment option in connection with the aforementioned offering. As a result, we received aggregate net proceeds of approximately $5.1 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC (“SEC”). The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial information. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, or for any other interim period or for any future year. The December 31, 2019 condensed balance sheet data has been derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on March 5, 2020. The Company’s significant accounting policies are more fully described in Note 2 of the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

On June 19, 2019, the Company’s Board of Directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1-for-10 reverse stock split of the Company’s common stock. The reverse stock split became effective on June 21, 2019. The par values of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock splits. All common stock, stock options, and restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Fair Value of Financial Instruments

The Company has evaluated the estimated fair value of its financial instruments as of September 30, 2020 and December 31, 2019. Financial instruments consist of cash and cash equivalents, accounts receivable and payable, and other current liabilities and borrowings. The carrying amounts of cash and cash equivalents, accounts receivable and payable, and other current liabilities approximate their respective fair values because of the short-term nature of those instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the borrowings approximate their fair value.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. As of September 30, 2020 and December 31, 2019, the Company’s cash equivalents are entirely comprised of investments in money market funds. Any related unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity. There were no unrealized gains and losses as of September 30, 2020 and December 31, 2019. Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method.

Concentration of Credit Risk, and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.

The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing.

The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2020 and December 31, 2019.

The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At September 30, 2020 and December 31, 2019, no customer represented 10% or more of the Company’s accounts receivable. For the three and nine months ended September 30, 2020 and 2019, there were no customers that represented 10% or more of revenues. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company’s financial position and results of operations.

The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.

The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.

Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this may have a material adverse impact on the Company.

Revenue Recognition

The Company’s revenues are derived from (1) sale of Lightboxes, (2) sale of disposables, which consist of catheters and accessories, and (3) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company’s revenue recognition policies generally result in revenue recognition at the following points:

Lightbox sales: The Company sells its products directly to hospitals and medical centers. Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form by the customer acknowledging that the training and installation process is complete.

Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured.

Service revenue: Service contract revenue is recognized ratably over the term of the service period and maintenance contract revenue is recognized as work is performed. To date, service revenue has been insignificant.

The Company offers its customers the ability to purchase or lease its Lightbox. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow certain strategic accounts to install and utilize the Lightbox for a limited trial period of typically three to six months. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.

The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases and ASU No. 2014 09, Revenue from Contracts with Customers (Topic 606). The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.

The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not reasonably predictable. Accordingly, the Company concluded the embedded lease did not meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.

For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training, and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do not allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.

The Company estimates reductions in revenue for potential returns of products by customers. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of its products. The Company expenses shipping and handling costs as incurred and includes them in the cost of revenues. When the Company bills shipping and handling costs to customers, such amounts billed are included as a component of revenue.

Cost of Revenues

Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs.

Product Warranty Costs

The Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Warranty provisions and claims are summarized as follows (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Beginning balance	$	221		$	215		$	215		$	272
Warranty provision		13			34			124			70
Usage/Release		(35	)		(35	)		(140	)		(128	)
Ending balance	$	199		$	214		$	199		$	214

Net Loss per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholder by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of September 30, 2020 and 2019, there were no shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.

Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Net loss attributable to common stockholders	$	(5,492	)	$	(5,518	)	$	(17,277	)	$	(17,014	)
Weighted average common stock outstanding, basic and diluted		69,459			7,900			37,246			6,189
Net loss per share attributable to common stockholders, basic and diluted	$	(0.08	)	$	(0.70	)	$	(0.46	)	$	(2.75	)

The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Common stock warrants equivalents		2,753,999		2,757,741		2,753,999		3,346,568
Common stock options		6,903		7,444		7,100		7,596
Convertible preferred stock		48,503		44,923		48,503		45,046
Unvested restricted stock units		749,512		371,651		820,743		316,575
		3,558,917		3,181,759		3,630,345		3,715,785

Segment and Geographical Information

The Company operates and manages its business as one reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company’s long-lived assets, which are comprised of property and equipment, are based in the United States. For the three months ended September 30, 2020 and 2019, 94% and 96%, respectively, of the Company’s revenues were in the United States. For both the nine months ended September 30, 2020 and 2019, 94% of the Company’s revenues were in the United States based on the shipping location of the external customer.

Recent Accounting Pronouncements

Recently adopted accounting standards

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The new standard became effective for the Company in the first quarter of 2020. The adoption of this standard did not have a material impact on the Company’s condensed financial statements.

Recent accounting standards not yet adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for the Company in the first quarter of 2021 and early adoption is permitted. This new standard is not expected to have a material impact on the Company’s condensed financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument. As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the first quarter of 2022 and early adoption is permitted. This new standard is not expected to have a material impact on the Company’s condensed financial statements.

3. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of September 30, 2020 and December 31, 2019, cash equivalents were all categorized as Level 1 and consisted of money market funds. As of September 30, 2020 and December 31, 2019, there were no financial assets and liabilities categorized as Level 2 or Level 3. There were no transfers between fair value hierarchy levels during the three months ended September 30, 2020.

4. Inventories

Inventories consisted of the following (in thousands):

	September 30,		December 31,
	2020		2019
Raw materials	$	1,403	$	1,426
Work-in-process		765		596
Finished products		1,826		1,890
Total inventories	$	3,994	$	3,912

5. Borrowings

CRG

On September 22, 2015, the Company entered into a Term Loan Agreement, as amended (the “Loan Agreement”) with CRG under which, subject to certain conditions, the Company had the right to borrow up to $50 million in principal amount from CRG on or before March 29, 2017. The Company borrowed $30 million on September 22, 2015. The Company borrowed an additional $10 million on June 15, 2016 under the Loan Agreement.

On February 14, 2018, the Company and CRG further amended the Loan Agreement concurrent with the conversion of $38 million of the principal amount of the senior secured term loan (plus $3.8 million in back-end fees and prepayment premium applicable thereto) into a newly authorized Series A convertible preferred stock (see below).

On March 2, 2020, the Company entered into Amendment No. 3 to the Loan Agreement to, among other things:

●

extend the period that the Company can make interest payments in payment in kind (“PIK”) to June 30, 2021;

●

lower the Minimum Revenue Covenants to $10 million for 2020, $12 million for 2021, and $15 million for 2022;

●

insert certain terms to clarify that all fees, including the prepayment premium, are due if the obligations are accelerated; and

●

insert a new provision to make clear that to the extent the Company divides its assets/liabilities into divisions, such assets/liabilities will be treated as transferred to a third party.

On May 12, 2020, the Company entered into Amendment No. 4 to the Loan Agreement to, among other things:

●

grant to the Company the right to optionally prepay in whole or in part the outstanding principal amount of the Loans for the Redemption Price, subject to certain conditions; and

●

waive the Company’s requirement to comply with the Minimum Revenue Covenant for 2020.

Under the amended Loan Agreement, no cash payments for either principal or interest are due until the third quarter of 2021. The accrued interest will be accrued and included in the debt balance based (to the extent not paid) on principal amounts outstanding at the beginning of the quarter at an interest rate of 12.5%. Beginning in the third quarter of 2021, the Company will be required to make quarterly principal payments (in addition to the interest) of $1.4 million with total principal payments of $2.7 million in 2021, $5.5 million in 2022 and $2.7 million in 2023. The maturity date of the Loan is June 30, 2023.

The Company may voluntarily prepay the borrowings in full, with a prepayment premium beginning at 5.0% and declining by 1.0% annually thereafter, with no premium being payable if prepayment occurs after seven and half years of the loan. Each tranche of borrowing required the payment, on the borrowing date, of a financing fee equal to 1.5% of the borrowed loan principal, which is recorded as a discount to the debt. In addition, a facility fee equal to 15.0% of the amounts borrowed plus any payment-in-kind (PIK) is to be payable at the end of the term or when the borrowings are repaid in full. A long-term liability is being accreted using the effective interest method for the facility fee over the term of the Loan Agreement with a corresponding discount to the debt. The borrowings are collateralized by a security interest in substantially all of the Company’s assets.

The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for pre-specified liquidity and revenue requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 million of cash and certain cash equivalents, and the Company has to achieve certain minimum revenues. If the Company fails to meet the applicable minimum revenue target in any calendar year, the Loan Agreement provides the Company with a cure right if it prepays a portion of the outstanding principal equal to 2.0 times the revenue shortfall. In addition, the Loan Agreement prohibits the payment of cash dividends on the Company’s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG may accelerate the payment terms of the Loan Agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the Loan Agreement, the failure of the Company to adhere to the covenants set forth in the Loan Agreement, the insolvency of the Company or upon the occurrence of a material adverse change.

As of September 30, 2020, the Company was in compliance with all applicable covenants under the Loan Agreement.

As of September 30, 2020, principal, final facility fee and PIK payments due under the Loan Agreement are as follows (in thousands):

Year Ending December 31,
2020 (remaining three months of the year)	$	—
2021		3,400
2022		6,266
2023		4,518
		14,184
Less: Amount of PIK additions and final facility fee to be accreted subsequent to September 30, 2020		(3,520	)
Less: Amount representing debt financing costs		(461	)
Borrowings, as of September 30, 2020	$	10,203

In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of September 30, 2020 and December 31, 2019, the balance of the aggregate debt discount was approximately $461,000 and $588,000, respectively. The Company’s interest expense associated with the amortization of debt discount was approximately $42,000 during both the three months ended September 30, 2020 and 2019. The Company’s interest expense associated with the amortization of debt discount was approximately $127,000 during both the nine months ended September 30, 2020 and 2019. For the three months ended September 30, 2020 and 2019, the Company incurred interest expense of approximately $427,000 and $377,000, respectively. For the nine months ended September 30, 2020 and 2019, the Company incurred interest expense of approximately $1.2 million and $1.1 million, respectively.

Due to the material adverse change clause in the Loan Agreement with CRG, the entire amount of borrowings at September 30, 2020 and December 31, 2019 is classified as current in these financial statements. CRG has not invoked the material adverse change clause.

Paycheck Protection Program

On April 23, 2020, we received loan proceeds of $2.3 million (the “ PPP Loan”) pursuant to the PPP under the CARES Act.

The Loan, which was in the form of a promissory note, dated April 20, 2020 (the “Promissory Note”), between the Company and Silicon Valley Bank as the lender, matures on April 20, 2022 and bears interest at a fixed rate of 1% per annum, payable monthly commencing six months from the date of the Loan. The Company may voluntarily prepay the borrowings in full with no associated penalty or premium.

Under the terms of the PPP, the principal may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs, benefits mortgage interest, rent, and utilities. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. In addition, details of the PPP continue to evolve regarding which companies are qualified to receive loans pursuant to the PPP and on what terms, and the Company may be required to repay some or all of the Loan due to these changes or different interpretations of the PPP requirements.

On June 5, 2020, the President of the United States signed the Paycheck Protection Program Flexibility Act (the “PPPFA”) into law. The PPPFA gives borrowers of a PPP loan more flexibility and time to spend the loan proceeds and allows the funds to be used on broader categories of expenses while still qualifying for loan forgiveness. We expect to apply for forgiveness of the PPP loan in the fourth quarter of 2020. While we believe that we have complied with the requirements to obtain forgiveness, there can be no assurance that any or all of the PPP loan amount will be forgiven. We also continue to evaluate and may still pursue additional programs under the CARES Act, but there is no guarantee that we will meet any eligibility requirements to participate in such programs or, even if we are able to participate, that such programs will provide meaningful benefit to our business.

As of September 30, 2020, principal and interest payments due under the PPP Loan are as follows (in thousands):

Year Ending December 31,
2020 (remaining three months of the year)	$	264
2021		1,575
2022		521
		2,360
Less: Amount of interest to be accreted subsequent to September 30, 2020		(20	)
Borrowings, as of September 30, 2020	$	2,340

For the three and nine months ended September 30, 2020, the Company incurred interest expense of approximately $6,000 related to the PPP Loan.

6. Commitments and Contingencies

Lease Commitments

The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease that originally were to expire in November 2019. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized using the straight-line method over the term of the lease. The Company records deferred rent calculated as the difference between rent expense and the cash rental payments.

On October 19, 2017, the Company entered into an agreement to sublease one of its facilities. The sublease agreement commenced on approximately December 1, 2017 and expired on November 15, 2019 (which was 15 days prior to the expiration of the facility lease). The sublessee paid a base rent of $82,410 per month. In addition to the base rent, the sublessee paid the Landlord’s operating expenses and property taxes due and payable with respect to the subleased facility.

Upon the adoption of Topic 842 on January 1, 2019, the Company recognized a right of use asset and a corresponding leasehold liability related to this lease of approximately $1.8 million, representing the present value of the remaining minimum lease payments as of that date. The asset was being reduced over the remaining period of the lease on a straight-line basis. The leasehold liability is being reduced as payments are made.

On April 1, 2019, we entered into an amendment to the lease which extended the lease term for an additional period of five years subsequent to the original expiration of November 30, 2019. As amended, the lease will expire on November 30, 2024. Under the terms of the amendment, we are obligated to pay approximately $5.8 million in base rent payments through November 2024, beginning on December 1, 2019. This amendment did not extend the term of the lease with respect to the building being subleased.

In connection with the amendment the Company adjusted its right-of-use asset and lease liability to $6.0 million. As of the date of the amendment, the operating lease was included on the balance sheet at the present value of the future base payments discounted at a 6.5% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease do provide an implicit rate.

For the three months ended September 30, 2020, our operating lease expense, excluding variable maintenance fees and other expenses paid by the Company on a monthly basis, was approximately $105,000, which totaled approximately $314,000 for each of the three month periods ended September 30, 2020 and 2019. Rent expense for the nine months ended September 30, 2020 and 2019 was approximately $942,000 and $1.1 million, respectively. Operating right-of-use asset amortization for the three months ended September 30, 2020 and 2019 was approximately $242,000 and $225,000, respectively. Operating right-of-use asset amortization for the nine months ended September 30, 2020 and 2019 was approximately $718,000 and $444,000, respectively. Due to payments being made in excess of operating lease expense recognized, the Company recorded approximately $331,000 as prepaid rent included in other assets on the condensed balance sheet as of September 30, 2020.

The following table presents the future operating lease payments and lease liability included on the condensed balance sheet related to the Company’s operating lease as of September 30, 2020 (in thousands):

Year Ending December 31,
2020 (remaining three months of the year)	$	274
2021		1,123
2022		1,162
2023		1,203
2024		1,138
		4,900
Less: Imputed interest		(630	)
Leasehold liability as of September 30, 2020	$	4,270

Purchase Obligations

Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $1.1 million as of September 30, 2020.

Indemnification

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company’s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.

The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance. This insurance allows the transfer of risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations for any period presented.

7. Stockholders’ Equity

Convertible Preferred Stock

As of September 30, 2020, the Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of convertible preferred stock with $0.001 par value per share, of which 48,503 shares were issued and outstanding.

Series A Convertible Preferred Stock

On February 14, 2018, the Company entered into a Series A Purchase Agreement with CRG, pursuant to which it agreed to convert $38.0 million of the outstanding principal amount of its senior secured term loan (plus $3.8 million in back-end fees, accrued interest, debt discount and prepayment premium applicable thereto), totaling $41.8 million, into a newly authorized Series A convertible preferred stock (the “Series A preferred stock”). The Series A preferred stock was initially convertible into 2,090,000 shares of common stock subject to certain limitations contained in the Series A Purchase Agreement. Under the terms of the Series A Purchase Agreement, the holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at the Company’s option. The shares of Series A preferred stock have no voting rights and rank senior to all other classes and series of the Company’s equity in terms of repayment and certain other rights. In January 2019 and December 2019, 2,945 and 3,580 additional shares, respectively, were issued to CRG as payment of dividends accrued through December 31, 2019. As of September 30, 2020, 48,325 shares of Series A preferred stock were outstanding. The Series A preferred stock accrued additional dividends of approximately $967,000 and $895,000 during the quarters ended September 30, 2020 and 2019, respectively and approximately $2.9 million and $2.7 million during the nine months ended September 30, 2020 and 2019, respectively.

Series B Convertible Preferred Stock

On February 16, 2018, the Company completed a public offering of 17,979 shares of Series B convertible preferred stock (the “Series B preferred stock”). As a result, the Company received net proceeds of approximately $15.5 million after underwriting discounts, commissions, legal and accounting fees. The Series B preferred stock has a liquidation preference of $0.001 per share, full ratchet price based anti-dilution protection, has no voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. During the year ended December 31, 2019, 1,523 of these shares converted into 380,750 shares of common stock. As of September 30, 2020 and December 31, 2019, 178 shares of Series B preferred stock remained outstanding which are currently convertible at $0.25 per share.

Series C Convertible Preferred Stock

On November 1, 2018, the Company completed a public offering of 728,500 shares of common stock and 8,586 shares of Series C convertible preferred stock (the “Series C preferred stock”). As a result, we received net proceeds of approximately $10.2 million after underwriting discounts, commissions, legal and accounting fees. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series C preferred stock will be entitled to receive distributions out of our assets, whether capital or surplus, of an amount equal to $0.001 per share of Series C preferred stock before any distributions shall be made on the common stock but after distributions shall be made on any outstanding Series A preferred stock and any of our existing or future indebtedness. The Series C preferred stock has no voting rights. During the nine months ended September 30, 2019, 2,170 shares of Series C preferred stock, which then constituted all the remaining Series C shares, were converted into 542,500 shares of common stock, leaving no shares of Series C preferred stock outstanding.

Common Stock

As of September 30, 2020, the Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 84,921,079 shares were issued and outstanding.

Common Stock Warrants

As of September 30, 2020, we had outstanding warrants to purchase common stock as follows:

	Total Outstanding and Exercisable		Underlying Shares of Common Stock		Exercise Price per Share		Expiration Date
Series 1 Warrants issued in February 2018 financing		8,979,000		897,900	$	20.00	February 2025
Series 2 Warrants issued in February 2018 financing		8,709,500		870,950	$	20.00	February 2025
Warrants issued in July 2018 financing		1,083,091		108,309	$	15.80	July 2021
Warrants issued in November 2018 financing		8,768,395		876,840	$	4.00	November 2023
Total		27,539,986		2,753,999

In connection with the issuance of the Company’s Series E convertible preferred stock in September 2014 through January 2015, the Company issued warrants to purchase an aggregate of up to the number of shares of common stock equal to 50% of the number of shares of the Company’s Series E Convertible preferred stock purchased by such investor, all of which expired on September 2, 2019.

On February 16, 2018, in connection with the Company’s completed public offering of Series B preferred stock, the Company issued two series of warrants that together provide for the purchase, by the investors in that offering, of an aggregate of 1,797,900 shares of common stock (the “Series B Warrants”). Each share of Series B preferred stock is accompanied by one warrant to purchase one share of common stock at $20.00 per share that expires on the seventh anniversary of the date of issuance to purchase up to 50 shares of common stock and one warrant that expires on the earlier of (i) the seventh anniversary of the date of issuance or (ii) the 60th calendar day following the receipt and announcement of FDA clearance of the Company’s Pantheris below-the-knee device (or the same or similar product with a different name) to purchase up to 50 shares of common stock; provided, however, if at any time during such 60-day period the volume weighted average price for any trading day is less than the then effective exercise price, the termination date shall be extended to the seven year anniversary of the initial exercise date. FDA clearance of Pantheris SV was received in April 2019, triggering this 60-day period. During the entire 60-day period following clearance, the volume weighted average price was less than the then effective exercise price. As such, all Series 2 warrants are currently deemed to expire on the seventh anniversary of the date of issuance. The Company determined that the Series B Warrants should be classified as equity. As of September 30, 2020, Series B Warrants to purchase an aggregate of 1,768,850 shares of common stock remain outstanding.

On July 13, 2018, in connection with the Company’s completed public offering of 216,618 shares of common stock, the Company issued warrants that provide for the purchase of 108,309 shares of common stock at $15.80 per share. Each share of common stock is accompanied by one half of one warrant that expires on the third anniversary of the date of issuance. The Company determined that these warrants should be classified as equity. As of September 30, 2020, all of these warrants remain outstanding.

On November 1, 2018, in connection with the Company’s completed public offering of 728,500 shares of common stock and 8,586 shares of Series C convertible preferred stock, the Company issued warrants to provide for the purchase of 2,875,000 shares of common stock. Each share of common stock is accompanied by one warrant to purchase one share of common stock at $4.00 per share. These warrants expire on the 5th anniversary of the date of issuance. Each share of preferred stock is accompanied by one warrant to purchase 250 shares of common stock. The Company determined that the warrants should be classified as equity. During the year ended December 31, 2019, warrants were exercised for an aggregate of 1,998,079 shares of common stock with proceeds to the Company of approximately $8.0 million. As of September 30, 2020 and December 31, 2019, warrants to purchase an aggregate of 876,840 shares of common stock were outstanding.

As of September 30, 2020 and December 31, 2019, warrants to purchase an aggregate of 2,753,999 shares of common stock were outstanding.

Stock Plans

In January 2015, the Board of Directors adopted, and the Company’s stockholders approved the 2015 Equity Incentive Plan (“2015 Plan”). The 2015 Plan replaced the 2009 Stock Plan (the “2009 Plan”) which was terminated immediately prior to consummation of the Company’s IPO (collectively the “Plans.)” The 2015 Plan provides for the grant of incentive stock options (“ISOs”) to employees and for the grant of non-statutory stock options (“NSOs”), restricted stock, RSUs, stock appreciation rights, performance units and performance shares to employees, directors and consultants. Initially a total of 3,300 shares of common stock were reserved for issuance pursuant to the 2015 Plan. The shares reserved for issuance under the 2015 Plan included shares reserved but not issued under the 2009 Plan, plus any share awards granted under the 2009 Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. In addition, the number of shares available for issuance under the 2015 Plan includes an automatic annual increase on the first day of each fiscal year beginning in fiscal 2016, equal to the lesser of 4,225 shares, 5.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year or an amount as determined by the Board of Directors. In addition, during fiscal 2018, the Board of Directors approved an additional 300,000 shares of common stock for issuance under the 2015 Plan. The Company’s stockholders approved this increase on June 8, 2018. On June 19, 2019, the Company’s stockholders approved an additional 800,000 increase to the 2015 Plan. As of September 30, 2020, 202,544 shares were available for grant under the 2015 Plan.

Pursuant to the Plans, ISOs and NSOs may be granted with exercise prices at not less than 100% of the fair value of the common stock on the date of grant and the exercise price of ISOs granted to a stockholder, who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the stock of the Company, shall be not less than 110% of the fair market value per share of common stock on the date of grant. The Company’s Board of Directors determines the vesting schedule of the options. Options granted generally vest over four years and expire ten years from the date of grant.

Stock option activity under the Plans is set forth below:

	Number of Shares (in thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Intrinsic Value (in thousands)
Balance at December 31, 2019		7,401		$	1,309.47		6.81	$	—
Granted		—		$	—
Exercised		—		$	—
Expired		(549	)	$	2,138.72
Forfeited		(26	)	$	820.00
Balance at September 30, 2020		6,826		$	1,241.89		6.05	$	—

Exercisable at September 30, 2020		6,781		$	1,244.72		6.05	$	—

Vested and expected to vest at September 30, 2020		6,826		$	1,241.89		6.05	$	—

There were no options granted or exercised during the nine months ended September 30, 2020 or 2019. As of September 30, 2020, there was approximately $11,000 of remaining unamortized stock-based compensation expense associated with unvested stock options, which will be expensed over a weighted average remaining service period of approximately 0.4 years. Because of the Company’s net operating losses, the Company did not realize any tax benefits from share-based payment arrangements for the three and nine months ended September 30, 2020 and 2019.

The Company’s RSUs generally vest annually over three or four years in equal increments. The Company measures the fair value of RSUs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSU activity is presented below:

	Number of Shares			Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term
Awards outstanding at December 31, 2019		908,504		$	4.09		1.81
Awarded		47,500		$	0.58		—
Released		(363,085	)	$	4.58		—
Forfeited		(152,727	)	$	3.04		—
Awards outstanding at September 30, 2020		440,192		$	3.67		1.20

As of September 30, 2020, there was approximately $1.5 million of remaining unamortized stock-based compensation expense associated with RSUs, which will be expensed over a weighted average remaining service period of approximately 1.2 years. The 440,192 outstanding non-vested and expected to vest RSUs have an aggregate fair value of approximately $0.1 million. The Company used the closing market price of $0.32 per share at September 30, 2020, to determine the aggregate fair value for the RSUs outstanding at that date. For the nine months ended September 30, 2020 and 2019, the fair value of RSUs vested was approximately $134,000 and $110,000, respectively.

2018 Officer and Director Share Purchase Plan

On August 22, 2018, the Board of Directors of the Company approved the adoption of an Officer and Director Share Purchase Plan (“ODPP”), which allows executive officers and directors to purchase shares of our common stock at fair market value in lieu of salary or, in the case of directors, director fees. Eligible individuals may voluntarily participate in the ODPP by authorizing payroll deductions or, in the case of directors, deductions from director fees for the purpose of purchasing common stock. The Board of Directors authorized 20,000 shares to be made available for purchase by officers and directors under the ODPP. Effective on August 28, 2019 and March 10, 2020, the Board of Directors approved an additional 40,000 and 125,000 shares, respectively, to be made available under the ODPP. Common stock issued under the ODPP during the nine months ended September 30, 2020 totaled 53,034 shares. As of September 30, 2020, there were 92,170 shares reserved for issuance under the ODPP.

8. Stock-Based Compensation

Total noncash stock-based compensation expense relating to the Company’s stock options and RSUs recognized during the three and nine months ended September 30, 2020 and 2019, is as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Cost of revenues	$	36	$	40	$	97	$	128
Research and development expenses		116		122		354		339
Selling, general and administrative expenses		232		361		709		1,065
	$	384	$	523	$	1,160	$	1,532

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections of this Quarterly Report on Form 10-Q, our Quarterly Report on Form 10-Q filed with the SEC on May 13, 2020, our Quarterly Report on Form 10-Q filed with the SEC on July 31, 2020, and our Annual Report on Form 10-K filed with the SEC on March 5, 2020 titled “Risk Factors.”

Overview

We are a commercial-stage medical device company that designs, manufactures, and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease, or PAD. Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. Our mission is to significantly improve the treatment of vascular disease through the introduction of products based on our Lumivascular platform, the only intravascular image-guided system available in this market.

We manufacture and sell a suite of products in the United States and select international markets. We are located in Redwood City, California. Our current products include our Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion, or CTO, and Pantheris, our image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. We received CE Marking for our original Ocelot product in September 2011 and received U.S. Food and Drug Administration, or FDA, 510(k) clearance in November 2012.We received 510(k) clearance from the FDA for commercialization of Pantheris in October 2015. We received an additional 510(k) clearance for an enhanced version of Pantheris in March 2016 and commenced sales of Pantheris in the United States and select European countries promptly thereafter. In May 2018, the Company also received 510(k) clearance from the FDA for its current next-generation version of Pantheris. In April 2019, the Company received 510(k) clearance from the FDA for its Pantheris SV, a version of Pantheris targeting smaller vessels, and commenced sales in July 2019. The Pantheris SV has a smaller diameter and longer length that we believe will optimize it for its targeted use.

In September of 2020, we received 510(k) clearance of Ocelaris (“Tigereye”), a next generation CTO crossing system utilizing Avinger’s proprietary image-guided technology platform. Tigereye is a product line extension of Avinger’s Ocelot family of image-guided CTO crossing catheters. Its design elements include an upgrade of the image capture rate to provide high definition, real-time intravascular imaging similar to the company’s Pantheris image-guided atherectomy system and a user-controlled deflectable tip designed to assist in steerability within the lumen. Tigereye also features a new distal tip configuration with faster rotational speeds designed to penetrate challenging lesions. The Tigereye catheter has a working length of 140 cm and 5 French sheath compatibility for treatment of lesions in the peripheral vessels both above and below the knee. The product became available in the fourth quarter of 2020 for first cases in the U.S.

Current treatments for PAD, including bypass surgery, can be costly and may result in complications, high levels of post-surgery pain, and lengthy hospital stays and recovery times. Minimally invasive, or endovascular, treatments for PAD include stenting, angioplasty, and atherectomy, which is the use of a catheter-based device for the removal of plaque. These treatments all have limitations in their safety or efficacy profiles and frequently result in recurrence of the disease, also known as restenosis. We believe one of the main contributing factors to high restenosis rates for PAD patients treated with endovascular technologies is the amount of vascular injury that occurs during an intervention. Specifically, these treatments often disrupt the membrane between the outermost layers of the artery, which is referred to as the external elastic lamina, or EEL.

We believe our Lumivascular platform is the only technology that offers real-time visualization of the inside of the artery during PAD treatment through the use of optical coherence tomography, or OCT, a high resolution, light-based, radiation-free imaging technology. Our Lumivascular platform provides physicians with real-time OCT images from the inside of an artery, and we believe Ocelot and Pantheris are the first products to offer intravascular visualization during CTO crossing and atherectomy, respectively. We believe this approach will significantly improve patient outcomes by providing physicians with a clearer picture of the artery using radiation-free image guidance during treatment, enabling them to better differentiate between plaque and healthy arterial structures. Our Lumivascular platform is designed to improve patient safety by enabling physicians to direct treatment towards the plaque, while avoiding damage to healthy portions of the artery.

During the first quarter of 2015, we completed enrollment of patients in VISION, a clinical trial designed to support our August 2015 510(k) submission to the FDA for our Pantheris atherectomy device. VISION was designed to evaluate the safety and efficacy of Pantheris to perform atherectomy using intravascular imaging and successfully achieved all primary and secondary safety and efficacy endpoints. We believe the data from VISION allows us to demonstrate that avoiding damage to healthy arterial structures, and in particular disruption of the external elastic lamina, which is the membrane between the outermost layers of the artery, reduces the likelihood of restenosis, or re-narrowing, of the diseased artery. Although the original VISION study protocol was not designed to follow patients beyond six months, we worked with 18 of the VISION sites to re-solicit consent from previous clinical trial patients in order for them to evaluate patient outcomes through 12 and 24 months following initial treatment. Data collection for the remaining patients from participating sites was completed in May 2017, and we released the final 12- and 24-month results for a total of 89 patients in July 2017.

During the fourth quarter of 2017, we began enrolling patients in INSIGHT, a clinical trial designed to support a submission to the FDA to expand the indication for our Pantheris atherectomy device to include in-stent restenosis. Patient enrollment began in October 2017 and is expected to continue through 2020. Patient outcomes will be evaluated at thirty days, six months and one year following treatment. We plan to submit a 510(k) application with the FDA seeking a specific indication for treating in-stent restenosis with Pantheris once the trial is fully enrolled and follow-up data through six months are available and analyzed.

We continue development efforts on the next generation of the Lightbox imaging console, the L300, which is being designed to provide enhanced imaging capabilities in a much smaller form factor and be available to users at a lower cost. We anticipate filing a 510(k) submission for the L300 in the first quarter of 2021.

We focus our direct sales force, marketing efforts and promotional activities on interventional cardiologists, vascular surgeons, and interventional radiologists. We also work on developing strong relationships with physicians and hospitals that we have identified as key opinion leaders. Although our sales and marketing efforts are directed at these physicians because they are the primary users of our technology, we consider the hospitals and medical centers where the procedure is performed to be our customers, as they typically are responsible for purchasing our products. We are designing future products to be compatible with our Lumivascular platform, which we expect to enhance the value proposition for hospitals to invest in our technology. Pantheris qualifies for existing reimbursement codes currently utilized by other atherectomy products, further facilitating adoption of our products.

We have assembled a team with extensive medical device development and commercialization experience in both start-up and large, multi-national medical device companies. We assemble all of our products at our manufacturing facility but certain critical processes, such as coating and sterilization, are performed by outside vendors. We expect our current manufacturing facility in California, will be sufficient through at least 2020. We generated revenues of $7.9 million in 2018, and $9.1 million in 2019. The growth experienced in 2019 was largely due to our next generation Pantheris and the launch of Pantheris SV.

Recent Developments

COVID-19 Update

As a result of the effects of the COVID-19 pandemic, experienced a significant decline in sales in the second quarter of 2020, particularly as individuals, as well as hospitals and other medical providers, deferred elective procedures in response to COVID-19. During the quarter ended September 30, 2020, we experienced a rebound of sales as practitioners began to once again perform elective procedures. While certain jurisdictions easing are restrictions on performing elective procedures, we cannot be certain that other jurisdictions in the United States will do so in the near future. Furthermore, some jurisdictions have experienced and continue to experience a resurgence in COVID-19 cases, which has prompted certain hospitals and other medical providers in such areas to again defer elective procedures or further prolong or reinstate existing restrictions on such procedures. If other jurisdictions experience a resurgence in COVID-19 cases, they may also prolong restrictions on elective procedures. This situation has created a significant amount of volatility in the medical industry which makes future developments and results difficult to predict. Consequently, it is unclear whether the reduction in sales was temporary and whether such sales may be recoverable in the future. If such lost sales are not fully recoverable in the future, our business and results of operations will be significantly adversely affected. In addition to the effects on sales, we have also experienced delays in site initiation and patient enrollment for one of our clinical studies. If we are unable to successfully complete these or other clinical studies, our business and results of operations could be harmed.

We have undertaken and continue to evaluate further action to manage our available cash and other resources to help mitigate the effects of COVID-19 on our business, including by adjusting production to match demand for our products and reducing discretionary costs. During the second quarter of 2020 we took certain actions to manage available cash and other resources to mitigate the effects of COVID-19 on our business, which included reduction of discretionary costs, reduction of base salaries for all of our non-manufacturing employees by 20% and reduction of hours worked by our manufacturing workers by 20%. While some measures, including salaries and hours worked, have returned to prior levels, we will continue to employ certain actions to manage our resources in the foreseeable future, such as managing discretionary costs. In addition, there can be no assurance that such strategies will be successful in effectively managing our resources and mitigating the negative impact of the COVID-19 on our business and operating results. In addition, the COVID-19 pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company.

We applied for and, on April 23, 2020, received loan proceeds of $2.3 million (the “Loan”) pursuant to the Paycheck Protection Program (“PPP”) under the CARES Act, (see Financing and Equity below for more details).

On June 5, 2020, the President of the United States signed the Paycheck Protection Program Flexibility Act (PPPFA) into law. The PPPFA gives borrowers of a PPP loan more flexibility and time to spend the loan proceeds and allows the funds to be used on broader categories of expenses while still qualifying for loan forgiveness. We are evaluating forgiveness requirements pursuant to the PPPFA but can provide no guarantee that we will meet any of the requirements of forgiveness. We also continue to evaluate and may still pursue additional programs under the CARES Act, but there is no guarantee that we will meet any eligibility requirements to participate in such programs or, even if we are able to participate, that such programs will provide meaningful benefit to our business.

Nasdaq Delisting Notice

On March 10, 2020, we received a letter from the Listing Qualifications Department of The NASDAQ Stock Market, LLC (“Nasdaq”) notifying us that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price for our common stock was less than $1 for the previous 30 consecutive business days. We initially had a period of 180 calendar days, or until September 8, 2020, to regain compliance with the rule referred to in this paragraph. On April 20, 2020, we received a subsequent written notice from Nasdaq indicating that Nasdaq filed an immediately effective rule change with SEC on April 16, 2020, pursuant which the compliance periods for bid price and market value of publicly held shares requirements were tolled through June 30, 2020. As a result, we have until November 20, 2020, to regain compliance with Nasdaq’s minimum bid price requirement.

To regain compliance, the bid price of our common stock must close at $1 or more for a minimum of ten consecutive business days. The notice has no present impact on the listing of our securities on Nasdaq. In the event that we do not regain compliance with the Nasdaq Listing Rules prior to the expiration of the compliance period, we will receive written notification that its securities are subject to delisting. At that time, we may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. We intend to actively monitor the bid price of our common stock and will consider available options to resolve the deficiency and regain compliance with the Nasdaq Listing Rules, including conducting a reverse stock split.

Financing and Equity

On June 19, 2019, the Company’s Board of Directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect an additional 1-for-10 reverse stock split of the Company’s common stock. The reverse stock split became effective on June 21, 2019. The par value of the common stock and convertible preferred stock was not adjusted as a result of the reverse stock split. All common stock, stock options, and restricted stock units, and per share amounts in this document have been retroactively adjusted for all periods presented to give effect to the reverse stock splits.

During the three and nine months ended September 30, 2020 our net loss and comprehensive net loss was $4.5 million and $14.4 million, respectively. We have not been profitable since inception, and as of September 30, 2020, accumulated deficit was $362.7 million. Since inception, we have financed our operations primarily through private and public placements of our preferred and common securities and, to a lesser extent, debt financing arrangements.

In September 2015, we entered into a Term Loan Agreement, or Loan Agreement, with CRG Partners III L.P. and certain of its affiliated funds, collectively CRG, under which we were able to borrow up to $50.0 million on or before March 29, 2017, subject to certain terms and conditions. We borrowed $30.0 million on September 22, 2015 and an additional $10.0 million on June 15, 2016 under the Loan Agreement. Contemporaneously with the execution of the Loan Agreement, we entered into a Securities Purchase Agreement with CRG, pursuant to which CRG purchased 870 shares of our common stock on September 22, 2015 at a price of $5,596.40 per share, which represents the 10-day average of closing prices of our common stock ending on September 21, 2015. Pursuant to the Securities Purchase Agreement, we filed a registration statement covering the resale of the shares sold to CRG and must comply with certain affirmative covenants during the time that such registration statement remains in effect.

On February 14, 2018, we entered into Amendment No. 2 to the Term Loan Agreement (the “Amendment No. 2 Loan Agreement”) with CRG. Under its terms, the Amendment No. 2 Loan Agreement, among other things: (1) extended the interest-only period through June 30, 2021; (2) extended the period during which the Company may elect to pay a portion of interest in payment-in-kind, or PIK, interest payments through June 30, 2021 so long as no default has occurred and is continuing; (3) permitted the Company to make its entire interest payments in PIK interest payments for through December 31, 2019 so long as no default has occurred and is continuing; (4) extended the maturity date to June 30, 2023; (5) reduced the minimum liquidity requirement to $3.5 million at all times; (6) eliminated the minimum revenue covenant for 2018 and 2019; (7) reduced the minimum revenue covenant to $15 million for 2020, $20 million for 2021 and $25 million for 2022; and (8) provided CRG with board observer rights.

In addition, on February 14, 2018, we entered into a Series A preferred stock Purchase Agreement (the “Series A Purchase Agreement”) with CRG, pursuant to which it agreed to convert $38.0 million of the outstanding principal amount of its senior secured term loan (plus the back-end fee and prepayment premium applicable thereto) under the Loan Agreement into a newly authorized Series A preferred stock. As discussed in the section of this report titled “Dividend Policy,” the holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at our option. The shares of Series A preferred stock have no voting rights and rank senior to all other classes and series of the Company’s equity in terms of repayment and certain other rights.

On March 2, 2020, we entered into Amendment No. 3 to the Term Loan Agreement (the “Amendment No. 3 Loan Agreement”) with CRG. Under its terms, the Amendment No. 3 Loan Agreement, among other things: (1) extended the period during which the Company may elect to pay its entire interest payments in PIK interest payments through June 30, 2021; and (2) reduced the minimum revenue covenants to $10 million for 2020, $12 million for 2021, and $15 million for 2022. On May 12, 202, we entered into Amendment No. 4 to the Term Loan Agreement (the “Amendment No. 4 Loan Agreement”) with CRG which, among other things, waived the Company’s requirement to comply with the minimum revenue covenant for 2020.

On March 7, 2019, we filed a universal shelf registration statement (the “Shelf Registration Statement”) to offer up to $50.0 million of our securities. We have established, and may in the future establish, “at-the-market” programs pursuant to which we may offer and sell shares of our common stock pursuant to the Shelf Registration Statement. Due to the SEC’s “baby shelf rules,” which prohibit companies with a public float of less than $75 million from issuing securities under a shelf registration statement in excess of one-third of such company’s public float in a twelve-month period, we are only able to issue a limited number of shares using the Shelf Registration Statement at this time. Under the Shelf Registration Statement, on August 26, 2019, we completed a public offering of 3,813,559 shares of common stock at an offering price of $1.18 per share. As a result, we received net proceeds of approximately $3.8 million after underwriting discounts, commissions, legal and accounting fees and the conversion price of the outstanding shares of Series B preferred stock, issued in our February 2018 offering, was reduced to $1.18 per share as a result.

On April 23, 2020, we received loan proceeds of $2.3 million pursuant to the Paycheck Protection Program under the CARES Act. The Loan, which was in the form of a promissory note, dated April 20, 2020, between the Company and Silicon Valley Bank as the lender, matures on April 20, 2022 and bears interest at a fixed rate of 1% per annum, payable monthly commencing in six months. Under the terms of the PPP and the PPPFA, the principal may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs, benefits mortgage interest, rent, and utilities. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. The Company may be required to repay some or all of the Loan due to changes or different interpretations of the PPP requirements that continue to evolve.

The Promissory Note evidencing the PPP Loan contains customary representations, warranties, and covenants for this type of transaction, including customary events of default relating to, among other things, payment defaults and breaches of representations and warranties or other provisions of the Promissory Note. The occurrence of an event of default may result in, among other things, the Company becoming obligated to repay all amounts outstanding. We continue to evaluate and may still apply for additional programs under the CARES Act, there is no guarantee that we will meet any eligibility requirements to participate in such programs or, even if we are able to participate, that such programs will provide meaningful benefit to our business.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenues, expenses and related disclosures of contingent assets and liabilities. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. There have been no significant and material changes in our critical accounting policies during the three months ended September 30, 2020, as compared to those disclosed in “Management’s Discussion and Analysis of Financial Conditions and Results of Operations - Critical Accounting Policies and Significant Judgments and Estimates” in our most recent Annual Report on Form 10-K, as filed with the SEC on March 5, 2020.

Components of Our Results of Operations

Revenues

All of our revenues are currently derived from sales of our Lightbox console, as well as related services, and sales of our various PAD catheters in the United States and select international markets. No single customer accounted for more than 10% of our revenues during the three and nine months ended September 30, 2020 and 2019.

Revenues may fluctuate from quarter to quarter due to a variety of factors including capital equipment purchasing patterns that are typically increased towards the end of the calendar year and decreased in the first quarter. In addition, during the first quarter, our results can be harmed by adverse weather and by resetting of annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures. In the third quarter, the number of elective procedures nationwide is historically lower than other quarters throughout the year, which we believe is primarily attributable to the summer vacations of physicians and their patients.

Cost of Revenues and Gross Margin

Cost of revenues consists primarily of costs related to manufacturing overhead, materials and direct labor. We expense all warranty costs and inventory provisions as cost of revenues. We periodically write down inventory for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions. A significant portion of our cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. We expect overhead costs as a percentage of revenues to become less significant as our production volume increases. Cost of revenues also includes depreciation expense for production equipment, depreciation and related maintenance expense for placed Lightboxes held by customers and certain direct costs such as those incurred for shipping our products.

We calculate gross margin as gross profit divided by revenues. Our gross margin has been and will continue to be affected by a variety of factors, primarily production volumes, manufacturing costs, product yields, headcount, charges for excess and obsolete inventories and cost-reduction strategies. We expect our gross margin to increase over the long term as our production volume increases and as we spread the fixed portion of our manufacturing overhead costs over a larger number of units produced, thereby reducing our per unit manufacturing costs. We intend to use our design, engineering, and manufacturing capabilities to further advance and improve the efficiency of our manufacturing processes, which we believe will reduce costs and increase our gross margin. In the future, we may seek to manufacture certain of our products outside the United States to further reduce costs. Our gross margin will likely fluctuate from quarter to quarter as we continue to introduce new products and sales channels, and as we adopt new manufacturing processes and technologies.

Research and Development Expenses

Research and development, or R&D, expenses consist primarily of engineering, product development, clinical and regulatory affairs, consulting services, materials, depreciation, and other costs associated with products and technologies in development. These expenses include employee compensation, including stock-based compensation, supplies, materials, quality assurance expenses allocated to R&D programs, consulting, related travel expenses and facilities expenses. Clinical expenses include clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of manufacturing products for clinical trials. We expect R&D expenses to vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trial, and other related activities.

Selling, General and Administrative Expenses

Selling, general and administrative, or SG&A, expenses consist primarily of compensation for personnel, including stock-based compensation, related to selling and marketing functions, physician education programs, business development, finance, information technology and human resource functions. Other SG&A expenses include commissions, training, travel expenses, educational and promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses and allocated facilities-related expenses. We expect SG&A expenses to fluctuate compared to the prior year as we navigate through and attempt to mitigate the effects of COVID-19.

Interest Income (Expense), net

Interest income (expense), net consists primarily of interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and issuance costs associated with our various debt agreements.

Other Income (Expense), net

Other income (expense), net primarily consists of gains and losses resulting from the remeasurement of foreign exchange transactions and sublease income.

Results of Operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
	(in thousands, except percentages)
Revenues	$	2,302		$	2,410		$	6,029		$	6,569
Cost of revenues		1,525			1,563			4,392			4,629
Gross profit		777			847			1,637			1,940
Gross margin		34	%		35	%		27	%		30	%
Operating expenses:
Research and development		1,417			1,371			4,308			4,120
Selling, general and administrative		3,461			4,091			10,501			12,168
Total operating expenses		4,878			5,462			14,809			16,288
Loss from operations		(4,101	)		(4,615	)		(13,172	)		(14,348	)
Interest expense, net		(432	)		(307	)		(1,212	)		(849	)
Other income, net		8			299			8			868
Net loss and comprehensive loss	$	(4,525	)	$	(4,623	)	$	(14,376	)	$	(14,329	)

Comparison of Three Months Ended September 30, 2020 and 2019

Revenues.

For the three months ended September 30, 2020, revenue decreased by approximately $0.1 million or 5% compared to the three months ended September 30, 2019. The decrease is primarily the result of the continuing deferral of elective procedures by hospitals and other medical providers in response to the COVID-19 pandemic; specifically, in jurisdictions that have yet to ease restrictions associated with elective procedures. We expect that sales will continue to be volatile as such restrictions are prolonged or other jurisdictions adopt or reinstate such restrictions.

Cost of Revenues and Gross Margin.

For the three months ended September 30, 2020, cost of revenues remained flat compared to the three months ended September 30, 2019. Stock-based compensation expense within cost of revenues totaled $36,000 and $40,000 for the three months ended September 30, 2020 and 2019, respectively.

Gross margin for the three months ended September 30, 2020 decreased to 34%, compared to 35% in the three months ended September 30, 2019. The decrease in gross margin was primarily a result of the decline in revenues due to COVID-19 and customer mix.

Research and Development Expenses (“R&D”).

R&D expense for the three months ended September 30, 2020 remained relatively flat compared to the three months ended September 30, 2019. Compensation expense decreased compared to the prior year period which was largely offset by higher project spending for next generation products including the L300 imaging console. Stock-based compensation expense within R&D totaled approximately $0.1 million during both the three months ended September 30, 2020 and 2019.

Selling, General and Administrative Expenses (“SG&A”).

SG&A expense for the three months ended September 30, 2020 decreased by approximately $0.6 million or 15%, compared to the three months ended September 30, 2019, primarily due to a decrease in compensation costs resulting from expense reduction measures, lower third-party expenses and decreased variable compensation resulting from the decline in sales prompted by COVID-19. Stock-based compensation expense within SG&A totaled approximately $0.2 million and $0.4 million during the three months ended September 30, 2020 and 2019, respectively.

Interest Expense, Net.

Interest expense, net for the three months ended September 30, 2020 increased by $0.1 million or 41%, compared to the three months ended September 30, 2019 primarily due to the higher CRG loan balance from interest being compounded and lower interest income as compared to the prior year period due to a decline in money market interest rates during the period.

Other Income, Net.

Other income, net primarily consists of gains and losses resulting from the remeasurement of foreign exchange transactions and other miscellaneous income and expenses. During the three months ended September 30, 2019, this also consisted of sublease income. Our subleasing arrangement of a portion of the Company’s facilities was concluded during 2019. Consequently, the three months ended September 30, 2020 consisted of only net gains due to remeasurement of foreign exchange transactions resulting in a decrease of approximately $0.3 million or 97%.

Comparison of Nine Months Ended September 30, 2020 and 2019

Revenues.

For the nine months ended September 30, 2020, revenue decreased by $0.5 million or 8% compared to the nine months ended September 30, 2019. The decrease reflects the effects of COVID-19 prompting hospitals and other medical providers to defer elective procedures. This decline was partially offset by increases in revenue from sales of Pantheris SV product, which was released commercially in July 2019.

Cost of Revenues and Gross Margin.

For the nine months ended September 30, 2020, cost of revenues decreased by $0.2 million or 5% compared to the nine months ended September 30, 2019. This decrease was primarily attributable to the decrease in revenues for the same period. Stock-based compensation expense within cost of revenues totaled $0.1 million for both the nine months ended September 30, 2020 and 2019.

Gross margin for the nine months ended September 30, 2020 decreased to 27%, compared to 30% in the nine months ended September 30, 2019. The decrease in gross margin was primarily a result of the decline in revenues due to COVID-19, higher excess and obsolete charges on inventory and an unfavorable customer mix shift.

Research and Development Expenses (“R&D”).

R&D expense for the nine months ended September 30, 2020 increased by $0.2 million or 5%, compared to the nine months ended September 30, 2019 primarily due to a higher project spending for next generation products including the L300 imaging console, largely offset by decreases in compensation expense. Stock-based compensation expense within R&D totaled approximately $0.4 million and $0.3 million during the nine months ended September 30, 2020 and 2019.

Selling, General and Administrative Expenses (“SG&A”).

SG&A expense for the nine months ended September 30, 2020 decreased by $1.7 million or 14%, compared to the nine months ended September 30, 2019, primarily due to a decrease in compensation costs resulting from expense reduction measures and decreased variable compensation. Stock-based compensation expense within SG&A totaled approximately $0.7 million and $1.1 million during the nine months ended September 30, 2020 and 2019, respectively.

Interest Expense, Net.

Interest expense, net for the nine months ended September 30, 2020 increased by $0.4 million or 43%, compared to the nine months ended September 30, 2019 primarily due to the higher CRG loan balance from interest being compounded and lower interest income as compared to the prior year period, due to the decline in the money market interest rates during the period.

Other Income, Net.

During the nine months ended September 30, 2019, other income, net consisted of sublease income. Our subleasing arrangement of a portion of the Company’s facilities was concluded during 2019. Consequently, the nine months ended September 30, 2020 consisted of only net gains and losses due to remeasurement of foreign exchange transactions resulting in a decrease of approximately $0.9 million or 99%.

Liquidity and Capital Resources

As of September 30, 2020, we had cash and cash equivalents of $25.3 million and an accumulated deficit of $362.7 million, compared to cash and cash equivalents of $10.9 million and an accumulated deficit of $348.3 million as of December 31, 2019. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $25.3 million at September 30, 2020 and expected revenues, debt and financing activities and funds from operations will be sufficient to allow the Company to fund its current operations through at least the fourth quarter of 2021. We do not know when or if our operations will generate sufficient cash to fund our ongoing operations. Additional debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders and require significant debt service payments, which divert resources from other activities. Additional financing may not be available at all, or if available, may not be in amounts or on terms acceptable to us. If we are unable to obtain additional financing, we may be required to delay the development, commercialization and marketing of our products and we may be required to significantly scale back our business and operations.

In addition, the COVID-19 pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company. While we have taken certain actions to manage our available cash and other resources to mitigate the effects of COVID-19 on our business, there can be no assurance that such strategies will be successful in mitigating the negative impacts of the COVID-19 pandemic on our liquidity and capital resources.

To date, we have financed our operations primarily through sales of our products and net proceeds from the issuance of our preferred stock and debt financings, our “at-the-market” program, our initial public offering, or IPO, our follow-on public offerings and other post-IPO private offerings, primarily of warrants. The warrants issued pursuant to the Series B Purchase Agreement entered into in connection with the Series B preferred stock follow-on in February 2018, or the Series B Offering, prohibit us from entering into certain transactions involving the issuance of securities for a price determined by reference to the trading price of our common stock or otherwise subject to modification following the date of issuance, in each case for a period of three years from the closing date of the Series B Offering (and excluding purchases pursuant to the Series B Purchase Agreement, which may be made on the 120 day anniversary of the closing date of the offering). This prohibition may be waived by holders of two-thirds of the outstanding Series 1 and Series 2 warrants at any time.

On March 7, 2019, we filed a universal shelf registration statement (the “Shelf Registration Statement”) to offer up to $50.0 million of our securities. We have established, and may in the future establish, “at-the-market” programs pursuant to which we may offer and sell shares of our common stock pursuant to the Shelf Registration Statement. Due to the SEC’s “baby shelf rules,” which prohibit companies with a public float of less than $75 million from issuing securities under a shelf registration statement in excess of one-third of such company’s public float in a twelve-month period, we are only able to issue a limited number of shares using the Shelf Registration Statement at this time. Under the Shelf Registration Statement, on August 26, 2019, we completed a public offering of 3,813,559 shares of common stock at an offering price of $1.18 per share. As a result, we received net proceeds of approximately $3.8 million after underwriting discounts, commissions, legal and accounting fees. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our February 2018 offering, was reduced to $1.18 per share.

During the year ended December 31, 2019, we received proceeds of approximately $8.0 million from the issuance of 1,998,079 shares of common stock related to warrant exercises associated with the Series C preferred stock.

On March 2, 2020, the Company and CRG further amended the Loan Agreement to change the date upon which cash payments for interest will commence from the first quarter of 2020 to the third quarter of 2021. No cash payments for principal will be made until the final two years of the loan, which matures in June 2023. On May 12, 2020, the Company and CRG entered into another amendment to waive the Company’s requirement to comply with the minimum required revenue covenant for 2020 and granted to Company the ability to optionally prepay in whole or in part the outstanding principal amount of the Loans for the Redemption Price.

On April 23, 2020, we received loan proceeds of $2.3 million pursuant to the Paycheck Protection Program under the CARES Act. The Loan, which was in the form of a promissory note, dated April 20, 2020, between the Company and Silicon Valley Bank as the lender, matures on April 20, 2022 and bears interest at a fixed rate of 1% per annum, payable monthly commencing in six months. Under the terms of the PPP, the principal may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act and the PPPFA, such as payroll costs, benefits mortgage interest, rent, and utilities. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. In addition, details of the PPP continue to evolve regarding which companies are qualified to receive loans pursuant to the PPP and on what terms, and the Company may be required to repay some or all of the Loan due to these changes or different interpretations of the PPP requirements.

Cash Flows

	Nine Months Ended September 30,
	2020			2019
	(in thousands)
Net cash (used in) provided by:
Operating activities	$	(11,671	)	$	(13,737	)
Investing activities		40			(70	)
Financing activities		26,014			11,858
Net increase (decrease) in cash and cash equivalents	$	14,383		$	(1,949	)

Net Cash Used in Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2020 was $11.7 million, consisting primarily of a net loss of $14.4 million and an increase in net operating assets of approximately $0.8 million, partially offset by non-cash charges of $3.5 million. Non-cash charges largely related to stock-based compensation of $1.2 million, non-cash interest expense of $1.1 million, depreciation of $0.7 million and provisions for excess and obsolete inventory of $0.4 million. The increase in net operating assets was primarily due to the increase in prepaid expenses and inventory and a decrease in accrued compensation; partially offset by a decrease in accounts payable.

Net cash used in operating activities for the nine months ended September 30, 2019 was $13.7 million, consisting primarily of a net loss of $14.3 million and an increase in net operating assets of $2.4 million, offset by non-cash charges of $3.0 million. The increase in net operating assets was due to fluctuations in inventories, prepaid expenses, accounts payable and accrued expenses and other current liabilities, due to timing of payments and reduction of leasehold liability. The non-cash charges primarily consisted of depreciation and amortization of $0.7 million, stock-based compensation of $1.5 million and non-cash interest expense of $1.0 million; partially offset by an increase in the right of use asset of $0.4 million.

Net Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities during the nine months ended September 30, 2020 was $40,000 resulting from the proceeds from the sale of property and equipment.

Net cash used in investing activities during the nine months ended September 30, 2019 was $70,000 consisting of purchases of property and equipment of $88,000, offset by proceeds from the sale of property and equipment.

Net Cash Provided by Financing Activities

Net cash provided by financing activities in the nine months ended September 30, 2020 of $26.0 million primarily relates to proceeds from the issuance of common stock in our public offerings, net of various issuance costs and proceeds of $2.3 million from borrowings pursuant to the PPP under the CARES Act.

Net cash provided by financing activities in the nine months ended September 30, 2019 of $11.9 million primarily relates to proceeds of $8.0 million from warrant exercises and proceeds of $3.8 million from issuance of common stock in a public offering.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements, such as structured finance, special purpose entities, or variable interest entities.

Contractual Obligations

Our principal obligations consist of the operating lease for our facilities, our Loan Agreement with CRG, our PPP Loan and non-cancelable purchase commitments. The following table sets out our contractual obligations as of September 30, 2020. Due by period (in thousands):

	Payments Due by Period
	Less Than 1 Year		1 - 3 Years		4-5 Years		More Than 5 Years		Total
Operating lease obligations	$	1,113	$	2,345	$	1,442	$	—	$	4,900
CRG Loan		1,722		12,462		—		—		14,184
PPP Loan		1,447		914		—		—		2,361
Noncancelable purchase commitments		984		91		5		—		1,080
	$	5,266	$	15,812	$	1,447	$	—	$	22,525

The total CRG Loan amount, shown as borrowings on the balance sheet as of September 30, 2020, is $9.8 million. The contractual obligation in the table above of $14.2 million under the CRG Loan includes future interest to be accrued but not paid in cash as well as a $1.6 million back-end fee to be paid in June 2023 upon maturity of the CRG Loan which is being accreted. For more information, see Part I, Item 1 “Unaudited Financial Statements, Footnote 5. Borrowings.”

The total PPP Loan amount, shown as borrowings on the balance sheet as of September 30, 2020, is $2.34 million. The contractual obligation in the table above of $2.36 million under the PPP Loan includes future interest to be accrued. For more information, see Part I, Item 1 “Unaudited Financial Statements, Footnote 5. Borrowings.”

Under the terms of the PPP, the principal may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act and the PPPFA, such as payroll costs, benefits mortgage interest, rent, and utilities. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

The risk associated with fluctuating interest rates is primarily limited to our cash equivalents, which are carried at quoted market prices. Due to the short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our cash equivalents. We do not currently use or plan to use financial derivatives in our investment portfolio.

Credit Risk

As of September 30, 2020 and December 31, 2019, our cash and cash equivalents were maintained with one financial institution in the United States, and our current deposits are likely in excess of insured limits. We have reviewed the financial statements of this institution and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us.

Our accounts receivable primarily relates to revenues from the sale and rental of our Lumivascular platform products to hospitals and medical centers in the United States. There were no customers that represented more than 10% of our accounts receivable as of September 30, 2020 and December 31, 2019.

Foreign Currency Risk

Our business is primarily conducted in U.S. dollars. Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our results of operations, financial position, or cash flows. Based on our foreign currency balances of monetary assets and liabilities, we estimate that a 10% adverse change in Euro exchange rates versus the U.S. dollar would not have a material effect on the fair value of our monetary assets.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2020. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of September 30, 2020, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended September 30, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.	OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS

None.

ITEM 1A.

RISK FACTORS

Except as described below, there have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2020.

Risks Related to Our Business

We have limited long-term data regarding the safety and efficacy of our Lumivascular platform products, including Pantheris. Any long-term data that is generated by clinical trials involving our Lumivascular platform may not be positive or consistent with our short-term data, which would harm our ability to obtain clearance to market and sell our products.

Our Lumivascular platform is a novel system, and our success depends on its acceptance by the medical community as being safe and effective, and improving clinical outcomes. Important factors upon which the efficacy of our Lumivascular platform products, including Pantheris, will be measured are long-term data on the rate of restenosis following our procedure, and the corresponding duration of patency, or openness of the artery, and publication of that data in peer-reviewed journals. Another important factor that physicians will consider is the rate of reintervention, or retreatment, following the use of our Lumivascular platform products. The long-term clinical benefits of procedures that use our Lumivascular platform products, including Pantheris, are not known.

The results of short-term clinical experience of our Lumivascular platform products, including Pantheris, do not necessarily predict long-term clinical benefit. Restenosis rates typically increase over time. We believe that physicians will compare the rates of long-term restenosis and reintervention for procedures using our Lumivascular platform products against alternative procedures, such as angioplasty, stenting, bypass surgery and other atherectomy procedures. If the long-term rates of restenosis and reintervention do not meet physicians’ expectations, our Lumivascular platform products may not become widely adopted and physicians may consider alternative treatments for their patients. Another significant factor that physicians will consider is acute safety data on complications that occur during the use of our Lumivascular platform products. If the results obtained from any post-market studies that we conduct or post-clearance surveillance indicate that the use of our Lumivascular platform products are not as safe or effective as other treatment options or as current short-term data would suggest, adoption of our product may suffer and our business would be harmed. In addition, we are responsible for the costs associated with conducting studies to obtain safety and efficacy data. If we are unable to obtain sufficient financing, whether through our operations or from third parties, we will not be able to conduct the studies necessary to obtain long-term data regarding the safety and efficacy of our products.

Even if we believe the data collected from clinical studies or clinical experience indicate positive results, each physician’s actual experience with our products will vary. Physicians who are technically proficient participate in our clinical trials and are high-volume users of our Lumivascular platform products. Consequently, the results of our clinical trials and their experiences using our products may lead to better patient outcomes than those of physicians that are less proficient, perform fewer procedures or who use our products infrequently.

The ongoing COVID-19 pandemic and responses thereto have adversely affected and we expect will continue to adversely affect our supply chain, workforce, approval process, and business operations.

In December 2019, a novel strain of coronavirus, SARS-CoV-2, was reported to have surfaced in Wuhan, China. Since then, SARS-CoV-2, and the resulting disease COVID-19 has spread to multiple countries, including the United States and all of the primary markets where we conduct business. On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the U.S. government-imposed restrictions on travel between the United States and Europe for a 30-day period. Further, on March 13, 2020, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response. Almost all U.S. states and many local jurisdictions have issued, and others in the future may issue, "shelter-in-place" orders, quarantines, executive orders and similar government orders, restrictions, and recommendations for their residents to control the spread of COVID-19. Such orders, restrictions and recommendations, and the perception that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed “essential,” work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events, as well as record declines in stock prices, among other effects. We continue to monitor our operations and government mandates and may elect or be required to temporarily close our offices to protect our employees, and limit our access to customers and limit customer use of our products as they are required to prioritize resources to address the public healthcare needs arising from the COVID-19 pandemic. The disruptions to our activities and operations will negatively impact our business, some of our operating results and may negatively impact our financial condition. There is a risk that government actions will not be effective at containing COVID-19, and that government actions, including the orders and restrictions described above, that are intended to contain the spread of COVID-19 will have a devastating negative impact on the world economy at large, in which case the risks to our sales, operating results and financial condition described herein would be elevated significantly.

The duration of COVID-19's impact on our business may be difficult to assess or predict. The widespread pandemic has resulted, and may continue to result for an extended period, in significant disruption of global financial markets, reducing our ability to access capital, which would negatively affect our liquidity. Further, quarantines or government reaction or shutdowns for could disrupt our supply chain. Travel and import restrictions may also disrupt our ability to manufacture or distribute our devices. Any import or export or other cargo restrictions related to our products or the raw materials used to manufacture our products would restrict our ability to manufacture and ship products and harm our business, financial condition and results of operations. Our key personnel and other employees could also be affected by COVID-19, potentially reducing their availability, and an outbreak such as COVID-19 or the procedures we take to mitigate its effect on our workforce could reduce the efficiency of our operations or prove insufficient. We may delay or reduce certain capital spending and related projects until the travel and logistical impacts related to COVID-19 are lifted, which will delay the completion of such projects.

In addition, the conduct of clinical trials required to obtain clearance of additional indications and studies gathering post-market data for some of our products previously cleared by the FDA have been, and we expect may continue to be, affected by the COVID-19 pandemic. Specifically, site initiation and patient enrollment have been delayed for one of our clinical studies, and we are experiencing delays in completing the INSIGHT clinical study with the current restrictions on clinical work. As hospital resources are prioritized for the COVID-19 outbreak and quarantines impede patient movement or interrupt healthcare services, these and other clinical studies may continue to be disrupted. If we are unable to successfully complete these or other clinical studies, and thus obtain regulatory approvals and efficacy data sought, our business and operating results may be harmed.

While certain jurisdictions have begun easing restrictions on performing elective procedures, we cannot be certain that other jurisdictions will do so, or that, once hospitals do begin easing restrictions on elective procedures, patients will begin requesting such procedures. Furthermore, some jurisdictions have experienced and continue to experience a resurgence in COVID-19 cases, which has prompted certain hospitals and other medical providers in such areas to again defer elective procedures or further prolong or reinstate restrictions on such procedures. If other jurisdictions experience a resurgence in COVID-19 cases, they may also prolong or reinstate restrictions on elective procedures.

The global outbreak of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 outbreak is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business or the global economy as a whole. However, these effects have harmed our business, financial condition, and results of operations in the near term and could have a continuing material impact on our operations, sales, and ability to continue as a going concern.

Customer demand for and our ability to sell and market our products have been and we expect will continue to be adversely affected by the COVID-19 pandemic and responses thereto.

Restrictions on the ability to travel, social distancing policies, orders and restrictions, including those described above, and recommendations and fears of COVID-19 spreading within medical centers has caused both patients and providers to delay or cancel procedures that use our devices. We are unable to accurately predict when these policies, orders and restrictions will be relaxed or lifted, and there can be no assurances that patients or providers will restart procedures that use our devices upon termination of these policies, orders and restrictions, particularly if there remains any continued community outbreak of COVID-19.

A prolonged economic contraction or recession may also result in employer layoffs of their employees in markets where we conduct business, which could result in lower procedure demand. In particular, as certain of the procedures that use our products have limited reimbursement and require patients to pay for the procedures in whole or in part, a reduction in employment would reduce utilization and sales of our products. We have already experienced reduced sales as a result of the effects of the COVID-19 pandemic. While we experienced a rebound in sales during the third quarter of 2020 as practitioners and hospitals began to once again perform elective procedures, it is unclear whether our sales will continue to increase and whether sales lost earlier in the year may be recoverable in the future. If our sales decline, or if such lost sales are not recoverable in the future, our business and results of operations will be significantly adversely affected.

Our sales and marketing personnel often rely on in-person and onsite access to healthcare providers which is currently restricted as hospitals reduce access to essential personnel only. These restrictions have harmed our sales and marketing efforts, and continued restrictions would have a negative impact on our sales and results of operations. An increase of COVID-19-related hospital admissions may overload hospitals with unexpected patients, thereby delaying further procedures that use our devices but that are deemed elective by the hospital. In addition, we made temporary salary and work hour reductions, though we have reverted salaries and hours to prior levels, we and may, in the future, take further actions including reinstating reductions to salary and work hours, furloughs, restructuring or layoffs which may negatively impact our workforce and our business.

The global outbreak of COVID-19 continues to evolve rapidly. The ultimate impact of the COVID-19 outbreak is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business or the global economy as a whole. However, these effects have harmed our business, financial condition, and results of operations in the near term and could have a continuing material impact on our operations, sales, and ability to continue as a going concern.

We may not be eligible to participate in the relief programs provided under the recently adopted Coronavirus Aid Relief, and Economic Security (CARES) Act and even if we are eligible we may not realize any material benefits from participating in such programs.

On March 27, 2020, the President of the United States signed the Coronavirus Aid Relief, and Economic Security (CARES) Act into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. We are evaluating the applicability of the CARES Act to the Company, and the potential impacts on our business. We applied for, and received, a loan (the “PPP Loan”) in the principal amount of $2.3 million under the Paycheck Protection Program (the “PPP”) of the Cares Act. The PPP Loan bears interest at a fixed rate of 1% annually and matures on April 20, 2022. Under the terms of the PPP, the principal may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs, benefits, rent, and utilities. In addition, on June 5, 2020, the President of the United States signed the Paycheck Protection Program Flexibility Act (the “PPPFA”) into law. The PPPFA gives borrowers of a PPP loan more flexibility and time to spend the loan proceeds and allows the funds to be used on broader categories of expenses while still qualifying for loan forgiveness. We are evaluating forgiveness requirements pursuant to the PPP and PPPFA but can provide no guarantee that we will meet any of the requirements of forgiveness. However, no assurance can be provided that the Company will obtain forgiveness of the PPP Loan in whole or in part. While we may determine to apply for additional programs available under the CARES Act, there is no guarantee that we will meet any eligibility requirements to participate in such programs or, even if we are able to participate, that such programs will provide meaningful benefit to our business.

We may not be entitled to forgiveness of our recently received PPP Loan, and our application for the PPP Loan could in the future be determined to have been impermissible or could result in damage to our reputation.

On April 23, 2020 we received proceeds of $2.3 million from a loan under the Paycheck Protection Program of the CARES Act, a portion of which may be forgiven, which we intend to use to retain current employees, maintain payroll and make lease and utility payments. The PPP Loan matures on April 20, 2022 and bears annual interest at a rate of 1.0%. Commencing on the date that is the later of (i) the date that is the 10th month after the end of the Company’s PPP Loan covered period (as described below) and (ii) assuming the Company has applied for PPP Loan forgiveness within the period described in clause (i), the date on which SBA remits the loan forgiveness amount on the Company’s PPP Loan to the PPP lender (or notifies such lender that no loan forgiveness is allowed), we are required to pay the lender equal monthly payments of principal and interest as required to fully amortize by April 20, 2022 any principal amount outstanding on the PPP Loan as of October 21, 2020. On June 5, 2020, the President of the United States signed the PPPFA into law. The PPPFA gives borrowers of a PPP loan more flexibility and time to spend the loan proceeds and allows the funds to be used on broader categories of expenses while still qualifying for loan forgiveness. A portion of the PPP Loan may be forgiven by the SBA upon our application and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act and the PPPFA, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty-four week period or, if elected by the Company, the eight week period beginning on the date of the loan is advanced. Not more than 40% of the forgiven amount may be for non-payroll costs. The amount of the PPP Loan eligible to be forgiven may be limited due to declines in headcount, whether voluntary or involuntary, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25% as compared to the period of January 1, 2020 through March 31, 2020. We will be required to repay any portion of the outstanding principal that is not forgiven, along with accrued interest, in accordance with the amortization schedule described above, and we cannot provide any assurance that we will be eligible for loan forgiveness, that we will ultimately apply for forgiveness, or that any amount of the PPP Loan will ultimately be forgiven by the SBA. Furthermore, on April 28, 2020, the Secretary of the U.S. Department of the Treasury stated that the SBA will perform a full review of any PPP loan over $2.0 million before forgiving the loan.

In order to apply for the PPP Loan, we were required to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support our ongoing operations. We made this certification in good faith after analyzing, among other things, our financial situation and access to alternative forms of capital, and believe that we satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan is consistent with the broad objectives of the Paycheck Protection Program of the CARES Act. The certification described above does not contain any objective criteria and is subject to interpretation. On April 23, 2020, the SBA issued guidance stating that it is unlikely that a public company with substantial market value and access to capital markets will be able to make the required certification in good faith. The lack of clarity regarding loan eligibility under the Paycheck Protection Program has resulted in significant media coverage and controversy with respect to public companies applying for and receiving loans. If, despite our good-faith belief that given our Company's circumstances we satisfied all eligible requirements for the PPP Loan, we are later determined to have violated any of the laws or governmental regulations that apply to us in connection with the PPP Loan, such as the False Claims Act, or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be subject to penalties, including significant civil, criminal and administrative penalties and could be required to repay the PPP Loan in its entirety. In addition, receipt of a PPP Loan may result in adverse publicity and damage to reputation, and a review or audit by the SBA or other government entity or claims under the False Claims Act could consume significant financial and management resources. Any of these events could have a material adverse effect on our business, results of operations and financial condition.

Risks Related to Our Common Stock

Nasdaq may delist our securities from its exchange, which could harm our business and limit our stockholders’ liquidity.

Our common stock is currently listed on the Nasdaq Capital Market, which has qualitative and quantitative listing criteria. However, we cannot assure you that our common stock will continue to be listed on Nasdaq in the future. In order to continue listing our common stock on Nasdaq, we must maintain certain financial, distribution and stock price levels. Generally, we must maintain a minimum amount in stockholders’ equity and a minimum number of holders of our common stock.

On March 10, 2020, we received a letter from Nasdaq’s Listing Qualifications Department notifying us that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price for the Company’s listed securities was less than $1 for the previous 30 consecutive business days. The Company initially had a period of 180 calendar days, or until September 8, 2020, to regain compliance with the rule referred to in this paragraph. On April 20, 2020, we received a subsequent written notice from Nasdaq indicating that Nasdaq filed an immediately effective rule change with SEC on April 16, 2020, pursuant which the compliance periods for bid price and market value of publicly held shares requirements were tolled through June 30, 2020. As a result, the Company now has until November 20, 2020 to regain compliance with Nasdaq’s minimum bid price requirement referred to in this paragraph. To regain compliance, the bid price of the Company’s common stock must close at $1 or more for a minimum of ten consecutive business days. The notice has no present impact on the listing of the Company’s securities on Nasdaq.

In the event that the Company does not regain compliance with the Nasdaq Listing Rules prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. The Company intends to actively monitor its bid price and will consider available options to resolve the deficiency and regain compliance with the Nasdaq Listing Rules, including conducting a reverse stock split.

The Company intends to present a proposal to its stockholders at the Company’s next annual meeting to be held on December 10, 2020 to effect a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-20. There is no guarantee that, if approved, a reverse stock split would result in the Company meeting the minimum bid price. Further, because the meeting to obtain stockholder approval will not be held until after November 20, 2020, Nasdaq may determine to delist our securities.

If Nasdaq delists our common stock from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:

●

a limited availability of market quotations for our securities;

●

reduced liquidity for our securities;

●

a determination that our common stock is a “penny stock” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

●

a limited amount of news and analyst coverage; and

●

a decreased ability to issue additional securities or obtain additional financing in the future.

The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as “covered securities.” If our common stock continues to be listed on NASDAQ, our common stock will be a covered security. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us or to our stockholders, (iii) any action asserting a claim arising pursuant to the Delaware General Corporation Law or our certificate of incorporation or bylaws (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws, or (v) any action asserting a claim governed by the internal affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers or employees. If a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse effect on our business, financial condition, results of operations and prospects.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

The following exhibits are being filed herewith:

Exhibit Number		Exhibit Title

31.1		Certification of the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

The certifications filed as Exhibits 32.1 are not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Company under the Securities Exchange Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof irrespective of any general incorporation by reference language contained in any such filing, except to the extent that the registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Avinger, Inc.
	(Registrant)


Date: November 10, 2020	/s/ JEFFERY M. SOINSKI
	Jeffrey M. Soinski
	Chief Executive Officer
	(Principal Executive Officer)

Date: November 10, 2020	/s/ MARK WEINSWIG
	Mark Weinswig
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-31.1 2 ex_211220.htm EXHIBIT 31.1 ex_211220.htm

Exhibit 31.1

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
Pursuant to

Securities Exchange Act Rules 13a-14(a) and 15d-14(a),

As Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Jeffrey Soinski, hereby certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Avinger, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 10, 2020

	/s/ Jeffrey M. Soinski
	Jeffrey M. Soinski
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 ex_211221.htm EXHIBIT 31.2 ex_211221.htm

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
Pursuant to

Securities Exchange Act Rules 13a-14(a) and 15d-14(a),

As Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Mark Weinswig, hereby certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Avinger, Inc.;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 10, 2020

	/s/ Mark Weinswig
	Mark Weinswig
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 ex_211222.htm EXHIBIT 32.1 ex_211222.htm

Exhibit 32.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER

AND CHIEF FINANCIAL OFFICER

PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Avinger, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (the “Report”), Jeffrey Soinski, as Chief Executive Officer of the Company, and Mark Weinswig, Chief Financial Officer of the Company, each hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), to his knowledge:

The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 10^th day of November, 2020.

/s/ Jeffrey M. Soinski		/s/ Mark Weinswig
Jeffrey M. Soinski		Mark Weinswig
Chief Executive Officer		Chief Financial Officer
(Principal Executive Officer)		(Principal Financial and Accounting Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 avgr-20200930.xml XBRL INSTANCE DOCUMENT 2901000 2685000 129000 -357000 P7Y P7Y 1998079 P60D 1 1 0.5 50 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Concentration of Credit Risk, and Other Risks and Uncertainties</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company's policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at <div style="display: inline; font-style: italic; font: inherit;">one</div> financial institution. The counterparties to the agreements relating to the Company's investments consist of financial institutions of high credit standing.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:center;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company's accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div><div style="display: inline; font-style: italic; font: inherit;">no</div> customer represented <div style="display: inline; font-style: italic; font: inherit;">10%</div> or more of the Company's accounts receivable. For the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> there were <div style="display: inline; font-style: italic; font: inherit;">no</div> customers that represented <div style="display: inline; font-style: italic; font: inherit;">10%</div> or more of revenues. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company's financial position and results of operations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company's product components and sub-assemblies continue to be manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company's financial position and results of operations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company is subject to certain risks, including that its devices <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance that the Company's products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, new technological innovations, dependence upon <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Existing or future devices developed by the Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company's operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it <div style="display: inline; font-style: italic; font: inherit;"> may </div>be necessary to adjust operations to align with the Company's currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this <div style="display: inline; font-style: italic; font: inherit;"> may </div>have a material adverse impact on the Company. </div></div></div></div></div></div></div></div> 2090000 3800000 3800000 3500000 2 10000000 12000000 15000000 -20000 -3520000 0.15 0.015 0.01 0.05 0 105000 82410 P15D 0.25 0.25 8000000 3800000 3900000 3000000 5500000 11300000 3800000 3900000 3000000 5500000 6200000 5100000 15500000 10200000 23648000 3811000 36000 54000 35000 35000 140000 128000 -129000 358000 0.2 0.2 4225 0.05 0.10 1998079 2000 7991000 7993000 -7000 380000 P1Y false --12-31 Q3 2020 2020-09-30 10-Q 0001506928 84922079 Yes true true Non-accelerated Filer Yes Avinger Inc false true Common Stock, par value $0.001 per share avgr

632000

663000

1341000

1458000

683000

654000

377080000

355220000

967000

895000

2901000

2685000

384000

451000

384000

523000

451000

523000

1160000

1532000

451000

1532000

36000

40000

97000

128000

116000

122000

354000

339000

232000

361000

709000

1065000

384000

523000

1160000

1532000

19000

42000

127000

126000

129000

2753999

2757741

2753999

3346568

6903

7444

7100

7596

48503

44923

48503

45046

749512

371651

820743

316575

3558917

3181759

3630345

3715785

36946000

23825000

31185000

16624000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div> Summary of Significant Accounting Policies</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Basis of Presentation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC (“SEC”). The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company's financial information. The results for the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>are <div style="display: inline; font-style: italic; font: inherit;">not</div> necessarily indicative of results to be expected for the year ending <div style="display: inline; font-style: italic; font: inherit;"> December </div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020,</div> or for any other interim period or for any future year. The <div style="display: inline; font-style: italic; font: inherit;"> December </div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2019</div> condensed balance sheet data has been derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements included in the Company's Form <div style="display: inline; font-style: italic; font: inherit;">10</div>-K for the fiscal year ended <div style="display: inline; font-style: italic; font: inherit;"> December </div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2019,</div> which was filed with the SEC on <div style="display: inline; font-style: italic; font: inherit;"> March </div><div style="display: inline; font-style: italic; font: inherit;">5,</div> <div style="display: inline; font-style: italic; font: inherit;">2020.</div> The Company's significant accounting policies are more fully described in Note <div style="display: inline; font-style: italic; font: inherit;">2</div> of the Notes to Financial Statements included in the Company's Annual Report on Form <div style="display: inline; font-style: italic; font: inherit;">10</div>-K for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December </div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> June 19, 2019, </div>the Company's Board of Directors approved an amendment to the Company's amended and restated certificate of incorporation to effect a <div style="display: inline; font-style: italic; font: inherit;">1</div>-for-<div style="display: inline; font-style: italic; font: inherit;">10</div> reverse stock split of the Company's common stock. The reverse stock split became effective on <div style="display: inline; font-style: italic; font: inherit;"> June 21, 2019. </div>The par values of the common stock and convertible preferred stock were <div style="display: inline; font-style: italic; font: inherit;">not</div> adjusted as a result of the reverse stock splits. All common stock, stock options, and restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font: inherit;">not</div> readily apparent from other sources. Although these estimates are based on the Company's knowledge of current events and actions it <div style="display: inline; font-style: italic; font: inherit;"> may </div>undertake in the future, actual results <div style="display: inline; font-style: italic; font: inherit;"> may </div>ultimately materially differ from these estimates and assumptions.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Fair Value of Financial Instruments</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has evaluated the estimated fair value of its financial instruments as of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>Financial instruments consist of cash and cash equivalents, accounts receivable and payable, and other current liabilities and borrowings. The carrying amounts of cash and cash equivalents, accounts receivable and payable, and other current liabilities approximate their respective fair values because of the short-term nature of those instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the borrowings approximate their fair value.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Cash and Cash Equivalents</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company considers all highly liquid investments with an original maturity of <div style="display: inline; font-style: italic; font: inherit;">three</div> months or less at the time of purchase to be cash equivalents. Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>the Company's cash equivalents are entirely comprised of investments in money market funds. Any related unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders' equity. There were <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">no</div></div> unrealized gains and losses as of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method. </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Concentration of Credit Risk, and Other Risks and Uncertainties</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company's policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at <div style="display: inline; font-style: italic; font: inherit;">one</div> financial institution. The counterparties to the agreements relating to the Company's investments consist of financial institutions of high credit standing.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:center;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company's accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div><div style="display: inline; font-style: italic; font: inherit;">no</div> customer represented <div style="display: inline; font-style: italic; font: inherit;">10%</div> or more of the Company's accounts receivable. For the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> there were <div style="display: inline; font-style: italic; font: inherit;">no</div> customers that represented <div style="display: inline; font-style: italic; font: inherit;">10%</div> or more of revenues. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company's financial position and results of operations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company's product components and sub-assemblies continue to be manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company's financial position and results of operations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company is subject to certain risks, including that its devices <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance that the Company's products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, new technological innovations, dependence upon <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Existing or future devices developed by the Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company's operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it <div style="display: inline; font-style: italic; font: inherit;"> may </div>be necessary to adjust operations to align with the Company's currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this <div style="display: inline; font-style: italic; font: inherit;"> may </div>have a material adverse impact on the Company. </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Revenue Recognition</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company's revenues are derived from (<div style="display: inline; font-style: italic; font: inherit;">1</div>) sale of Lightboxes, (<div style="display: inline; font-style: italic; font: inherit;">2</div>) sale of disposables, which consist of catheters and accessories, and (<div style="display: inline; font-style: italic; font: inherit;">3</div>) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company's revenue recognition policies generally result in revenue recognition at the following points:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;"> </div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">1.</div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Lightbox sales: The Company sells its products directly to hospitals and medical centers. Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form by the customer acknowledging that the training and installation process is complete.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;"> </div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">2.</div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Sales of disposables: Disposable revenues consist of sales of the Company's catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;"> </div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">3.</div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Service revenue: Service contract revenue is recognized ratably over the term of the service period and maintenance contract revenue is recognized as work is performed. To date, service revenue has been insignificant.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company offers its customers the ability to purchase or lease its Lightbox. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow certain strategic accounts to install and utilize the Lightbox for a limited trial period of typically <div style="display: inline; font-style: italic; font: inherit;">three</div> to <div style="display: inline; font-style: italic; font: inherit;">six</div> months. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) <div style="display: inline; font-style: italic; font: inherit;">842,</div> <div style="display: inline; font-style: italic;">Leases</div> and ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2014</div> <div style="display: inline; font-style: italic; font: inherit;">09,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font: inherit;">606</div>)</div>. The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company's assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is <div style="display: inline; font-style: italic; font: inherit;">not</div> reasonably predictable. Accordingly, the Company concluded the embedded lease did <div style="display: inline; font-style: italic; font: inherit;">not</div> meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training, and warranty in their respective territories. The standard terms and conditions contained in the Company's distribution agreements do <div style="display: inline; font-style: italic; font: inherit;">not</div> provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do <div style="display: inline; font-style: italic; font: inherit;">not</div> allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company estimates reductions in revenue for potential returns of products by customers. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of its products. The Company expenses shipping and handling costs as incurred and includes them in the cost of revenues. When the Company bills shipping and handling costs to customers, such amounts billed are included as a component of revenue.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Cost of Revenues</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company's cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;text-indent:36pt;"></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Product Warranty Costs</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company typically offers a <div style="display: inline; font-style: italic; font: inherit;">one</div>-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Warranty provisions and claims are summarized as follows (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine Months Ended<br /> September 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Beginning balance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">221</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">215</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">215</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">272</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Warranty provision</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">124</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Usage/Release</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(35</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(35</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(140</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(128</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Ending balance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">199</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">214</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">199</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">214</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div><div style="display: inline; font-weight: bold;"> </div></div> <div style="display: inline; font-style: italic; font: inherit;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Net Loss per Share Attributable to Common Stockholders</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholder by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders' continued service to the Company. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> there were <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">no</div></div> shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(5,492</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(5,518</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(17,277</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(17,014</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Weighted average common stock outstanding, basic and diluted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">69,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,900</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">37,246</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,189</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Net loss per share attributable to common stockholders, basic and diluted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.08</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 14.7pt 0pt 9pt; text-align: justify; text-indent: 27pt;">The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Common stock warrants equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,757,741</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,346,568</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,903</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,444</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,596</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Convertible preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">48,503</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">44,923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">48,503</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">45,046</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Unvested restricted stock units</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">749,512</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">371,651</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">820,743</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">316,575</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,558,917</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,181,759</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,630,345</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,715,785</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td> </tr> </table> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Segment and Geographical Information</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company operates and manages its business as <div style="display: inline; font-style: italic; font: inherit;">one</div> reportable and operating segment. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company's long-lived assets, which are comprised of property and equipment, are based in the United States. For the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> <div style="display: inline; font-style: italic; font: inherit;">94%</div> and <div style="display: inline; font-style: italic; font: inherit;">96%,</div> respectively, of the Company's revenues were in the United States. For both the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">94%</div></div> of the Company's revenues were in the United States based on the shipping location of the external customer. </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Recently adopted accounting standards</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> June 2016, </div>the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13,</div> <div style="display: inline; font-style: italic;">Financial Instruments – Credit Losses</div>, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables.  The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset.  The new standard became effective for the Company in the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020.</div> The adoption of this standard did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a material impact on the Company's condensed financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Recent accounting standards <div style="display: inline; font-style: italic; font: inherit;">not</div> yet adopted</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> December 2019, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12,</div> <div style="display: inline; font-style: italic;">Income Taxes (Topic <div style="display: inline; font-style: italic; font: inherit;">740</div>): Simplifying the Accounting for Income Taxes</div>, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.  The standard becomes effective for the Company in the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2021</div> and early adoption is permitted.  This new standard is <div style="display: inline; font-style: italic; font: inherit;">not</div> expected to have a material impact on the Company's condensed financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> August 2020, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2020</div>-<div style="display: inline; font-style: italic; font: inherit;">06,</div> <div style="display: inline; font-style: italic;">Debt—Debt with Conversion and Other Options (Subtopic <div style="display: inline; font-style: italic; font: inherit;">470</div>-<div style="display: inline; font-style: italic; font: inherit;">20</div>) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic <div style="display: inline; font-style: italic; font: inherit;">815</div>-<div style="display: inline; font-style: italic; font: inherit;">40</div>): Accounting for Convertible Instruments and Contracts in an Entity's Own </div><div style="display: inline; font-style: italic;">Equity</div>, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU's guidance, entities will <div style="display: inline; font-style: italic; font: inherit;">not</div> separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC <div style="display: inline; font-style: italic; font: inherit;">815</div> or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2022</div> and early adoption is permitted.  This new standard is <div style="display: inline; font-style: italic; font: inherit;">not</div> expected to have a material impact on the Company's condensed financial statements.</div></div></div>

25326000

10943000

16410000

25326000

14461000

14383000

-1949000

15.80

250

1797900

1768850

108309

2875000

2753999

897900

870950

108309

876840

8979000

8709500

1083091

8768395

27539986

0.001

100000000

84921079

53034

10364663

84921079

10364663

85000

10000

0.94

0.96

0.94

1523

380750

542500

1525000

1563000

4392000

4629000

41800000

38000000

30000000

10000000

0.125

2700000

5500000

2700000

1400000

1300000

461000

588000

461000

676000

654000

2900000

967000

895000

2900000

2700000

-0.08

-0.70

-0.46

-2.75

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Net Loss per Share Attributable to Common Stockholders</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholder by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders' continued service to the Company. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> there were <div style="display: inline; font-style: italic; font: inherit;">no</div> shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(5,492</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(5,518</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(17,277</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(17,014</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Weighted average common stock outstanding, basic and diluted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">69,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,900</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">37,246</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,189</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Net loss per share attributable to common stockholders, basic and diluted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.08</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 14.7pt 0pt 9pt; text-align: justify; text-indent: 27pt;">The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Common stock warrants equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,757,741</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,346,568</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,903</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,444</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,596</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Convertible preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">48,503</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">44,923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">48,503</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">45,046</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Unvested restricted stock units</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">749,512</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">371,651</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">820,743</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">316,575</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,558,917</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,181,759</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,630,345</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,715,785</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr></table></div></div></div></div></div></div></div></div>

1455000

1782000

11000

1500000

P146D

P1Y73D

777000

847000

1637000

1940000

-31000

-229000

-142000

147000

29000

-768000

-327000

-8000

464000

1149000

-5000

16000

-32000

197000

59000

433000

377000

1245000

1091000

427000

377000

1200000

1100000

6000

1826000

1890000

3994000

3912000

1403000

1426000

765000

596000

390000

80000

1000

70000

33000

242000

0.065

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="margin-left: 36pt; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: auto; min-; min-width: 700px;"> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Year Ending December 31,</div></div> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2020 (remaining three months of the year)</div> </td> <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">274</div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2021</div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">1,123</div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2022</div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">1,162</div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2023</div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">1,203</div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2024</div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">1,138</div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">4,900</div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Less: Imputed interest</div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">(630</div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 81.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Leasehold liability as of September 30, 2020</div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); width: 1.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); width: 14.7%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">4,270</div></div> </td> <td style="vertical-align: bottom; width: 1.1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> </table></div>

5800000

4900000

1123000

1138000

1203000

1162000

630000

P5Y

22492000

16930000

36946000

23825000

18089000

12788000

50000000

14184000

2360000

3400000

1575000

4518000

6266000

521000

264000

274000

26014000

11858000

40000

-70000

-11671000

-13737000

-14376000

-14329000

-4525000

-4623000

-4525000

-4623000

-14376000

-14329000

-5492000

-5518000

-17277000

-17014000

4878000

5462000

14809000

16288000

-4101000

-4615000

-13172000

-14348000

314000

942000

1100000

4270000

787000

722000

3483000

4135000

1800000

6000000

4269000

4856000

242000

225000

718000

444000

550000

684000

9000

7000

52000

8000

299000

8000

868000

1119000

962000

88000

0.08

967000

895000

2901000

2685000

2945

3580

48503000

0.001

5000000

48503

48325

178

2170

48503

524000

311000

331000

2330000

2300000

40000

18000

8000000

7993000

221000

215000

272000

199000

214000

13000

34000

124000

70000

942000

1661000

1100000

1417000

1371000

4308000

4120000

-362711000

-348335000

2302000

2410000

6029000

6569000

4680000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Common stock warrants equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,757,741</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,346,568</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,903</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,444</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,596</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Convertible preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">48,503</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">44,923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">48,503</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">45,046</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Unvested restricted stock units</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">749,512</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">371,651</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">820,743</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">316,575</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,558,917</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,181,759</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,630,345</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,715,785</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Year Ending December 31,</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020 (remaining three months of the year)</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,266</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,518</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">14,184</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: Amount of PIK additions and final facility fee to be accreted subsequent to September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(3,520</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: Amount representing debt financing costs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(461</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Borrowings, as of September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">10,203</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Year Ending December 31,</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020 (remaining three months of the year)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">264</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,575</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">521</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: Amount of interest to be accreted subsequent to September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Borrowings, as of September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,340</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(5,492</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(5,518</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(17,277</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(17,014</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt;">Weighted average common stock outstanding, basic and diluted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">69,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,900</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">37,246</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,189</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Net loss per share attributable to common stockholders, basic and diluted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.08</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">20</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Cost of revenues</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">36</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">128</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Research and development expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">116</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">354</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">339</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Selling, general and administrative expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">232</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">361</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">709</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,065</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">384</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">523</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,160</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,532</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine Months Ended<br /> September 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Beginning balance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">221</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">215</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">215</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">272</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Warranty provision</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">124</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Usage/Release</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(35</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(35</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(140</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(128</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Ending balance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">199</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">214</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">199</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">214</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Grant Date</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Term</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 49%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Awards outstanding at December 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">908,504</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Awarded</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">47,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.58</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Released</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(363,085</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.58</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(152,727</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Awards outstanding at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">440,192</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of<br /> Shares</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">thousands)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average<br /> Exercise</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Intri</div><div style="display: inline; font-weight: bold;">n</div><div style="display: inline; font-weight: bold;">sic</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Value</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">thousands)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,401</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,309.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,138.72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">820.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,826</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,241.89</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.05</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,781</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,244.72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.05</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,826</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,241.89</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.05</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">and</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercisable</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Underlying</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares of</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Common </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Stock</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price per</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16.7%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Expiration Date</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 35.3%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series 1 Warrants issued in February 2018 financing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8,979,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">897,900</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">20.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">February 2025</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series 2 Warrants issued in February 2018 financing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8,709,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">870,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">20.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">February 2025</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants issued in July 2018 financing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,083,091</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">108,309</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">July 2021</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants issued in November 2018 financing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,768,395</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">876,840</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">November 2023</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">27,539,986</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> </tr> </table></div>

10203000

2340000

11632000

8967000

911000

3461000

4091000

10501000

12168000

1160000

1532000

P4Y

P3Y

P4Y

152727

3.04

47500

0.58

440192

908504

4.09

3.67

P1Y295D

P1Y73D

363085

134000

110000

4.58

300000

800000

3300

20000

40000

125000

202544

92170

6781000

1244.72

549000

26000

7401000

6826000

1309.47

1241.89

6826000

1241.89

2138.72

820

1.18

0.70

0.25

0.27

0.70

0.38

0.47

0.32

P10Y

P6Y18D

P6Y295D

P6Y18D

1.1

48503

51339024

48503

84921079

44923

6421317

44923

10342179

48503

10364663

45671

3492200

2945

2918000

-1523

380750

-2170

542500

360330

107303

416119

115091

3813559

6428572

12600000

1890000

20000000

3000000

15789474

2368421

11063830

1000000

17979

728500

8586

216618

728500

33221725

3813559

74140297

3813559

1000

-1000

1000

18000

1000

27000

28000

54000

33000

11979000

12012000

4000

3807000

3811000

74000

23574000

23648000

4000

3807000

3811000

2918000

51000

365684000

-358186000

7549000

85000

377080000

-362711000

14454000

6000

348505000

-338591000

9920000

10000

351958000

-343214000

8754000

10000

355220000

-348335000

6895000

3000

338342000

-328885000

9460000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">7.</div> Stockholders' Equity</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Convertible Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>the Company's certificate of incorporation, as amended and restated, authorizes the Company to issue up to <div style="display: inline; font-style: italic; font: inherit;">5,000,000</div> shares of convertible preferred stock with <div style="display: inline; font-style: italic; font: inherit;">$0.001</div> par value per share, of which <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">48,503</div></div> shares were issued and outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Series A Convertible Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.4pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> February </div><div style="display: inline; font-style: italic; font: inherit;">14,</div> <div style="display: inline; font-style: italic; font: inherit;">2018,</div> the Company entered into a Series A Purchase Agreement with CRG, pursuant to which it agreed to convert <div style="display: inline; font-style: italic; font: inherit;">$38.0</div> million of the outstanding principal amount of its senior secured term loan (plus <div style="display: inline; font-style: italic; font: inherit;">$3.8</div> million in back-end fees, accrued interest, debt discount and prepayment premium applicable thereto), totaling <div style="display: inline; font-style: italic; font: inherit;">$41.8</div> million, into a newly authorized Series A convertible preferred stock (the “Series A preferred stock”). The Series A preferred stock was initially convertible into <div style="display: inline; font-style: italic; font: inherit;">2,090,000</div> shares of common stock subject to certain limitations contained in the Series A Purchase Agreement. Under the terms of the Series A Purchase Agreement, the holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of <div style="display: inline; font-style: italic; font: inherit;">8%,</div> payable in additional shares of Series A preferred stock or cash, at the Company's option. The shares of Series A preferred stock have <div style="display: inline; font-style: italic; font: inherit;">no</div> voting rights and rank senior to all other classes and series of the Company's equity in terms of repayment and certain other rights. In <div style="display: inline; font-style: italic; font: inherit;"> January 2019 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 2019, </div><div style="display: inline; font-style: italic; font: inherit;">2,945</div> and <div style="display: inline; font-style: italic; font: inherit;">3,580</div> additional shares, respectively, were issued to CRG as payment of dividends accrued through <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div><div style="display: inline; font-style: italic; font: inherit;">48,325</div> shares of Series A preferred stock were outstanding. The Series A preferred stock accrued additional dividends of approximately <div style="display: inline; font-style: italic; font: inherit;">$967,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$895,000</div> during the quarters ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively and approximately <div style="display: inline; font-style: italic; font: inherit;">$2.9</div> million and <div style="display: inline; font-style: italic; font: inherit;">$2.7</div> million during the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Series B Convertible Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.4pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> February </div><div style="display: inline; font-style: italic; font: inherit;">16,</div> <div style="display: inline; font-style: italic; font: inherit;">2018,</div> the Company completed a public offering of <div style="display: inline; font-style: italic; font: inherit;">17,979</div> shares of Series B convertible preferred stock (the “Series B preferred stock”). As a result, the Company received net proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$15.5</div> million after underwriting discounts, commissions, legal and accounting fees. The Series B preferred stock has a liquidation preference of <div style="display: inline; font-style: italic; font: inherit;">$0.001</div> per share, full ratchet price based anti-dilution protection, has <div style="display: inline; font-style: italic; font: inherit;">no</div> voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has <div style="display: inline; font-style: italic; font: inherit;">no</div> stated maturity, and does <div style="display: inline; font-style: italic; font: inherit;">not</div> pay regularly stated dividends or interest. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div><div style="display: inline; font-style: italic; font: inherit;">1,523</div> of these shares converted into <div style="display: inline; font-style: italic; font: inherit;">380,750</div> shares of common stock. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">178</div></div> shares of Series B preferred stock remained outstanding which are currently convertible at <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$0.25</div></div> per share.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.4pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Series C Convertible Preferred Stock </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.4pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> November 1, 2018, </div>the Company completed a public offering of <div style="display: inline; font-style: italic; font: inherit;">728,500</div> shares of common stock and <div style="display: inline; font-style: italic; font: inherit;">8,586</div> shares of Series C convertible preferred stock (the “Series C preferred stock”). As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$10.2</div> million after underwriting discounts, commissions, legal and accounting fees. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series C preferred stock will be entitled to receive distributions out of our assets, whether capital or surplus, of an amount equal to <div style="display: inline; font-style: italic; font: inherit;">$0.001</div> per share of Series C preferred stock before any distributions shall be made on the common stock but after distributions shall be made on any outstanding Series A preferred stock and any of our existing or future indebtedness. The Series C preferred stock has <div style="display: inline; font-style: italic; font: inherit;">no</div> voting rights. During the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2019, </div><div style="display: inline; font-style: italic; font: inherit;">2,170</div> shares of Series C preferred stock, which then constituted all the remaining Series C shares, were converted into <div style="display: inline; font-style: italic; font: inherit;">542,500</div> shares of common stock, leaving <div style="display: inline; font-style: italic; font: inherit;">no</div> shares of Series C preferred stock outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Common Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>the Company's certificate of incorporation, as amended and restated, authorizes the Company to issue up to <div style="display: inline; font-style: italic; font: inherit;">100,000,000</div> shares of common stock with <div style="display: inline; font-style: italic; font: inherit;">$0.001</div> par value per share, of which <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">84,921,079</div></div> shares were issued and outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Common Stock Warrants</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>we had outstanding warrants to purchase common stock as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">and</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercisable</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Underlying</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares of</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Common </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Stock</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price per</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16.7%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Expiration Date</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 35.3%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series 1 Warrants issued in February 2018 financing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8,979,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">897,900</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">20.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">February 2025</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series 2 Warrants issued in February 2018 financing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8,709,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">870,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">20.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">February 2025</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants issued in July 2018 financing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,083,091</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">108,309</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">July 2021</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants issued in November 2018 financing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,768,395</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">876,840</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><div style="display: inline; font-style: italic; font: inherit;">November 2023</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">27,539,986</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In connection with the issuance of the Company's Series E convertible preferred stock in <div style="display: inline; font-style: italic; font: inherit;"> September </div><div style="display: inline; font-style: italic; font: inherit;">2014</div> through <div style="display: inline; font-style: italic; font: inherit;"> January </div><div style="display: inline; font-style: italic; font: inherit;">2015,</div> the Company issued warrants to purchase an aggregate of up to the number of shares of common stock equal to <div style="display: inline; font-style: italic; font: inherit;">50%</div> of the number of shares of the Company's Series E Convertible preferred stock purchased by such investor, all of which expired on <div style="display: inline; font-style: italic; font: inherit;"> September </div><div style="display: inline; font-style: italic; font: inherit;">2,</div> <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> February </div><div style="display: inline; font-style: italic; font: inherit;">16,</div> <div style="display: inline; font-style: italic; font: inherit;">2018,</div> in connection with the Company's completed public offering of Series B preferred stock, the Company issued <div style="display: inline; font-style: italic; font: inherit;">two</div> series of warrants that together provide for the purchase, by the investors in that offering, of an aggregate of <div style="display: inline; font-style: italic; font: inherit;">1,797,900</div> shares of common stock (the “Series B Warrants”). Each share of Series B preferred stock is accompanied by <div style="display: inline; font-style: italic; font: inherit;">one</div> warrant to purchase <div style="display: inline; font-style: italic; font: inherit;">one</div> share of common stock at <div style="display: inline; font-style: italic; font: inherit;">$20.00</div> per share that expires on the <div style="display: inline; font-style: italic; font: inherit;">seventh</div> anniversary of the date of issuance to purchase up to <div style="display: inline; font-style: italic; font: inherit;">50</div> shares of common stock and <div style="display: inline; font-style: italic; font: inherit;">one</div> warrant that expires on the earlier of (i) the <div style="display: inline; font-style: italic; font: inherit;">seventh</div> anniversary of the date of issuance or (ii) the <div style="display: inline; font-style: italic; font: inherit;">60th</div> calendar day following the receipt and announcement of FDA clearance of the Company's Pantheris below-the-knee device (or the same or similar product with a different name) to purchase up to <div style="display: inline; font-style: italic; font: inherit;">50</div> shares of common stock; provided, however, if at any time during such <div style="display: inline; font-style: italic; font: inherit;">60</div>-day period the volume weighted average price for any trading day is less than the then effective exercise price, the termination date shall be extended to the <div style="display: inline; font-style: italic; font: inherit;">seven</div> year anniversary of the initial exercise date. FDA clearance of Pantheris SV was received in <div style="display: inline; font-style: italic; font: inherit;"> April 2019, </div>triggering this <div style="display: inline; font-style: italic; font: inherit;">60</div>-day period. During the entire <div style="display: inline; font-style: italic; font: inherit;">60</div>-day period following clearance, the volume weighted average price was less than the then effective exercise price. As such, all Series <div style="display: inline; font-style: italic; font: inherit;">2</div> warrants are currently deemed to expire on the <div style="display: inline; font-style: italic; font: inherit;">seventh</div> anniversary of the date of issuance. The Company determined that the Series B Warrants should be classified as equity. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>Series B Warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font: inherit;">1,768,850</div> shares of common stock remain outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> July 13, 2018, </div>in connection with the Company's completed public offering of <div style="display: inline; font-style: italic; font: inherit;">216,618</div> shares of common stock, the Company issued warrants that provide for the purchase of <div style="display: inline; font-style: italic; font: inherit;">108,309</div> shares of common stock at <div style="display: inline; font-style: italic; font: inherit;">$15.80</div> per share. Each share of common stock is accompanied by <div style="display: inline; font-style: italic; font: inherit;">one</div> half of <div style="display: inline; font-style: italic; font: inherit;">one</div> warrant that expires on the <div style="display: inline; font-style: italic; font: inherit;">third</div> anniversary of the date of issuance. The Company determined that these warrants should be classified as equity. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>all of these warrants remain outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> November 1, 2018, </div>in connection with the Company's completed public offering of <div style="display: inline; font-style: italic; font: inherit;">728,500</div> shares of common stock and <div style="display: inline; font-style: italic; font: inherit;">8,586</div> shares of Series C convertible preferred stock, the Company issued warrants to provide for the purchase of <div style="display: inline; font-style: italic; font: inherit;">2,875,000</div> shares of common stock. Each share of common stock is accompanied by <div style="display: inline; font-style: italic; font: inherit;">one</div> warrant to purchase <div style="display: inline; font-style: italic; font: inherit;">one</div> share of common stock at <div style="display: inline; font-style: italic; font: inherit;">$4.00</div> per share. These warrants expire on the <div style="display: inline; font-style: italic; font: inherit;">5th</div> anniversary of the date of issuance. Each share of preferred stock is accompanied by <div style="display: inline; font-style: italic; font: inherit;">one</div> warrant to purchase <div style="display: inline; font-style: italic; font: inherit;">250</div> shares of common stock. The Company determined that the warrants should be classified as equity. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>warrants were exercised for an aggregate of <div style="display: inline; font-style: italic; font: inherit;">1,998,079</div> shares of common stock with proceeds to the Company of approximately <div style="display: inline; font-style: italic; font: inherit;">$8.0</div> million. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">876,840</div></div> shares of common stock were outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December </div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2019,</div> warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">2,753,999</div></div> shares of common stock were outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Stock Plans</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> January </div><div style="display: inline; font-style: italic; font: inherit;">2015,</div> the Board of Directors adopted, and the Company's stockholders approved the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Equity Incentive Plan (<div style="display: inline; font-style: italic; font: inherit;">“2015</div> Plan”). The <div style="display: inline; font-style: italic; font: inherit;">2015</div> Plan replaced the <div style="display: inline; font-style: italic; font: inherit;">2009</div> Stock Plan (the <div style="display: inline; font-style: italic; font: inherit;">“2009</div> Plan”) which was terminated immediately prior to consummation of the Company's IPO (collectively the “Plans.)” The <div style="display: inline; font-style: italic; font: inherit;">2015</div> Plan provides for the grant of incentive stock options (“ISOs”) to employees and for the grant of non-statutory stock options (“NSOs”), restricted stock, RSUs, stock appreciation rights, performance units and performance shares to employees, directors and consultants. Initially a total of <div style="display: inline; font-style: italic; font: inherit;">3,300</div> shares of common stock were reserved for issuance pursuant to the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Plan. The shares reserved for issuance under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Plan included shares reserved but <div style="display: inline; font-style: italic; font: inherit;">not</div> issued under the <div style="display: inline; font-style: italic; font: inherit;">2009</div> Plan, plus any share awards granted under the <div style="display: inline; font-style: italic; font: inherit;">2009</div> Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. In addition, the number of shares available for issuance under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Plan includes an automatic annual increase on the <div style="display: inline; font-style: italic; font: inherit;">first</div> day of each fiscal year beginning in fiscal <div style="display: inline; font-style: italic; font: inherit;">2016,</div> equal to the lesser of <div style="display: inline; font-style: italic; font: inherit;">4,225</div> shares, <div style="display: inline; font-style: italic; font: inherit;">5.0%</div> of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year or an amount as determined by the Board of Directors. In addition, during fiscal <div style="display: inline; font-style: italic; font: inherit;">2018,</div> the Board of Directors approved an additional <div style="display: inline; font-style: italic; font: inherit;">300,000</div> shares of common stock for issuance under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Plan. The Company's stockholders approved this increase on <div style="display: inline; font-style: italic; font: inherit;"> June 8, 2018. </div>On <div style="display: inline; font-style: italic; font: inherit;"> June 19, 2019, </div>the Company's stockholders approved an additional <div style="display: inline; font-style: italic; font: inherit;">800,000</div> increase to the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Plan. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div><div style="display: inline; font-style: italic; font: inherit;">202,544</div> shares were available for grant under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Plan.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to the Plans, ISOs and NSOs <div style="display: inline; font-style: italic; font: inherit;"> may </div>be granted with exercise prices at <div style="display: inline; font-style: italic; font: inherit;">not</div> less than <div style="display: inline; font-style: italic; font: inherit;">100%</div> of the fair value of the common stock on the date of grant and the exercise price of ISOs granted to a stockholder, who, at the time of grant, owns stock representing more than <div style="display: inline; font-style: italic; font: inherit;">10%</div> of the voting power of all classes of the stock of the Company, shall be <div style="display: inline; font-style: italic; font: inherit;">not</div> less than <div style="display: inline; font-style: italic; font: inherit;">110%</div> of the fair market value per share of common stock on the date of grant. The Company's Board of Directors determines the vesting schedule of the options. Options granted generally vest over <div style="display: inline; font-style: italic; font: inherit;">four</div> years and expire <div style="display: inline; font-style: italic; font: inherit;">ten</div> years from the date of grant. </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Stock option activity under the Plans is set forth below:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of<br /> Shares</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">thousands)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average<br /> Exercise</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Intri</div><div style="display: inline; font-weight: bold;">n</div><div style="display: inline; font-weight: bold;">sic</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Value</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">thousands)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,401</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,309.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,138.72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">820.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,826</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,241.89</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.05</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,781</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,244.72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.05</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,826</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,241.89</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.05</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">There were <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">no</div></div> options granted or exercised during the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>or <div style="display: inline; font-style: italic; font: inherit;">2019.</div> As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>there was approximately <div style="display: inline; font-style: italic; font: inherit;">$11,000</div> of remaining unamortized stock-based compensation expense associated with unvested stock options, which will be expensed over a weighted average remaining service period of approximately <div style="display: inline; font-style: italic; font: inherit;">0.4</div> years. Because of the Company's net operating losses, the Company did <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">not</div></div></div></div> realize any tax benefits from share-based payment arrangements for the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company's RSUs generally vest annually over <div style="display: inline; font-style: italic; font: inherit;">three</div> or <div style="display: inline; font-style: italic; font: inherit;">four</div> years in equal increments. The Company measures the fair value of RSUs using the closing stock price of a share of the Company's common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSU activity is presented below:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Grant Date</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Term</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 49%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Awards outstanding at December 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">908,504</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Awarded</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">47,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.58</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Released</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(363,085</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.58</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(152,727</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Awards outstanding at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">440,192</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>there was approximately <div style="display: inline; font-style: italic; font: inherit;">$1.5</div> million of remaining unamortized stock-based compensation expense associated with RSUs, which will be expensed over a weighted average remaining service period of approximately <div style="display: inline; font-style: italic; font: inherit;">1.2</div> years. The <div style="display: inline; font-style: italic; font: inherit;">440,192</div> outstanding non-vested and expected to vest RSUs have an aggregate fair value of approximately <div style="display: inline; font-style: italic; font: inherit;">$0.1</div> million. The Company used the closing market price of <div style="display: inline; font-style: italic; font: inherit;">$0.32</div> per share at <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>to determine the aggregate fair value for the RSUs outstanding at that date. For the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the fair value of RSUs vested was approximately <div style="display: inline; font-style: italic; font: inherit;">$134,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$110,000,</div> respectively.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> <div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2018</div> Officer and Director Share Purchase Plan</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 21.9pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> August 22, 2018, </div>the Board of Directors of the Company approved the adoption of an Officer and Director Share Purchase Plan (“ODPP”), which allows executive officers and directors to purchase shares of our common stock at fair market value in lieu of salary or, in the case of directors, director fees. Eligible individuals <div style="display: inline; font-style: italic; font: inherit;"> may </div>voluntarily participate in the ODPP by authorizing payroll deductions or, in the case of directors, deductions from director fees for the purpose of purchasing common stock. The Board of Directors authorized <div style="display: inline; font-style: italic; font: inherit;">20,000</div> shares to be made available for purchase by officers and directors under the ODPP. Effective on <div style="display: inline; font-style: italic; font: inherit;"> August 28, 2019 </div>and <div style="display: inline; font-style: italic; font: inherit;"> March 10, 2020, </div>the Board of Directors approved an additional <div style="display: inline; font-style: italic; font: inherit;">40,000</div> and <div style="display: inline; font-style: italic; font: inherit;">125,000</div> shares, respectively, to be made available under the ODPP. Common stock issued under the ODPP during the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>totaled <div style="display: inline; font-style: italic; font: inherit;">53,034</div> shares. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>there were <div style="display: inline; font-style: italic; font: inherit;">92,170</div> shares reserved for issuance under the ODPP.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14.7pt;margin-top:0pt;text-align:justify;"> </div></div>

69459000

7900000

37246000

6189000

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001506928 avgr:FacilitySubleaseMember 2017-12-01 2017-12-01 0001506928 avgr:The2015EmployeeStockPurchasePlanMember 2018-01-01 2018-12-31 0001506928 avgr:ConversionOfPrincipalAmountOfSeniorSecuredLoanToNewlyAuthorizedSeriesAPreferredStockMember avgr:CRGMember 2018-02-14 2018-02-14 0001506928 avgr:ConversionOfPrincipalAmountOfSeniorSecuredLoanToNewlyAuthorizedSeriesAPreferredStockMember us-gaap:SeriesAPreferredStockMember 2018-02-14 2018-02-14 0001506928 avgr:SeriesAPreferredStockPurchaseAgreementWithCRGMember avgr:CRGMember avgr:LoanAgreementMember 2018-02-14 2018-02-14 0001506928 2018-02-16 2018-02-16 0001506928 avgr:CommonStockWarrantsIssuedWithSeriesBPreferredStockWarrantOneMember 2018-02-16 2018-02-16 0001506928 avgr:CommonStockWarrantsIssuedWithSeriesBPreferredStockWarrantTwoMember 2018-02-16 2018-02-16 0001506928 us-gaap:SeriesBPreferredStockMember 2018-02-16 2018-02-16 0001506928 us-gaap:CommonStockMember avgr:PlacementAgencySaleProspectusSupplementOfJuly122018Member 2018-07-13 2018-07-13 0001506928 us-gaap:SeriesCPreferredStockMember 2018-11-01 2018-11-01 0001506928 us-gaap:CommonStockMember 2018-11-01 2018-11-01 0001506928 us-gaap:CommonStockMember avgr:NovemberPublicOfferingMember 2018-11-01 2018-11-01 0001506928 avgr:CRGMember us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-01-31 0001506928 2019-01-01 2019-09-30 0001506928 avgr:CommonStockOptionsMember 2019-01-01 2019-09-30 0001506928 avgr:CommonStockWarrantsMember 2019-01-01 2019-09-30 0001506928 us-gaap:PreferredStockMember 2019-01-01 2019-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember country:US 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesBPreferredStockIntoCommonStockMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesBPreferredStockIntoCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesBPreferredStockIntoCommonStockMember us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesBPreferredStockIntoCommonStockMember us-gaap:PreferredStockMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesBPreferredStockIntoCommonStockMember us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesCPreferredStockIntoCommonStockMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesCPreferredStockIntoCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesCPreferredStockIntoCommonStockMember us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesCPreferredStockIntoCommonStockMember us-gaap:PreferredStockMember 2019-01-01 2019-09-30 0001506928 avgr:ConversionOfSeriesCPreferredStockIntoCommonStockMember us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001506928 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2019-01-01 2019-09-30 0001506928 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-09-30 0001506928 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001506928 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001506928 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-09-30 0001506928 us-gaap:SeriesAPreferredStockMember us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001506928 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember avgr:August2019PublicOfferingMember 2019-01-01 2019-09-30 0001506928 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001506928 us-gaap:CommonStockMember avgr:August2019PublicOfferingMember 2019-01-01 2019-09-30 0001506928 us-gaap:PreferredStockMember 2019-01-01 2019-09-30 0001506928 us-gaap:PreferredStockMember avgr:August2019PublicOfferingMember 2019-01-01 2019-09-30 0001506928 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001506928 us-gaap:RetainedEarningsMember avgr:August2019PublicOfferingMember 2019-01-01 2019-09-30 0001506928 avgr:August2019PublicOfferingMember 2019-01-01 2019-09-30 0001506928 2019-01-01 2019-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001506928 avgr:CommonStockWarrantsMember avgr:NovemberPublicOfferingMember 2019-01-01 2019-12-31 0001506928 avgr:ConversionOfSeriesBPreferredStockIntoCommonStockMember 2019-01-01 2019-12-31 0001506928 avgr:AprilAndMay2019OfferingMember 2019-04-01 2019-05-31 0001506928 avgr:ReverseStockSplitMember 2019-06-19 2019-06-19 0001506928 avgr:The2015EmployeeStockPurchasePlanMember 2019-06-19 2019-06-19 0001506928 2019-07-01 2019-09-30 0001506928 avgr:CommonStockOptionsMember 2019-07-01 2019-09-30 0001506928 avgr:CommonStockWarrantsMember 2019-07-01 2019-09-30 0001506928 us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember country:US 2019-07-01 2019-09-30 0001506928 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2019-07-01 2019-09-30 0001506928 us-gaap:SeriesAPreferredStockMember 2019-07-01 2019-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember avgr:August2019PublicOfferingMember 2019-07-01 2019-09-30 0001506928 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001506928 us-gaap:CommonStockMember avgr:August2019PublicOfferingMember 2019-07-01 2019-09-30 0001506928 us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0001506928 us-gaap:PreferredStockMember avgr:August2019PublicOfferingMember 2019-07-01 2019-09-30 0001506928 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001506928 us-gaap:RetainedEarningsMember avgr:August2019PublicOfferingMember 2019-07-01 2019-09-30 0001506928 avgr:August2019PublicOfferingMember 2019-07-01 2019-09-30 0001506928 avgr:August2019PublicOfferingMember 2019-08-01 2019-08-30 0001506928 avgr:August2019PublicOfferingMember 2019-08-26 2019-08-26 0001506928 avgr:CRGMember us-gaap:SeriesAPreferredStockMember 2019-12-01 2019-12-31 0001506928 avgr:January2020PublicOfferingMember 2020-01-01 2020-01-31 0001506928 2020-01-01 2020-09-30 0001506928 avgr:CommonStockOptionsMember 2020-01-01 2020-09-30 0001506928 avgr:CommonStockWarrantsMember 2020-01-01 2020-09-30 0001506928 us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001506928 avgr:CommonStockOptionsMember srt:MinimumMember 2020-01-01 2020-09-30 0001506928 avgr:CommonStockOptionsMember srt:MinimumMember avgr:StockholderWithMoreThan10VotingPowerMember 2020-01-01 2020-09-30 0001506928 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember srt:MaximumMember 2020-01-01 2020-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember srt:MinimumMember 2020-01-01 2020-09-30 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember country:US 2020-01-01 2020-09-30 0001506928 avgr:PaycheckProtectionProgramCaresActMember 2020-01-01 2020-09-30 0001506928 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2020-01-01 2020-09-30 0001506928 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-09-30 0001506928 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember avgr:August2019PublicOfferingMember 2020-01-01 2020-09-30 0001506928 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001506928 us-gaap:CommonStockMember avgr:August2019PublicOfferingMember 2020-01-01 2020-09-30 0001506928 us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001506928 us-gaap:PreferredStockMember avgr:August2019PublicOfferingMember 2020-01-01 2020-09-30 0001506928 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001506928 us-gaap:RetainedEarningsMember avgr:August2019PublicOfferingMember 2020-01-01 2020-09-30 0001506928 avgr:August2019PublicOfferingMember 2020-01-01 2020-09-30 0001506928 avgr:Covid19Member 2020-01-01 2020-09-30 0001506928 avgr:January2020PublicOfferingMember 2020-01-31 2020-01-31 0001506928 avgr:PaycheckProtectionProgramCaresActMember 2020-04-01 2020-04-30 0001506928 avgr:AprilAndMay2020PublicOfferingMember 2020-04-01 2020-05-31 0001506928 avgr:PaycheckProtectionProgramCaresActMember 2020-04-23 2020-04-23 0001506928 avgr:April2020PublicOfferingMember 2020-04-30 2020-04-30 0001506928 avgr:May2020PublicOfferingMember 2020-05-06 2020-05-06 0001506928 avgr:JuneAndJuly2020PublicOfferingMember 2020-06-01 2020-07-31 0001506928 avgr:June2020PublicOfferingMember 2020-06-26 2020-06-26 0001506928 2020-07-01 2020-09-30 0001506928 avgr:CommonStockOptionsMember 2020-07-01 2020-09-30 0001506928 avgr:CommonStockWarrantsMember 2020-07-01 2020-09-30 0001506928 us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember country:US 2020-07-01 2020-09-30 0001506928 avgr:PaycheckProtectionProgramCaresActMember 2020-07-01 2020-09-30 0001506928 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2020-07-01 2020-09-30 0001506928 us-gaap:SeriesAPreferredStockMember 2020-07-01 2020-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember avgr:August2019PublicOfferingMember 2020-07-01 2020-09-30 0001506928 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001506928 us-gaap:CommonStockMember avgr:August2019PublicOfferingMember 2020-07-01 2020-09-30 0001506928 us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001506928 us-gaap:PreferredStockMember avgr:August2019PublicOfferingMember 2020-07-01 2020-09-30 0001506928 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001506928 us-gaap:RetainedEarningsMember avgr:August2019PublicOfferingMember 2020-07-01 2020-09-30 0001506928 avgr:August2019PublicOfferingMember 2020-07-01 2020-09-30 0001506928 avgr:July2020PublicOfferingMember 2020-07-09 2020-07-09 0001506928 avgr:AugustAndSeptember2020PublicOfferingMember 2020-08-01 2020-09-30 0001506928 avgr:August2020PublicOfferingMember 2020-08-06 2020-08-06 0001506928 avgr:August2020PublicOfferingMember 2020-08-11 2020-08-11 0001506928 avgr:August2020PublicOfferingMember 2020-08-25 2020-08-25 0001506928 avgr:September2020PublicOfferingMember 2020-09-01 2020-09-01 0001506928 avgr:CRGMember avgr:LoanAgreementMember srt:ScenarioForecastMember 2021-07-01 2021-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember srt:ScenarioForecastMember 2022-01-01 2022-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember srt:ScenarioForecastMember 2023-01-01 2023-12-31 0001506928 avgr:CommonStockWarrantsIssuedWithSeriesEConvertiblePreferredStockMember 2015-01-31 0001506928 avgr:The2015EmployeeStockPurchasePlanMember 2015-01-31 0001506928 2015-09-22 0001506928 avgr:SeriesAPreferredStockPurchaseAgreementWithCRGMember avgr:CRGMember avgr:LoanAgreementMember 2015-09-22 0001506928 avgr:FirstTrancheBorrowedOnSeptember222015Member avgr:CRGMember avgr:LoanAgreementMember 2015-09-22 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2015-09-22 0001506928 avgr:SecondTrancheBorrowedOnJune152016Member avgr:CRGMember avgr:LoanAgreementMember 2016-06-15 0001506928 avgr:FacilitySubleaseMember 2017-12-01 0001506928 avgr:ConversionOfPrincipalAmountOfSeniorSecuredLoanToNewlyAuthorizedSeriesAPreferredStockMember us-gaap:SeriesAPreferredStockMember 2018-02-14 0001506928 avgr:CommonStockWarrantsIssuedWithSeriesBPreferredStockMember 2018-02-16 0001506928 avgr:CommonStockWarrantsIssuedWithSeriesBPreferredStockWarrantOneMember 2018-02-16 0001506928 avgr:CommonStockWarrantsIssuedWithSeriesBPreferredStockWarrantTwoMember 2018-02-16 0001506928 us-gaap:SeriesBPreferredStockMember 2018-02-16 0001506928 avgr:CommonStockWarrantsMember avgr:PlacementAgencySaleProspectusSupplementOfJuly122018Member 2018-07-13 0001506928 avgr:OfficerAndDirectorSharePurchasePlanMember 2018-08-22 0001506928 avgr:CommonStockWarrantsMember avgr:NovemberPublicOfferingMember 2018-11-01 0001506928 avgr:PreferredStockWarrantsMember avgr:NovemberPublicOfferingMember 2018-11-01 0001506928 us-gaap:SeriesCPreferredStockMember 2018-11-01 0001506928 2018-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001506928 us-gaap:CommonStockMember 2018-12-31 0001506928 us-gaap:PreferredStockMember 2018-12-31 0001506928 us-gaap:RetainedEarningsMember 2018-12-31 0001506928 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001506928 2019-03-07 0001506928 2019-04-01 0001506928 2019-06-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001506928 us-gaap:CommonStockMember 2019-06-30 0001506928 us-gaap:PreferredStockMember 2019-06-30 0001506928 us-gaap:RetainedEarningsMember 2019-06-30 0001506928 avgr:August2019PublicOfferingMember 2019-08-26 0001506928 avgr:OfficerAndDirectorSharePurchasePlanMember 2019-08-28 0001506928 2019-09-30 0001506928 us-gaap:SeriesCPreferredStockMember 2019-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001506928 us-gaap:CommonStockMember 2019-09-30 0001506928 us-gaap:PreferredStockMember 2019-09-30 0001506928 us-gaap:RetainedEarningsMember 2019-09-30 0001506928 2019-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001506928 avgr:CommonStockWarrantsMember avgr:NovemberPublicOfferingMember 2019-12-31 0001506928 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001506928 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2019-12-31 0001506928 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001506928 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001506928 us-gaap:CommonStockMember 2019-12-31 0001506928 us-gaap:PreferredStockMember 2019-12-31 0001506928 us-gaap:RetainedEarningsMember 2019-12-31 0001506928 avgr:January2020PublicOfferingMember 2020-01-31 0001506928 2020-03-02 0001506928 avgr:OfficerAndDirectorSharePurchasePlanMember 2020-03-10 0001506928 avgr:April2020PublicOfferingMember 2020-04-30 0001506928 avgr:June2020PublicOfferingMember 2020-06-26 0001506928 2020-06-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001506928 us-gaap:CommonStockMember 2020-06-30 0001506928 us-gaap:PreferredStockMember 2020-06-30 0001506928 us-gaap:RetainedEarningsMember 2020-06-30 0001506928 avgr:July2020PublicOfferingMember 2020-07-09 0001506928 avgr:August2020PublicOfferingMember 2020-08-06 0001506928 avgr:August2020PublicOfferingMember 2020-08-25 0001506928 2020-09-30 0001506928 us-gaap:EmployeeStockOptionMember 2020-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001506928 avgr:CommonStockWarrantsIssuedWithSeriesBPreferredStockMember 2020-09-30 0001506928 avgr:CommonStockWarrantsMember avgr:NovemberPublicOfferingMember 2020-09-30 0001506928 avgr:July2018WarrantsMember 2020-09-30 0001506928 avgr:November2018WarrantsMember 2020-09-30 0001506928 avgr:Series1February2018WarrantsMember 2020-09-30 0001506928 avgr:Series2February2018WarrantsMember 2020-09-30 0001506928 avgr:LoanAgreementMember avgr:CRGMember 2020-09-30 0001506928 avgr:PaycheckProtectionProgramCaresActMember 2020-09-30 0001506928 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001506928 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2020-09-30 0001506928 avgr:OfficerAndDirectorSharePurchasePlanMember 2020-09-30 0001506928 avgr:The2015EmployeeStockPurchasePlanMember 2020-09-30 0001506928 us-gaap:PurchaseCommitmentMember 2020-09-30 0001506928 us-gaap:SeriesAPreferredStockMember 2020-09-30 0001506928 us-gaap:SeriesBPreferredStockMember 2020-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001506928 us-gaap:CommonStockMember 2020-09-30 0001506928 us-gaap:PreferredStockMember 2020-09-30 0001506928 us-gaap:RetainedEarningsMember 2020-09-30 0001506928 2020-11-06

EX-101.SCH 6 avgr-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Organization link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Borrowings link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 4 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 5 - Borrowings (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 6 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 7 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 8 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 1 - Organization (Details Textual) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 3 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 4 - Inventories - Schedule of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - Borrowings (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 5 - Borrowings - Schedule of Debt (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 6 - Commitments and Contingencies - Future Operating Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Stockholder's Equity - Outstanding Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Stockholders' Equity - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Stockholders' Equity - Restricted Stock Units Award Activity (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 avgr-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 avgr-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 avgr-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueNextTwelveMonths Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the next twelve months during which the agreement is in effect. Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies Note 4 - Inventories Note 5 - Borrowings Note 6 - Commitments and Contingencies Borrowings, long-term portion Note 7 - Stockholders' Equity Note 8 - Stock-based Compensation Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Note 4 - Inventories - Schedule of Inventory (Details) Note 5 - Borrowings - Schedule of Debt (Details) Note 6 - Commitments and Contingencies - Future Operating Lease Payments (Details) Note 7 - Stockholder's Equity - Outstanding Warrants (Details) us-gaap_LiabilitiesCurrent Total current liabilities June 2020 Public Offering [Member] Represents June 2020 Public Offering. Note 7 - Stockholders' Equity - Stock Option Activity (Details) July 2020 Public Offering [Member] Represents the July 2020 Public Offering Schedule of Debt [Table Text Block] Note 7 - Stockholders' Equity - Restricted Stock Units Award Activity (Details) August 2020 Public Offering [Member] Represents the August 2020 public offering. Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) September 2020 Public Offering [Member] Represents the September 2020 Public Offering. Notes To Financial Statements August and September 2020 Public Offering [Member] Represents the public offering for August and September 2020. Notes To Financial Statements [Abstract] April 2020 Public Offering [Member] Represents April 2020 public offering. May 2020 Public Offering [Member] Represents May 2020 public offering. Awards outstanding, Weighted average remaining contractual term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Purchase Commitment, Excluding Long-term Commitment [Axis] Purchase Commitment, Excluding Long-term Commitment [Domain] Purchase Commitment [Member] Proceeds from the issuance of common stock under officers and directors purchase plan The cash inflow from the additional capital contribution to the entity on issuance of common stock under officers' and directors' purchase plan. Proceeds from the issuance of common stock in public offerings, net The cash inflow from issuance of common stocks, and preferred stocks identified as being convertible, into another form of financial instrument, typically the entity's common stock, after deduction of issuance costs. Share-based Payment Arrangement, Option, Activity [Table Text Block] Awarded, Weighted grant date fair value (in dollars per share) Released, Weighted grant date fair value (in dollars per share) Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Forfeited, Weighted grant date fair value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Awards outstanding, Weighted grant date fair value (in dollars per share) Awards outstanding, Weighted grant date fair value (in dollars per share) Exercises of warrants for common stock Aggregate change in value for shares issued as a result of the exercise of warrants. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, Shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) Awards outstanding, Shares (in shares) Awards outstanding, Shares (in shares) Awarded, Shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Released, Shares (in shares) The 2015 Employee Stock Purchase Plan [Member] Represents information about the 2015 employee stock purchase plan. Vested and expected to vest, weighted average remaining contractual life (Year) Conversion of Series C Preferred Stock into Common Stock [Member] Information pertaining to the conversion of Series C Preferred Stock into common stock. November Public Offering [Member] Information pertaining to the November public offering. Vested and expected to vest (in shares) Vested and expected to vest, weighted average exercise price (in dollars per share) Exercisable, weighted average exercise price (in dollars per share) Exercisable, weighted average remaining contractual life (Year) Reclassification of right of use asset to prepaid rent The amount of right of use asset reclassified to prepaid rent. avgr_ClassOfWarrantOrRightExercised Class of Warrant or Right, Exercised (in shares) The number of warrants or rights exercised during the period. Exercisable (in shares) Loan Agreement [Member] Represents information about Term Loan Agreement (Loan Agreement). CRG [Member] Represents information about CRG. Balance, weighted average remaining contractual life (Year) Borrowings, current portion Borrowings, as of September 30, 2020 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options, weighted average exercise price (in dollars per share) Options, weighted average exercise price (in dollars per share) Forfeited, weighted average exercise price (in dollars per share) Less: Amount of PIK additions and final facility fee to be accreted subsequent to September 30, 2020 Cumulative paid-in-kind interest treated as additional principal and added to the total carrying amount of the debt. Expired, weighted average exercise price (in dollars per share) avgr_DebtConversionFeesAndPrepaymentPremiumAmount Debt Conversion, Fees and Prepayment Premium Amount The amount of related back-end fees and prepayment premium being converted together with the original debt in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Accrued expenses and other current liabilities Accrued compensation avgr_ConvertiblePreferredStockSharesOfCommonStockIssuableOnConversion Convertible Preferred Stock, Shares of Common Stock Issuable on Conversion (in shares) The initial number of shares of common stock issuable for the class of convertible preferred stock upon conversion. Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] Represents information bout conversion of principal amount of senior secured loan to newly authorized series A preferred stock. Series A preferred stock dividends payable Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options (in shares) Options (in shares) Common Stock Warrants, Issued with Series E Convertible Preferred Stock [Member] Represents information about common stock warrants, issued with series E convertible preferred stock. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired (in shares) Conversion of Series B Preferred Stock into Common Stock [Member] Represents information about conversion of series B preferred stock into common stock. Credit Facility [Axis] Proceeds from sale of property and equipment Preferred Stock Warrants [Member] Information pertaining to preferred stock warrants. Credit Facility [Domain] avgr_ClassOfWarrantOrRightContingentExpirationPeriodFollowingInitialExerciseDate Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date (Year) Period following the initial exercise date, upon which the warrant expires, if the volume weighted average price of the entity's common stock for any trading day during the 60-day period following FDA clearance of a specified product of the entity is less than the effective exercise price. Common Stock Warrants, Issued with Series B Preferred Stock, Warrant One [Member] Represents information about common stock warrants, issued with series B preferred stock warrant one. avgr_ClassOfWarrantOrRightNumberOfWarrantsIssuedForEachShareOfPreferredStock Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock (in shares) Number of warrants issued during the period for each share of preferred stock issued. us-gaap_PolicyTextBlockAbstract Accounting Policies Common Stock Warrants, Issued with Series B Preferred Stock [Member] Represents information about common stock warrants, issued with series B preferred stock. Common Stock Warrants [Member] Represents information about common stock warrants. Exercises of warrants for common stock (in shares) Number of shares issued as a result of the exercise of warrants. avgr_ClassOfWarrantOrRightExpirationPeriodFollowingFDAClearance Class of Warrant or Right, Expiration Period Following FDA Clearance (Day) Represents information about class of warrant or right, expiration period following FDA clearance. Common Stock Warrants, Issued with Series B Preferred Stock, Warrant Two [Member] Represents information about common stock warrants, issued with series B preferred stock warrant two. Common Stock Options [ member] Stockholder with More than 10% Voting Power [Member] Represents information about stockholder with more than 10% voting power. Unusual or Infrequent Item, or Both [Axis] avgr_ShareBasedCompensationArrangementBySharebasedPaymentAwardAdditionalSharesReservedForIssuancePercentageOnSharesOutstanding Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Reserved for Issuance, Percentage on Shares Outstanding Represents the maximum automatic annual increase in shares reserved for issuance as a percentage of outstanding shares. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_StockIssued1 Issuance of Series A preferred stock to pay dividends Unusual or Infrequent Item, or Both [Domain] avgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesReservedForIssuanceAnnual Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Reserved for Issuance, Annual (in shares) Represents the maximum automatic annual increase in the number of shares reserved for issuance. avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear Debt Instrument, Covenant, Compliance Target Minimum Revenue Second Year The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the second fiscal year during which the agreement is in effect. avgr_ClassOfWarrantOrRightSecuritiesCalledAsPercentageOfConvertiblePreferredStockShares Class of Warrant or Right, Securities Called as Percentage of Convertible Preferred Stock Shares The percentage of the number of shares of convertible preferred stock purchased by an investor used to determine the number of securities into which the class of warrant or right may be converted. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent avgr_WarrantyPeriod Warranty Period (Year) Represents the typical period of product warranty for parts and labor. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block] Disclosure of accounting policies for credit risk and other risks and uncertainties. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) avgr_ProductWarrantyAccrualPaymentsAndRelease Usage/Release Represents the aggregate decrease in the liability related to payments to satisfy claims for standard and extended product warranties and adjustment to release accrued amounts. Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member] Represents information about placement agency sale - prospectus supplement of July 12, 2018. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Current liabilities: avgr_CommonStockOfferingMaximumAggregateValue Common Stock Offering, Maximum Aggregate Value Maximum value of common stock that may be issued pursuant to a universal shelf registration statement. us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Net loss attributable to common stockholders Net loss attributable to common stockholders First Tranche, Borrowed on September 22, 2015 [Member] Represents information about first tranche, borrowed on September 22, 2015. us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Share-based Payment Arrangement, Expense, Tax Benefit Second Tranche, Borrowed on June 15, 2016 [Member] Represents information about second tranche, borrowed on June 15, 2016. Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Accretion of Series A preferred stock dividends Value of accretion of preferred stock dividends. Series A Preferred Stock Purchase Agreement with CRG [Member] Represents information about series A preferred stock purchase agreement with CRG. avgr_DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage Debt Instrument, Redemption Initial Prepayment Premium Percentage The initial premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument. Award Type [Domain] us-gaap_PreferredStockDividendsIncomeStatementImpact Accretion of preferred stock dividends avgr_DebtInstrumentFinancingFeePercentage Debt Instrument, Financing Fee Percentage The debt instrument fee required on the borrowing date for each tranche of borrowing, as a percentage of the principal amount borrowed. avgr_DebtInstrumentRedemptionPrepaymentPremiumPercentageAfterFifthYear Debt Instrument, Redemption Prepayment Premium Percentage after Fifth Year The premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument after the fifth year of the loan. avgr_DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage The annual decline in the premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument. Basis of Presentation and Significant Accounting Policies [Text Block] Award Type [Axis] Net loss Net loss and comprehensive loss Net and comprehensive loss avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear Debt Instrument, Covenant Compliance Target Minimum Revenue Third Year The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the third fiscal year during which the agreement is in effect. avgr_DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum The minimum amount of cash and certain cash equivalents the entity is required to maintain under the terms of the debt agreement. avgr_DebtInstrumentFinalFacilityFeePercentage Debt Instrument, Final Facility Fee Percentage The facility fee payable at the end of the debt instrument term or upon prepayment in full, as a percentage of the amount borrowed. avgr_DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall Debt Instrument, Covenant Compliance Prepayment Multiplier for Revenue Shortfall The multiplier applied to the amount of a revenue shortfall relative to required minimum targets, to determine the amount of outstanding principal the entity must prepay to be eligible for a cure right under the terms of the debt agreement. Restricted Stock Units (RSUs) [Member] Transfers between inventory and property and equipment Represents amount of transfer between inventories and property and equipment. Share-based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Cash flows from investing activities us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Accrued compensation us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_OperatingExpenses Total operating expenses Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Other long-term liabilities Allocated Share-based Compensation Expense Amendment Flag Use of Estimates, Policy [Policy Text Block] us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment, Total New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Accrued expenses and other current liabilities us-gaap_DebtInstrumentPeriodicPaymentPrincipal Debt Instrument, Periodic Payment, Principal us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding, Ending Balance (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding, Ending Balance (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Increase to right of use asset and leasehold liability arising from lease amendment Entity Ex Transition Period Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company Document Information [Line Items] us-gaap_DividendsPreferredStock Dividends, Preferred Stock, Total Document Information [Table] Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Accretion of Series A preferred stock dividends EX-101.PRE 10 avgr-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2020	Nov. 06, 2020
Document Information [Line Items]
Entity Registrant Name	Avinger Inc
Entity Central Index Key	0001506928
Trading Symbol	avgr
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		84,922,079
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.001 per share

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 25,326,000	$ 10,943,000
Accounts receivable, net of allowance for doubtful accounts of $19 at both September 30, 2020 and December 31, 2019	1,341,000	1,458,000
Inventories	3,994,000	3,912,000
Prepaid expenses and other current assets	524,000	311,000
Total current assets	31,185,000	16,624,000
Right of use asset	4,269,000	4,856,000
Property and equipment, net	942,000	1,661,000
Other assets	550,000	684,000
Total assets	36,946,000	23,825,000
Current liabilities:
Accounts payable	632,000	663,000
Accrued compensation	1,455,000	1,782,000
Accrued expenses and other current liabilities	683,000	654,000
Leasehold liability, current portion	787,000	722,000
Borrowings, current portion	11,632,000	8,967,000
Total current liabilities	18,089,000	12,788,000
Leasehold liability, long-term portion	3,483,000	4,135,000
Borrowings, long-term portion	911,000
Other long-term liabilities	9,000	7,000
Total liabilities	22,492,000	16,930,000
Commitments and contingencies (Note 6)
Stockholders’ equity:
Convertible preferred stock issuable in series, par value of $0.001; Shares authorized: 5,000,000 at June 30, 2020 and December 31, 2019; Shares issued and outstanding: 48,503 at September 30, 2020 and December 31, 2019; aggregate liquidation preference of $48,503 at September 30, 2020 and December 31, 2019
Common stock, par value of $0.001; Shares authorized: 100,000,000 at September 30, 2020 and December 31, 2019; Shares issued and outstanding: 84,921,079 and 10,364,663 at September 30, 2020 and December 31, 2019, respectively	85,000	10,000
Additional paid-in capital	377,080,000	355,220,000
Accumulated deficit	(362,711,000)	(348,335,000)
Total stockholders’ equity	14,454,000	6,895,000
Total liabilities and stockholders’ equity	36,946,000	23,825,000
Series A Preferred Stock [Member]
Current liabilities:
Series A preferred stock dividends payable	$ 2,900,000

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 19	$ 19
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	48,503	48,503
Preferred stock, shares outstanding (in shares)	48,503	48,503
Preferred stock, liquidation preference	$ 48,503	$ 48,503
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	84,921,079	10,364,663
Common stock, shares outstanding (in shares)	84,921,079	10,364,663

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues	$ 2,302	$ 2,410	$ 6,029	$ 6,569
Cost of revenues	1,525	1,563	4,392	4,629
Gross profit	777	847	1,637	1,940
Operating expenses:
Research and development	1,417	1,371	4,308	4,120
Selling, general and administrative	3,461	4,091	10,501	12,168
Total operating expenses	4,878	5,462	14,809	16,288
Loss from operations	(4,101)	(4,615)	(13,172)	(14,348)
Interest income	1	70	33	242
Interest expense	(433)	(377)	(1,245)	(1,091)
Other income, net	8	299	8	868
Net loss and comprehensive loss	(4,525)	(4,623)	(14,376)	(14,329)
Accretion of preferred stock dividends	(967)	(895)	(2,901)	(2,685)
Net loss attributable to common stockholders	$ (5,492)	$ (5,518)	$ (17,277)	$ (17,014)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.08)	$ (0.70)	$ (0.46)	$ (2.75)
Weighted average common shares used to compute net loss per share, basic and diluted (in shares)	69,459	7,900	37,246	6,189

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	August 2019 Public Offering [Member] Common Stock [Member]	August 2019 Public Offering [Member] Additional Paid-in Capital [Member]	August 2019 Public Offering [Member]	Conversion of Series B Preferred Stock into Common Stock [Member] Preferred Stock [Member]	Conversion of Series B Preferred Stock into Common Stock [Member] Common Stock [Member]	Conversion of Series C Preferred Stock into Common Stock [Member] Preferred Stock [Member]	Conversion of Series C Preferred Stock into Common Stock [Member] Common Stock [Member]	Conversion of Series C Preferred Stock into Common Stock [Member] Additional Paid-in Capital [Member]	Series A Preferred Stock [Member] Preferred Stock [Member]	Series A Preferred Stock [Member] Additional Paid-in Capital [Member]	Series A Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018												45,671	3,492,200
Balance at Dec. 31, 2018													$ 3	$ 338,342	$ (328,885)	$ 9,460
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares)	3,813,559
Issuance of common stock in public offerings, net of commissions and issuance costs	$ 4	$ 3,807	$ 3,811
Vesting of restricted stock units (in shares)													115,091
Vesting of restricted stock units														54		54
Employee stock-based compensation														1,532	451	1,532
Accretion of Series A preferred stock dividends														(2,685)		(2,685)
Net and comprehensive loss															(14,329)	(14,329)
Conversion of Series B preferred stock into common stock (in shares)				(1,523)	380,750	(2,170)	542,500
Conversion of Series B preferred stock into common stock							$ 1	$ (1)
Exercises of warrants for common stock (in shares)													1,998,079
Exercises of warrants for common stock													$ 2	7,991		7,993
Issuance of Series A preferred stock to pay dividends (in shares)									2,945
Issuance of Series A preferred stock to pay dividends										$ 2,918	$ 2,918
Balance (in shares) at Sep. 30, 2019												44,923	10,342,179
Balance at Sep. 30, 2019													$ 10	351,958	(343,214)	8,754
Balance (in shares) at Jun. 30, 2019												44,923	6,421,317
Balance at Jun. 30, 2019													$ 6	348,505	(338,591)	9,920
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares)													3,813,559
Issuance of common stock in public offerings, net of commissions and issuance costs													$ 4	3,807		3,811
Vesting of restricted stock units (in shares)	107,303
Vesting of restricted stock units		18	18
Employee stock-based compensation														523	451	523
Accretion of Series A preferred stock dividends														(895)		(895)
Net and comprehensive loss															(4,623)	(4,623)
Balance (in shares) at Sep. 30, 2019												44,923	10,342,179
Balance at Sep. 30, 2019													$ 10	351,958	(343,214)	8,754
Balance (in shares) at Dec. 31, 2019												48,503	10,364,663
Balance at Dec. 31, 2019													$ 10	355,220	(348,335)	6,895
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares)	74,140,297
Issuance of common stock in public offerings, net of commissions and issuance costs	$ 74	23,574	23,648
Vesting of restricted stock units (in shares)													416,119
Vesting of restricted stock units													$ 1	27		28
Employee stock-based compensation														1,160		1,160
Accretion of Series A preferred stock dividends														(2,901)		(2,901)
Net and comprehensive loss															(14,376)	(14,376)
Balance (in shares) at Sep. 30, 2020												48,503	84,921,079
Balance at Sep. 30, 2020													$ 85	377,080	(362,711)	14,454
Balance (in shares) at Jun. 30, 2020												48,503	51,339,024
Balance at Jun. 30, 2020													$ 51	365,684	(358,186)	7,549
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares)	33,221,725
Issuance of common stock in public offerings, net of commissions and issuance costs	$ 33	$ 11,979	$ 12,012
Vesting of restricted stock units (in shares)													360,330
Vesting of restricted stock units													$ 1			1
Employee stock-based compensation														384	451	384
Accretion of Series A preferred stock dividends														(967)		(967)
Net and comprehensive loss															(4,525)	(4,525)
Balance (in shares) at Sep. 30, 2020												48,503	84,921,079
Balance at Sep. 30, 2020													$ 85	$ 377,080	$ (362,711)	$ 14,454

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (4,525)	$ (4,623)	$ (14,376)	$ (14,329)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			676	654
Amortization of debt issuance costs and debt discount			126	129
Stock-based compensation			1,160	1,532
Noncash interest expense			1,119	962
Change in right of use asset			129	(357)
Provision for excess and obsolete inventories			390	80
Other non-cash (gains) losses, net			(52)
Changes in operating assets and liabilities:
Accounts receivable			142	(147)
Inventories			(464)	(1,149)
Prepaid expenses and other current assets			(197)	(59)
Other assets			5	(16)
Accounts payable			(31)	(229)
Accrued compensation			(327)	(8)
Accrued expenses and other current liabilities			29	(768)
Other long-term liabilities				(32)
Net cash used in operating activities			(11,671)	(13,737)
Cash flows from investing activities
Purchases of property and equipment				(88)
Proceeds from sale of property and equipment			40	18
Net cash provided by (used in) investing activities			40	(70)
Cash flows from financing activities
Proceeds from borrowings			2,330
Proceeds from the issuance of common stock related to warrant exercises				7,993
Proceeds from the issuance of common stock in public offerings, net			23,648	3,811
Proceeds from the issuance of common stock under officers and directors purchase plan			36	54
Net cash provided by financing activities			26,014	11,858
Net change in cash and cash equivalents			14,383	(1,949)
Cash and cash equivalents, beginning of period			10,943	16,410	$ 16,410
Cash and cash equivalents, end of period	$ 25,326	$ 14,461	25,326	14,461	$ 10,943
Noncash investing and financing activities:
Accretion of Series A preferred stock dividends			2,901	2,685
Issuance of Series A preferred stock to pay dividends				2,918
Reclassification of right of use asset to prepaid rent			(129)	358
Increase to right of use asset and leasehold liability arising from lease amendment				4,680
Transfers between inventory and property and equipment			$ (7)	$ 380

XML 17 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Organization	9 Months Ended
Note 1 - Organization	Sep. 30, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. Organization Organization, Nature of Business Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography ( “OCT”) visualization with interventional catheters and is the industry's only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company's Lumivascular platform consists of a capital component, Lightbox, as well as a variety of disposable catheter products. The Company's current products include its non-imaging catheters, Wildcat and Kittycat, as well as its Lumivascular platform products, Ocelot, Ocelot PIXL, Ocelot MVRX and Ocelaris (“Tigereye”), all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy systems under its suite of Lumivascular products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is located in Redwood City, California. Liquidity Matters The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014 - 15, Presentation of Financial Statements - Going Concern (Subtopic 205 - 40 ) requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity's ability to continue as a going concern within one year from the date of the issuance of these financial statements. In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of September 30, 2020, the Company had an accumulated deficit of $362.7 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $25.3 million at September 30, 2020 and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through at least the fourth quarter of 2021. Even though we received net proceeds of approximately $8 million from the issuance of common stock upon the exercise of warrants during April and May of 2019, net proceeds of $3.8 million from the sales of our common stock in our August 2019 offering, $3.9 million from the sale of our common stock in our January 2020 offering, $2.3 million of loan proceeds in April 2020 pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act, $3.0 million from the sale of our common stock in April and May 2020, $5.5 million from the sale of our common stock in June and July 2020 and $11.3 million from the sale of our common stock in August and September 2020, the Company will need to raise additional funds through future equity or debt financings within the next twelve months to meet its operational needs and capital requirements for product development, clinical trials and commercialization and may subsequently require additional fundraising. The Company can provide no assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for our existing stockholders. Given the recent decline in the Company's stock price, any financing that we undertake in the next twelve months could cause substantial dilution to our existing stockholders, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. In addition, the COVID- 19 pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company. During the second quarter of 2020 we took certain actions to manage available cash and other resources to mitigate the effects of COVID- 19 on our business, which included reduction of discretionary costs, reduction of base salaries for all of our non-manufacturing employees by 20% and reduction of hours worked by our manufacturing workers by 20%. While salaries and hours worked largely returned to prior levels in July 2020, we will continue to employ certain actions to manage our resources in the foreseeable future. There can be no assurance that such strategies will be successful in mitigating the negative impacts of the COVID- 19 pandemic on our business. These conditions raise substantial doubt about the Company's ability to continue as a going concern. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development of one or more of its products. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company's ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding. Additionally, due to the substantial doubt about the Company's ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of borrowings at September 30, 2020 and December 31, 2019 has been classified as current in these financial statements. CRG has not invoked the material adverse change clause. Public Offerings On March 7, 2019, we filed a universal shelf registration statement (the “Shelf Registration Statement”) to offer up to $50.0 million of our securities. We have established, and may in the future establish, “at-the-market” programs pursuant to which we may offer and sell shares of our common stock pursuant to the Shelf Registration Statement. Due to the SEC's “baby shelf rules,” which prohibit companies with a public float of less than $75 million from issuing securities under a shelf registration statement in excess of one - third of such company's public float in a twelve -month period, we are only able to issue a limited number of shares using the Shelf Registration Statement at this time. On August 26, 2019, we completed a public offering of 3,813,559 shares of common stock at an offering price of $1.18 per share. As a result, we received net proceeds of approximately $3.8 million after underwriting discounts, commissions, legal and accounting fees and the conversion price of the outstanding shares of Series B preferred stock, issued in our February 2018 offering, was reduced to $1.18 per share as a result. On January 31, 2020, we completed a public offering of 6,428,572 shares of common stock at an offering price of $0.70 per share. As a result, we received net proceeds of approximately $3.9 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our February 2018 offering, was reduced to $0.70 per share. On April 30, 2020, we completed a public offering of 12,600,000 shares of common stock at an offering price of $0.25 per share. On May 6, 2020 we issued an additional 1,890,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter's over-allotment option in connection with the aforementioned offering. As a result, we received aggregate net proceeds of approximately $3.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our February 2018 offering, was reduced to $0.25 per share. On June 26, 2020, we completed a public offering of 20,000,000 shares of common stock at an offering price of $0.27 per share. On July 9, 2020 we issued an additional 3,000,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter's over-allotment option in connection with the aforementioned offering resulting in $0.7 million of additional net proceeds. As a result, we received aggregate net proceeds of approximately $5.5 million including the overallotment option and after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. On August 6, 2020, under the Shelf Registration Statement, we completed a public offering of 15,789,474 shares of common stock at an offering price of $0.38 per share. On August 11, 2020 we issued an additional 2,368,421 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter's over-allotment option in connection with the aforementioned offering. As a result, we received aggregate net proceeds of approximately $6.2 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. On August 25, 2020, under the Shelf Registration Statement, we completed a public offering of 11,063,830 shares of common stock at an offering price of $0.47 per share. On September 1, 2020 we issued an additional 1,000,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter's over-allotment option in connection with the aforementioned offering. As a result, we received aggregate net proceeds of approximately $5.1 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

Basis of Presentation

three

and

nine

months ended

September 30, 2020

are

not

necessarily indicative of results to be expected for the year ending

December

31,

2020,

or for any other interim period or for any future year. The

December

31,

2019

condensed balance sheet data has been derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements included in the Company's Form

-K for the fiscal year ended

December

31,

2019,

which was filed with the SEC on

March

2020.

The Company's significant accounting policies are more fully described in Note

of the Notes to Financial Statements included in the Company's Annual Report on Form

-K for the year ended

December

31,

2019.

June 19, 2019,

the Company's Board of Directors approved an amendment to the Company's amended and restated certificate of incorporation to effect a

-for-

reverse stock split of the Company's common stock. The reverse stock split became effective on

June 21, 2019.

The par values of the common stock and convertible preferred stock were

not

adjusted as a result of the reverse stock splits. All common stock, stock options, and restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.

Use of Estimates

not

readily apparent from other sources. Although these estimates are based on the Company's knowledge of current events and actions it

may

undertake in the future, actual results

may

ultimately materially differ from these estimates and assumptions.

Fair Value of Financial Instruments

The Company has evaluated the estimated fair value of its financial instruments as of

September 30, 2020

and

December 31, 2019.

Financial instruments consist of cash and cash equivalents, accounts receivable and payable, and other current liabilities and borrowings. The carrying amounts of cash and cash equivalents, accounts receivable and payable, and other current liabilities approximate their respective fair values because of the short-term nature of those instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the borrowings approximate their fair value.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of

three

months or less at the time of purchase to be cash equivalents. Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. As of

September 30, 2020

and

December 31, 2019,

the Company's cash equivalents are entirely comprised of investments in money market funds. Any related unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders' equity. There were

unrealized gains and losses as of

September 30, 2020

and

December 31, 2019.

Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method.

Concentration of Credit Risk, and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.

The Company's policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at

one

financial institution. The counterparties to the agreements relating to the Company's investments consist of financial institutions of high credit standing.

The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at

September 30, 2020

and

December 31, 2019.

The Company's accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At

September 30, 2020

and

December 31, 2019,

customer represented

10%

or more of the Company's accounts receivable. For the

three

and

nine

months ended

September 30, 2020

and

2019,

there were

customers that represented

10%

or more of revenues. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company's financial position and results of operations.

The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company's product components and sub-assemblies continue to be manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company's financial position and results of operations.

The Company is subject to certain risks, including that its devices

may

not

be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be

assurance that the Company's products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but

not

limited to, new technological innovations, dependence upon

third

-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.

Existing or future devices developed by the Company

may

require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company's operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it

may

be necessary to adjust operations to align with the Company's currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this

may

have a material adverse impact on the Company.

Revenue Recognition

The Company's revenues are derived from (

) sale of Lightboxes, (

) sale of disposables, which consist of catheters and accessories, and (

) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company's revenue recognition policies generally result in revenue recognition at the following points:

Sales of disposables: Disposable revenues consist of sales of the Company's catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured.

three

six

months. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.

The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”)

842,

Leases

and ASU

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

)

. The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.

The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company's assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is

not

reasonably predictable. Accordingly, the Company concluded the embedded lease did

not

meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.

not

provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do

not

allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.

Cost of Revenues

Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company's cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs.

Product Warranty Costs

The Company typically offers a

one

-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Warranty provisions and claims are summarized as follows (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Beginning balance	$	221		$	215		$	215		$	272
Warranty provision		13			34			124			70
Usage/Release		(35	)		(35	)		(140	)		(128	)
Ending balance	$	199		$	214		$	199		$	214

Net Loss per Share Attributable to Common Stockholders

September 30, 2020

and

2019,

there were

shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.

Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	20 20			201 9			20 20			201 9
Net loss attributable to common stockholders	$	(5,492	)	$	(5,518	)	$	(17,277	)	$	(17,014	)
Weighted average common stock outstanding, basic and diluted		69,459			7,900			37,246			6,189
Net loss per share attributable to common stockholders, basic and diluted	$	(0.08	)	$	(0.70	)	$	(0.46	)	$	(2.75	)

	Three Months Ended September 30,				Nine Months Ended September 30,
	20 20		201 9		20 20		2019
Common stock warrants equivalents		2,753,999		2,757,741		2,753,999		3,346,568
Common stock options		6,903		7,444		7,100		7,596
Convertible preferred stock		48,503		44,923		48,503		45,046
Unvested restricted stock units		749,512		371,651		820,743		316,575
		3,558,917		3,181,759		3,630,345		3,715,785

Segment and Geographical Information

The Company operates and manages its business as

one

reportable and operating segment. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company's long-lived assets, which are comprised of property and equipment, are based in the United States. For the

three

months ended

September 30, 2020

and

2019,

94%

and

96%,

respectively, of the Company's revenues were in the United States. For both the

nine

months ended

September 30, 2020

and

2019,

94%

of the Company's revenues were in the United States based on the shipping location of the external customer.

Recent Accounting Pronouncements

Recently adopted accounting standards

June 2016,

the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)

2016

13,

Financial Instruments – Credit Losses

, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The new standard became effective for the Company in the

first

quarter of

2020.

The adoption of this standard did

not

have a material impact on the Company's condensed financial statements.

Recent accounting standards

not

yet adopted

December 2019,

the FASB issued ASU

2019

12,

Income Taxes (Topic

740

): Simplifying the Accounting for Income Taxes

, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for the Company in the

first

quarter of

2021

and early adoption is permitted. This new standard is

not

expected to have a material impact on the Company's condensed financial statements.

August 2020,

the FASB issued ASU

2020

06,

Debt—Debt with Conversion and Other Options (Subtopic

470

) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic

815

): Accounting for Convertible Instruments and Contracts in an Entity's Own

Equity

, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument. As a result, after adopting the ASU's guidance, entities will

not

separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC

815

or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the

first

quarter of

2022

and early adoption is permitted. This new standard is

not

expected to have a material impact on the Company's condensed financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurements	9 Months Ended
Note 3 - Fair Value Measurements	Sep. 30, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three -tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. As of September 30, 2020 and December 31, 2019, cash equivalents were all categorized as Level 1 and consisted of money market funds. As of September 30, 2020 and December 31, 2019, there were no financial assets and liabilities categorized as Level 2 or Level 3. There were no transfers between fair value hierarchy levels during the three months ended September 30, 2020.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Inventories

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Inventory Disclosure [Text Block]

Inventories

Inventories consisted of the following (in thousands):

	September 30,		December 31,
	20 20		201 9
Raw materials	$	1,403	$	1,426
Work-in-process		765		596
Finished products		1,826		1,890
Total inventories	$	3,994	$	3,912

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Borrowings

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Debt Disclosure [Text Block]

Borrowings

CRG

September

22,

2015,

the Company entered into a Term Loan Agreement, as amended (the “Loan Agreement”) with CRG under which, subject to certain conditions, the Company had the right to borrow up to

$50

million in principal amount from CRG on or before

March

29,

2017.

The Company borrowed

$30

million on

September

22,

2015.

The Company borrowed an additional

$10

million on

June

15,

2016

under the Loan Agreement.

February

14,

2018,

the Company and CRG further amended the Loan Agreement concurrent with the conversion of

$38

million of the principal amount of the senior secured term loan (plus

$3.8

million in back-end fees and prepayment premium applicable thereto) into a newly authorized Series A convertible preferred stock (see below).

March 2, 2020,

the Company entered into Amendment

No.

to the Loan Agreement to, among other things:

●

extend the period that the Company can make interest payments in payment in kind (“PIK”) to

June 30, 2021;

●

lower the Minimum Revenue Covenants to

$10

million for

2020,

$12

million for

2021,

and

$15

million for

2022;

●

insert certain terms to clarify that all fees, including the prepayment premium, are due if the obligations are accelerated; and

●

insert a new provision to make clear that to the extent the Company divides its assets/liabilities into divisions, such assets/liabilities will be treated as transferred to a

third

party.

May 12, 2020,

the Company entered into Amendment

No.

to the Loan Agreement to, among other things:

●

grant to the Company the right to optionally prepay in whole or in part the outstanding principal amount of the Loans for the Redemption Price, subject to certain conditions; and

●

waive the Company's requirement to comply with the Minimum Revenue Covenant for

2020.

Under the amended Loan Agreement,

cash payments for either principal or interest are due until the

third

quarter of

2021.

The accrued interest will be accrued and included in the debt balance based (to the extent

not

paid) on principal amounts outstanding at the beginning of the quarter at an interest rate of

12.5%.

Beginning in the

third

quarter of

2021,

the Company will be required to make quarterly principal payments (in addition to the interest) of

$1.4

million with total principal payments of

$2.7

million in

2021,

$5.5

million in

2022

and

$2.7

million in

2023.

The maturity date of the Loan is

June 30, 2023.

The Company

may

voluntarily prepay the borrowings in full, with a prepayment premium beginning at

5.0%

and declining by

1.0%

annually thereafter, with

premium being payable if prepayment occurs after

seven

and half years of the loan. Each tranche of borrowing required the payment, on the borrowing date, of a financing fee equal to

1.5%

of the borrowed loan principal, which is recorded as a discount to the debt. In addition, a facility fee equal to

15.0%

of the amounts borrowed plus any payment-in-kind (PIK) is to be payable at the end of the term or when the borrowings are repaid in full. A long-term liability is being accreted using the effective interest method for the facility fee over the term of the Loan Agreement with a corresponding discount to the debt. The borrowings are collateralized by a security interest in substantially all of the Company's assets.

$3.5

million of cash and certain cash equivalents, and the Company has to achieve certain minimum revenues. If the Company fails to meet the applicable minimum revenue target in any calendar year, the Loan Agreement provides the Company with a cure right if it prepays a portion of the outstanding principal equal to

2.0

times the revenue shortfall. In addition, the Loan Agreement prohibits the payment of cash dividends on the Company's capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG

may

accelerate the payment terms of the Loan Agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the Loan Agreement, the failure of the Company to adhere to the covenants set forth in the Loan Agreement, the insolvency of the Company or upon the occurrence of a material adverse change.

As of

September 30, 2020,

the Company was in compliance with all applicable covenants under the Loan Agreement.

As of

September 30, 2020,

principal, final facility fee and PIK payments due under the Loan Agreement are as follows (in thousands):

Year Ending December 31,
2020 (remaining three months of the year)	$	—
2021		3,400
2022		6,266
2023		4,518
		14,184
Less: Amount of PIK additions and final facility fee to be accreted subsequent to September 30, 2020		(3,520	)
Less: Amount representing debt financing costs		(461	)
Borrowings, as of September 30, 2020	$	10,203

In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of

$1.3

million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of

September 30, 2020

and

December

31,

2019,

the balance of the aggregate debt discount was approximately

$461,000

and

$588,000,

respectively. The Company's interest expense associated with the amortization of debt discount was approximately

$42,000

during both the

three

months ended

September 30, 2020

and

2019.

The Company's interest expense associated with the amortization of debt discount was approximately

$127,000

during both the

nine

months ended

September 30, 2020

and

2019.

For the

three

months ended

September 30, 2020

and

2019,

the Company incurred interest expense of approximately

$427,000

and

$377,000,

respectively. For the

nine

months ended

September 30, 2020

and

2019,

the Company incurred interest expense of approximately

$1.2

million and

$1.1

million, respectively.

Due to the material adverse change clause in the Loan Agreement with CRG, the entire amount of borrowings at

September 30, 2020

and

December 31, 2019

is classified as current in these financial statements. CRG has

not

invoked the material adverse change clause.

Paycheck Protection Program

April 23, 2020,

we received loan proceeds of

$2.3

million (the “ PPP Loan”) pursuant to the PPP under the CARES Act.

The Loan, which was in the form of a promissory note, dated

April 20, 2020 (

the “Promissory Note”), between the Company and Silicon Valley Bank as the lender, matures on

April 20, 2022

and bears interest at a fixed rate of

per annum, payable monthly commencing

six

months from the date of the Loan. The Company

may

voluntarily prepay the borrowings in full with

associated penalty or premium.

Under the terms of the PPP, the principal

may

be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs, benefits mortgage interest, rent, and utilities.

assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. In addition, details of the PPP continue to evolve regarding which companies are qualified to receive loans pursuant to the PPP and on what terms, and the Company

may

be required to repay some or all of the Loan due to these changes or different interpretations of the PPP requirements.

may

result in, among other things, the Company becoming obligated to repay all amounts outstanding.

June 5, 2020,

the President of the United States signed the Paycheck Protection Program Flexibility Act (the “PPPFA”) into law. The PPPFA gives borrowers of a PPP loan more flexibility and time to spend the loan proceeds and allows the funds to be used on broader categories of expenses while still qualifying for loan forgiveness. We expect to apply for forgiveness of the PPP loan in the

fourth

quarter of

2020.

While we believe that we have complied with the requirements to obtain forgiveness, there can be

assurance that any or all of the PPP loan amount will be forgiven. We also continue to evaluate and

may

still pursue additional programs under the CARES Act, but there is

guarantee that we will meet any eligibility requirements to participate in such programs or, even if we are able to participate, that such programs will provide meaningful benefit to our business.

As of

September 30, 2020,

principal and interest payments due under the PPP Loan are as follows (in thousands):

Year Ending December 31,
2020 (remaining three months of the year)	$	264
2021		1,575
2022		521
		2,360
Less: Amount of interest to be accreted subsequent to September 30, 2020		(20	)
Borrowings, as of September 30, 2020	$	2,340

For the

three

and

nine

months ended

September 30, 2020,

the Company incurred interest expense of approximately

$6,000

related to the PPP Loan.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Commitments and Contingencies

Lease Commitments

The Company's operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease that originally were to expire in

November

2019.

In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized using the straight-line method over the term of the lease. The Company records deferred rent calculated as the difference between rent expense and the cash rental payments.

October

19,

2017,

the Company entered into an agreement to sublease

one

of its facilities. The sublease agreement commenced on approximately

December

2017

and expired on

November

15,

2019

(which was

days prior to the expiration of the facility lease). The sublessee paid a base rent of

$82,410

per month. In addition to the base rent, the sublessee paid the Landlord's operating expenses and property taxes due and payable with respect to the subleased facility.

Upon the adoption of Topic

842

January 1, 2019,

the Company recognized a right of use asset and a corresponding leasehold liability related to this lease of approximately

$1.8

million, representing the present value of the remaining minimum lease payments as of that date. The asset was being reduced over the remaining period of the lease on a straight-line basis. The leasehold liability is being reduced as payments are made.

April 1, 2019,

we entered into an amendment to the lease which extended the lease term for an additional period of

five

years subsequent to the original expiration of

November 30, 2019.

As amended, the lease will expire on

November 30, 2024.

Under the terms of the amendment, we are obligated to pay approximately

$5.8

million in base rent payments through

November

2024,

beginning on

December 1, 2019.

This amendment did

not

extend the term of the lease with respect to the building being subleased.

In connection with the amendment the Company adjusted its right-of-use asset and lease liability to

$6.0

million. As of the date of the amendment, the operating lease was included on the balance sheet at the present value of the future base payments discounted at a

6.5%

discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease do provide an implicit rate.

For the

three

months ended

September 30, 2020,

our operating lease expense, excluding variable maintenance fees and other expenses paid by the Company on a monthly basis, was approximately

$105,000,

which totaled approximately

$314,000

for each of the

three

month periods ended

September 30, 2020

and

2019.

Rent expense for the

nine

months ended

September 30, 2020

and

2019

was approximately

$942,000

and

$1.1

million, respectively. Operating right-of-use asset amortization for the

three

months ended

September 30, 2020

and

2019

was approximately

$242,000

and

$225,000,

respectively. Operating right-of-use asset amortization for the

nine

months ended

September 30, 2020

and

2019

was approximately

$718,000

and

$444,000,

respectively. Due to payments being made in excess of operating lease expense recognized, the Company recorded approximately

$331,000

as prepaid rent included in other assets on the condensed balance sheet as of

September 30, 2020.

The following table presents the future operating lease payments and lease liability included on the condensed balance sheet related to the Company's operating lease as of

September 30, 2020 (

in thousands):

Year Ending December 31,
2020 (remaining three months of the year)	$	274
2021		1,123
2022		1,162
2023		1,203
2024		1,138
		4,900
Less: Imputed interest		(630	)
Leasehold liability as of September 30, 2020	$	4,270

Purchase Obligations

$1.1

million as of

September 30, 2020.

Indemnification

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and

may

provide for indemnification of the counterparty. The Company's exposure under these agreements is unknown because it involves claims that

may

be made against it in the future but have

not

yet been made. To date, the Company has

not

been subject to any claims or been required to defend any action related to its indemnification obligations.

The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director

may

be subject to any proceeding arising out of acts or omissions of such director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and

may

enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has

not

recognized any liabilities relating to these obligations for any period presented.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Stockholders' Equity

Convertible Preferred Stock

As of

September 30, 2020,

the Company's certificate of incorporation, as amended and restated, authorizes the Company to issue up to

5,000,000

shares of convertible preferred stock with

$0.001

par value per share, of which

48,503

shares were issued and outstanding.

Series A Convertible Preferred Stock

February

14,

2018,

the Company entered into a Series A Purchase Agreement with CRG, pursuant to which it agreed to convert

$38.0

million of the outstanding principal amount of its senior secured term loan (plus

$3.8

million in back-end fees, accrued interest, debt discount and prepayment premium applicable thereto), totaling

$41.8

million, into a newly authorized Series A convertible preferred stock (the “Series A preferred stock”). The Series A preferred stock was initially convertible into

2,090,000

shares of common stock subject to certain limitations contained in the Series A Purchase Agreement. Under the terms of the Series A Purchase Agreement, the holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of

8%,

payable in additional shares of Series A preferred stock or cash, at the Company's option. The shares of Series A preferred stock have

voting rights and rank senior to all other classes and series of the Company's equity in terms of repayment and certain other rights. In

January 2019

and

December 2019,

2,945

and

3,580

additional shares, respectively, were issued to CRG as payment of dividends accrued through

December 31, 2019.

As of

September 30, 2020,

48,325

shares of Series A preferred stock were outstanding. The Series A preferred stock accrued additional dividends of approximately

$967,000

and

$895,000

during the quarters ended

September 30, 2020

and

2019,

respectively and approximately

$2.9

million and

$2.7

million during the

nine

months ended

September 30, 2020

and

2019,

respectively.

Series B Convertible Preferred Stock

February

16,

2018,

the Company completed a public offering of

17,979

shares of Series B convertible preferred stock (the “Series B preferred stock”). As a result, the Company received net proceeds of approximately

$15.5

million after underwriting discounts, commissions, legal and accounting fees. The Series B preferred stock has a liquidation preference of

$0.001

per share, full ratchet price based anti-dilution protection, has

voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has

stated maturity, and does

not

pay regularly stated dividends or interest. During the year ended

December 31, 2019,

1,523

of these shares converted into

380,750

shares of common stock. As of

September 30, 2020

and

December 31, 2019,

178

shares of Series B preferred stock remained outstanding which are currently convertible at

$0.25

per share.

Series C Convertible Preferred Stock

November 1, 2018,

the Company completed a public offering of

728,500

shares of common stock and

8,586

shares of Series C convertible preferred stock (the “Series C preferred stock”). As a result, we received net proceeds of approximately

$10.2

million after underwriting discounts, commissions, legal and accounting fees. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series C preferred stock will be entitled to receive distributions out of our assets, whether capital or surplus, of an amount equal to

$0.001

per share of Series C preferred stock before any distributions shall be made on the common stock but after distributions shall be made on any outstanding Series A preferred stock and any of our existing or future indebtedness. The Series C preferred stock has

voting rights. During the

nine

months ended

September 30, 2019,

2,170

shares of Series C preferred stock, which then constituted all the remaining Series C shares, were converted into

542,500

shares of common stock, leaving

shares of Series C preferred stock outstanding.

Common Stock

As of

September 30, 2020,

the Company's certificate of incorporation, as amended and restated, authorizes the Company to issue up to

100,000,000

shares of common stock with

$0.001

par value per share, of which

84,921,079

shares were issued and outstanding.

Common Stock Warrants

As of

September 30, 2020,

we had outstanding warrants to purchase common stock as follows:

	Total Outstanding and Exercisable		Underlying Shares of Common Stock		Exercise Price per Share		Expiration Date
Series 1 Warrants issued in February 2018 financing		8,979,000		897,900	$	20.00	February 2025
Series 2 Warrants issued in February 2018 financing		8,709,500		870,950	$	20.00	February 2025
Warrants issued in July 2018 financing		1,083,091		108,309	$	15.80	July 2021
Warrants issued in November 2018 financing		8,768,395		876,840	$	4.00	November 2023
Total		27,539,986		2,753,999

In connection with the issuance of the Company's Series E convertible preferred stock in

September

2014

through

January

2015,

the Company issued warrants to purchase an aggregate of up to the number of shares of common stock equal to

50%

of the number of shares of the Company's Series E Convertible preferred stock purchased by such investor, all of which expired on

September

2019.

February

16,

2018,

in connection with the Company's completed public offering of Series B preferred stock, the Company issued

two

series of warrants that together provide for the purchase, by the investors in that offering, of an aggregate of

1,797,900

shares of common stock (the “Series B Warrants”). Each share of Series B preferred stock is accompanied by

one

warrant to purchase

one

share of common stock at

$20.00

per share that expires on the

seventh

anniversary of the date of issuance to purchase up to

shares of common stock and

one

warrant that expires on the earlier of (i) the

seventh

anniversary of the date of issuance or (ii) the

60th

calendar day following the receipt and announcement of FDA clearance of the Company's Pantheris below-the-knee device (or the same or similar product with a different name) to purchase up to

shares of common stock; provided, however, if at any time during such

-day period the volume weighted average price for any trading day is less than the then effective exercise price, the termination date shall be extended to the

seven

year anniversary of the initial exercise date. FDA clearance of Pantheris SV was received in

April 2019,

triggering this

-day period. During the entire

-day period following clearance, the volume weighted average price was less than the then effective exercise price. As such, all Series

warrants are currently deemed to expire on the

seventh

anniversary of the date of issuance. The Company determined that the Series B Warrants should be classified as equity. As of

September 30, 2020,

Series B Warrants to purchase an aggregate of

1,768,850

shares of common stock remain outstanding.

July 13, 2018,

in connection with the Company's completed public offering of

216,618

shares of common stock, the Company issued warrants that provide for the purchase of

108,309

shares of common stock at

$15.80

per share. Each share of common stock is accompanied by

one

half of

one

warrant that expires on the

third

anniversary of the date of issuance. The Company determined that these warrants should be classified as equity. As of

September 30, 2020,

all of these warrants remain outstanding.

November 1, 2018,

in connection with the Company's completed public offering of

728,500

shares of common stock and

8,586

shares of Series C convertible preferred stock, the Company issued warrants to provide for the purchase of

2,875,000

shares of common stock. Each share of common stock is accompanied by

one

warrant to purchase

one

share of common stock at

$4.00

per share. These warrants expire on the

5th

anniversary of the date of issuance. Each share of preferred stock is accompanied by

one

warrant to purchase

250

shares of common stock. The Company determined that the warrants should be classified as equity. During the year ended

December 31, 2019,

warrants were exercised for an aggregate of

1,998,079

shares of common stock with proceeds to the Company of approximately

$8.0

million. As of

September 30, 2020

and

December 31, 2019,

warrants to purchase an aggregate of

876,840

shares of common stock were outstanding.

As of

September 30, 2020

and

December

31,

2019,

warrants to purchase an aggregate of

2,753,999

shares of common stock were outstanding.

Stock Plans

January

2015,

the Board of Directors adopted, and the Company's stockholders approved the

2015

Equity Incentive Plan (

“2015

Plan”). The

2015

Plan replaced the

2009

Stock Plan (the

“2009

Plan”) which was terminated immediately prior to consummation of the Company's IPO (collectively the “Plans.)” The

2015

Plan provides for the grant of incentive stock options (“ISOs”) to employees and for the grant of non-statutory stock options (“NSOs”), restricted stock, RSUs, stock appreciation rights, performance units and performance shares to employees, directors and consultants. Initially a total of

3,300

shares of common stock were reserved for issuance pursuant to the

2015

Plan. The shares reserved for issuance under the

2015

Plan included shares reserved but

not

issued under the

2009

Plan, plus any share awards granted under the

2009

Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. In addition, the number of shares available for issuance under the

2015

Plan includes an automatic annual increase on the

first

day of each fiscal year beginning in fiscal

2016,

equal to the lesser of

4,225

shares,

5.0%

of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year or an amount as determined by the Board of Directors. In addition, during fiscal

2018,

the Board of Directors approved an additional

300,000

shares of common stock for issuance under the

2015

Plan. The Company's stockholders approved this increase on

June 8, 2018.

June 19, 2019,

the Company's stockholders approved an additional

800,000

increase to the

2015

Plan. As of

September 30, 2020,

202,544

shares were available for grant under the

2015

Plan.

Pursuant to the Plans, ISOs and NSOs

may

be granted with exercise prices at

not

less than

100%

of the fair value of the common stock on the date of grant and the exercise price of ISOs granted to a stockholder, who, at the time of grant, owns stock representing more than

10%

of the voting power of all classes of the stock of the Company, shall be

not

less than

110%

of the fair market value per share of common stock on the date of grant. The Company's Board of Directors determines the vesting schedule of the options. Options granted generally vest over

four

years and expire

ten

years from the date of grant.

Stock option activity under the Plans is set forth below:

	Number of Shares (in thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Intri n sic Value (in thousands)
Balance at December 31, 2019		7,401		$	1,309.47		6.81	$	—
Granted		—		$	—
Exercised		—		$	—
Expired		(549	)	$	2,138.72
Forfeited		(26	)	$	820.00
Balance at September 30, 2020		6,826		$	1,241.89		6.05	$	—

Exercisable at September 30, 2020		6,781		$	1,244.72		6.05	$	—

Vested and expected to vest at September 30, 2020		6,826		$	1,241.89		6.05	$	—

There were

options granted or exercised during the

nine

months ended

September 30, 2020

2019.

As of

September 30, 2020,

there was approximately

$11,000

of remaining unamortized stock-based compensation expense associated with unvested stock options, which will be expensed over a weighted average remaining service period of approximately

0.4

years. Because of the Company's net operating losses, the Company did

not

realize any tax benefits from share-based payment arrangements for the

three

and

nine

months ended

September 30, 2020

and

2019.

The Company's RSUs generally vest annually over

three

four

years in equal increments. The Company measures the fair value of RSUs using the closing stock price of a share of the Company's common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSU activity is presented below:

	Number of Shares			Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term
Awards outstanding at December 31, 2019		908,504		$	4.09		1.81
Awarded		47,500		$	0.58		—
Released		(363,085	)	$	4.58		—
Forfeited		(152,727	)	$	3.04		—
Awards outstanding at September 30, 2020		440,192		$	3.67		1.20

As of

September 30, 2020,

there was approximately

$1.5

million of remaining unamortized stock-based compensation expense associated with RSUs, which will be expensed over a weighted average remaining service period of approximately

1.2

years. The

440,192

outstanding non-vested and expected to vest RSUs have an aggregate fair value of approximately

$0.1

million. The Company used the closing market price of

$0.32

per share at

September 30, 2020,

to determine the aggregate fair value for the RSUs outstanding at that date. For the

nine

months ended

September 30, 2020

and

2019,

the fair value of RSUs vested was approximately

$134,000

and

$110,000,

respectively.

2018

Officer and Director Share Purchase Plan

August 22, 2018,

the Board of Directors of the Company approved the adoption of an Officer and Director Share Purchase Plan (“ODPP”), which allows executive officers and directors to purchase shares of our common stock at fair market value in lieu of salary or, in the case of directors, director fees. Eligible individuals

may

voluntarily participate in the ODPP by authorizing payroll deductions or, in the case of directors, deductions from director fees for the purpose of purchasing common stock. The Board of Directors authorized

20,000

shares to be made available for purchase by officers and directors under the ODPP. Effective on

August 28, 2019

and

March 10, 2020,

the Board of Directors approved an additional

40,000

and

125,000

shares, respectively, to be made available under the ODPP. Common stock issued under the ODPP during the

nine

months ended

September 30, 2020

totaled

53,034

shares. As of

September 30, 2020,

there were

92,170

shares reserved for issuance under the ODPP.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

Stock-Based Compensation

Total noncash stock-based compensation expense relating to the Company's stock options and RSUs recognized during the

three

and

nine

months ended

September

30,

2020

and

2019,

is as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	20 20		201 9		20 20		201 9
Cost of revenues	$	36	$	40	$	97	$	128
Research and development expenses		116		122		354		339
Selling, general and administrative expenses		232		361		709		1,065
	$	384	$	523	$	1,160	$	1,532

XML 25 R15.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

three

and

nine

months ended

September 30, 2020

are

not

necessarily indicative of results to be expected for the year ending

December

31,

2020,

or for any other interim period or for any future year. The

December

31,

2019

-K for the fiscal year ended

December

31,

2019,

which was filed with the SEC on

March

2020.

The Company's significant accounting policies are more fully described in Note

of the Notes to Financial Statements included in the Company's Annual Report on Form

-K for the year ended

December

31,

2019.

June 19, 2019,

the Company's Board of Directors approved an amendment to the Company's amended and restated certificate of incorporation to effect a

-for-

reverse stock split of the Company's common stock. The reverse stock split became effective on

June 21, 2019.

The par values of the common stock and convertible preferred stock were

not

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

not

readily apparent from other sources. Although these estimates are based on the Company's knowledge of current events and actions it

may

undertake in the future, actual results

may

ultimately materially differ from these estimates and assumptions.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value of Financial Instruments

The Company has evaluated the estimated fair value of its financial instruments as of

September 30, 2020

and

December 31, 2019.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of

three

September 30, 2020

and

December 31, 2019,

unrealized gains and losses as of

September 30, 2020

and

December 31, 2019.

Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method.

Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block]

Concentration of Credit Risk, and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.

The Company's policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at

one

financial institution. The counterparties to the agreements relating to the Company's investments consist of financial institutions of high credit standing.

September 30, 2020

and

December 31, 2019.

The Company's accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At

September 30, 2020

and

December 31, 2019,

customer represented

10%

or more of the Company's accounts receivable. For the

three

and

nine

months ended

September 30, 2020

and

2019,

there were

customers that represented

10%

or more of revenues. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company's financial position and results of operations.

The Company is subject to certain risks, including that its devices

may

not

be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be

not

limited to, new technological innovations, dependence upon

third

Existing or future devices developed by the Company

may

be necessary to adjust operations to align with the Company's currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this

may

have a material adverse impact on the Company.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

The Company's revenues are derived from (

) sale of Lightboxes, (

) sale of disposables, which consist of catheters and accessories, and (

three

six

The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”)

842,

Leases

and ASU

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

)

. The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.

not

reasonably predictable. Accordingly, the Company concluded the embedded lease did

not

provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do

not

allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.

Cost of Goods and Service [Policy Text Block]

Cost of Revenues

Standard Product Warranty, Policy [Policy Text Block]

Product Warranty Costs

The Company typically offers a

one

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Beginning balance	$	221		$	215		$	215		$	272
Warranty provision		13			34			124			70
Usage/Release		(35	)		(35	)		(140	)		(128	)
Ending balance	$	199		$	214		$	199		$	214

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share Attributable to Common Stockholders

September 30, 2020

and

2019,

there were

Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	20 20			201 9			20 20			201 9
Net loss attributable to common stockholders	$	(5,492	)	$	(5,518	)	$	(17,277	)	$	(17,014	)
Weighted average common stock outstanding, basic and diluted		69,459			7,900			37,246			6,189
Net loss per share attributable to common stockholders, basic and diluted	$	(0.08	)	$	(0.70	)	$	(0.46	)	$	(2.75	)

	Three Months Ended September 30,				Nine Months Ended September 30,
	20 20		201 9		20 20		2019
Common stock warrants equivalents		2,753,999		2,757,741		2,753,999		3,346,568
Common stock options		6,903		7,444		7,100		7,596
Convertible preferred stock		48,503		44,923		48,503		45,046
Unvested restricted stock units		749,512		371,651		820,743		316,575
		3,558,917		3,181,759		3,630,345		3,715,785

Segment Reporting, Policy [Policy Text Block]

Segment and Geographical Information

The Company operates and manages its business as

one

three

months ended

September 30, 2020

and

2019,

94%

and

96%,

respectively, of the Company's revenues were in the United States. For both the

nine

months ended

September 30, 2020

and

2019,

94%

of the Company's revenues were in the United States based on the shipping location of the external customer.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Recently adopted accounting standards

June 2016,

the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)

2016

13,

Financial Instruments – Credit Losses

first

quarter of

2020.

The adoption of this standard did

not

have a material impact on the Company's condensed financial statements.

Recent accounting standards

not

yet adopted

December 2019,

the FASB issued ASU

2019

12,

Income Taxes (Topic

740

): Simplifying the Accounting for Income Taxes

first

quarter of

2021

and early adoption is permitted. This new standard is

not

expected to have a material impact on the Company's condensed financial statements.

August 2020,

the FASB issued ASU

2020

06,

Debt—Debt with Conversion and Other Options (Subtopic

470

) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic

815

): Accounting for Convertible Instruments and Contracts in an Entity's Own

Equity

not

815

or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the

first

quarter of

2022

and early adoption is permitted. This new standard is

not

expected to have a material impact on the Company's condensed financial statements.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Schedule of Product Warranty Liability [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Beginning balance	$	221		$	215		$	215		$	272
Warranty provision		13			34			124			70
Usage/Release		(35	)		(35	)		(140	)		(128	)
Ending balance	$	199		$	214		$	199		$	214

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	20 20			201 9			20 20			201 9
Net loss attributable to common stockholders	$	(5,492	)	$	(5,518	)	$	(17,277	)	$	(17,014	)
Weighted average common stock outstanding, basic and diluted		69,459			7,900			37,246			6,189
Net loss per share attributable to common stockholders, basic and diluted	$	(0.08	)	$	(0.70	)	$	(0.46	)	$	(2.75	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	20 20		201 9		20 20		2019
Common stock warrants equivalents		2,753,999		2,757,741		2,753,999		3,346,568
Common stock options		6,903		7,444		7,100		7,596
Convertible preferred stock		48,503		44,923		48,503		45,046
Unvested restricted stock units		749,512		371,651		820,743		316,575
		3,558,917		3,181,759		3,630,345		3,715,785

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 4 - Inventories (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	September 30,		December 31,
	20 20		201 9
Raw materials	$	1,403	$	1,426
Work-in-process		765		596
Finished products		1,826		1,890
Total inventories	$	3,994	$	3,912

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 5 - Borrowings (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Schedule of Debt [Table Text Block]

Year Ending December 31,
2020 (remaining three months of the year)	$	—
2021		3,400
2022		6,266
2023		4,518
		14,184
Less: Amount of PIK additions and final facility fee to be accreted subsequent to September 30, 2020		(3,520	)
Less: Amount representing debt financing costs		(461	)
Borrowings, as of September 30, 2020	$	10,203

Year Ending December 31,
2020 (remaining three months of the year)	$	264
2021		1,575
2022		521
		2,360
Less: Amount of interest to be accreted subsequent to September 30, 2020		(20	)
Borrowings, as of September 30, 2020	$	2,340

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Year Ending December 31,
2020 (remaining three months of the year)	$	274
2021		1,123
2022		1,162
2023		1,203
2024		1,138
		4,900
Less: Imputed interest		(630	)
Leasehold liability as of September 30, 2020	$	4,270

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Total Outstanding and Exercisable		Underlying Shares of Common Stock		Exercise Price per Share		Expiration Date
Series 1 Warrants issued in February 2018 financing		8,979,000		897,900	$	20.00	February 2025
Series 2 Warrants issued in February 2018 financing		8,709,500		870,950	$	20.00	February 2025
Warrants issued in July 2018 financing		1,083,091		108,309	$	15.80	July 2021
Warrants issued in November 2018 financing		8,768,395		876,840	$	4.00	November 2023
Total		27,539,986		2,753,999

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Shares (in thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Intri n sic Value (in thousands)
Balance at December 31, 2019		7,401		$	1,309.47		6.81	$	—
Granted		—		$	—
Exercised		—		$	—
Expired		(549	)	$	2,138.72
Forfeited		(26	)	$	820.00
Balance at September 30, 2020		6,826		$	1,241.89		6.05	$	—

Exercisable at September 30, 2020		6,781		$	1,244.72		6.05	$	—

Vested and expected to vest at September 30, 2020		6,826		$	1,241.89		6.05	$	—

Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

	Number of Shares			Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term
Awards outstanding at December 31, 2019		908,504		$	4.09		1.81
Awarded		47,500		$	0.58		—
Released		(363,085	)	$	4.58		—
Forfeited		(152,727	)	$	3.04		—
Awards outstanding at September 30, 2020		440,192		$	3.67		1.20

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	20 20		201 9		20 20		201 9
Cost of revenues	$	36	$	40	$	97	$	128
Research and development expenses		116		122		354		339
Selling, general and administrative expenses		232		361		709		1,065
	$	384	$	523	$	1,160	$	1,532

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 1 - Organization (Details Textual) - USD ($)													1 Months Ended			2 Months Ended				9 Months Ended
Note 1 - Organization (Details Textual) - USD ($)	Sep. 01, 2020	Aug. 25, 2020	Aug. 11, 2020	Aug. 06, 2020	Jul. 09, 2020	Jun. 26, 2020	May 06, 2020	Apr. 30, 2020	Apr. 23, 2020	Jan. 31, 2020	Aug. 26, 2019	Feb. 16, 2018	Apr. 30, 2020	Jan. 31, 2020	Aug. 30, 2019	Sep. 30, 2020	Jul. 31, 2020	May 31, 2020	May 31, 2019	Sep. 30, 2020	Dec. 31, 2019	Mar. 07, 2019
Retained Earnings (Accumulated Deficit), Ending Balance																$ (362,711,000)				$ (362,711,000)	$ (348,335,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance																25,326,000				$ 25,326,000	$ 10,943,000
Proceeds from Issuance or Sale of Equity, Net												$ 15,500,000
Common Stock Offering, Maximum Aggregate Value																						$ 50
COVID 19 [Member]
Reduction of Non-manufacturing Employees Salaries																				20.00%
Reduction of Hours Worked by Manufacturing Workers, Percentage																				20.00%
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total									$ 2,300,000				$ 2,300,000
April and May 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Net																			$ 8,000,000
August 2019 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net											$ 3,800,000				$ 3,800,000
Stock Issued During Period, Shares, New Issues (in shares)											3,813,559
Share Price (in dollars per share)											$ 1.18
January 2020 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net										$ 3,900,000				$ 3,900,000
Stock Issued During Period, Shares, New Issues (in shares)										6,428,572
Share Price (in dollars per share)										$ 0.70				$ 0.70
April and May 2020 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net																		$ 3,000,000
June and July 2020 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net																	$ 5,500,000
August and September 2020 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net																$ 11,300,000
April 2020 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)								12,600,000
Share Price (in dollars per share)								$ 0.25					$ 0.25
May 2020 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net							$ 3,000,000
Stock Issued During Period, Shares, New Issues (in shares)							1,890,000
June 2020 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)						20,000,000
Share Price (in dollars per share)						$ 0.27
July 2020 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net					$ 5,500,000
Stock Issued During Period, Shares, New Issues (in shares)					3,000,000
Share Price (in dollars per share)					$ 0.70
August 2020 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net			$ 6,200,000
Stock Issued During Period, Shares, New Issues (in shares)		11,063,830	2,368,421	15,789,474
Share Price (in dollars per share)		$ 0.47		$ 0.38
September 2020 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net	$ 5,100,000
Stock Issued During Period, Shares, New Issues (in shares)	1,000,000

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
	Jun. 19, 2019	Sep. 30, 2020 USD ($)	Sep. 30, 2019	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 shares	Dec. 31, 2019 USD ($)
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax, Total \| $		$ 0		$ 0		$ 0
Warranty Period (Year)				1 year
Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation (in shares) \| shares				0	0
Number of Reportable Segments				1
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| UNITED STATES
Concentration Risk, Percentage		94.00%	96.00%	94.00%	94.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Beginning balance	$ 221	$ 215	$ 215	$ 272
Warranty provision	13	34	124	70
Usage/Release	(35)	(35)	(140)	(128)
Ending balance	$ 199	$ 214	$ 199	$ 214

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net loss attributable to common stockholders	$ (5,492)	$ (5,518)	$ (17,277)	$ (17,014)
Weighted average common stock outstanding, basic and diluted (in shares)	69,459	7,900	37,246	6,189
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.08)	$ (0.70)	$ (0.46)	$ (2.75)

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities (in shares)	3,558,917	3,181,759	3,630,345	3,715,785
Common Stock Warrants [Member]
Antidilutive Securities (in shares)	2,753,999	2,757,741	2,753,999	3,346,568
Common Stock Options [ member]
Antidilutive Securities (in shares)	6,903	7,444	7,100	7,596
Preferred Stock [Member]
Antidilutive Securities (in shares)	48,503	44,923	48,503	45,046
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)	749,512	371,651	820,743	316,575

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure	$ 0	$ 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure	0	0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 4 - Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Raw materials	$ 1,403	$ 1,426
Work-in-process	765	596
Finished products	1,826	1,890
Total inventories	$ 3,994	$ 3,912

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 5 - Borrowings (Details Textual)			1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
Note 5 - Borrowings (Details Textual)	Apr. 23, 2020 USD ($)	Feb. 14, 2018 USD ($)	Apr. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 02, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 15, 2016 USD ($)	Sep. 22, 2015 USD ($)
Line of Credit Facility, Maximum Borrowing Capacity														$ 50,000,000
Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months											$ 10,000,000
Debt Instrument, Covenant, Compliance Target Minimum Revenue Second Year											12,000,000
Debt Instrument, Covenant Compliance Target Minimum Revenue Third Year											$ 15,000,000
Debt Instrument, Redemption Initial Prepayment Premium Percentage														5.00%
Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage														1.00%
Debt Instrument, Redemption Prepayment Premium Percentage after Fifth Year														0.00%
Debt Instrument, Financing Fee Percentage														1.50%
Debt Instrument, Final Facility Fee Percentage														15.00%
Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum														$ 3,500,000
Debt Instrument, Covenant Compliance Prepayment Multiplier for Revenue Shortfall														2
Paycheck Protection Program CARES Act [Member]
Interest Expense, Debt, Total				$ 6,000			$ 6,000
Proceeds from Issuance of Long-term Debt, Total	$ 2,300,000		$ 2,300,000
CRG [Member] \| Loan Agreement [Member]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total				461,000			461,000					$ 588,000		$ 1,300,000
Amortization of Debt Discount (Premium)				42,000	$ 42,000		127,000	$ 127,000
Interest Expense, Debt, Total				$ 427,000	$ 377,000		$ 1,200,000	$ 1,100,000
CRG [Member] \| Loan Agreement [Member] \| Forecast [Member]
Debt Instrument, Periodic Payment, Principal						$ 1,400,000
Debt Instrument, Periodic Payment, Total						$ 2,700,000			$ 2,700,000	$ 5,500,000
CRG [Member] \| Loan Agreement [Member] \| Series A Preferred Stock Purchase Agreement with CRG [Member]
Debt Conversion, Original Debt, Amount		$ 38,000,000
Debt Conversion, Fees and Prepayment Premium Amount		$ 3,800,000
Debt Instrument, Interest Rate, Stated Percentage														12.50%
CRG [Member] \| Loan Agreement [Member] \| First Tranche, Borrowed on September 22, 2015 [Member]
Debt Instrument, Face Amount														$ 30,000,000
CRG [Member] \| Loan Agreement [Member] \| Second Tranche, Borrowed on June 15, 2016 [Member]
Debt Instrument, Face Amount													$ 10,000,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 5 - Borrowings - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
2020 (remaining three months of the year)	$ 274
Borrowings, as of September 30, 2020	11,632	$ 8,967
Paycheck Protection Program CARES Act [Member]
2020 (remaining three months of the year)	264
2021	1,575
2022	521
Long-term Debt, Total	2,360
Borrowings, as of September 30, 2020	2,340
Less: Amount of interest to be accreted subsequent to September 30, 2020	(20)
CRG [Member] \| Loan Agreement [Member]
2020 (remaining three months of the year)
2021	3,400
2022	6,266
2023	4,518
Long-term Debt, Total	14,184
Less: Amount of PIK additions and final facility fee to be accreted subsequent to September 30, 2020	(3,520)
Less: Amount representing debt financing costs	(461)
Borrowings, as of September 30, 2020	$ 10,203

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)		3 Months Ended		9 Months Ended
	Dec. 01, 2017	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Apr. 01, 2019	Jan. 01, 2019
Operating Lease, Right-of-Use Asset		$ 4,269,000		$ 4,269,000		$ 4,856,000	$ 6,000,000
Lessee, Operating Lease, Term of Contract (Year)							5 years
Lessee, Operating Lease, Liability, Payments, Due, Total		4,900,000		4,900,000			$ 5,800,000
Lessee, Operating Lease, Discount Rate							6.50%
Operating Lease, Expense, Excluding Maintenance Fee and Other Expense, Monthly		105,000
Operating Lease, Expense		314,000	$ 314,000	942,000	$ 1,100,000
Operating Lease, Right-of-Use Asset, Amortization Expense		242,000	$ 225,000	718,000	$ 444,000
Prepaid Rent		331,000		331,000
Purchase Commitment [Member]
Purchase Obligation, Total		$ 1,100,000		$ 1,100,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset								$ 1,800,000
Facility Sublease [Member]
Operating Leases Sublease Expiration Prior to Base Lease (Day)	15 days
Operating Leases, Monthly Minimum Sublease Rental Payments Receivable Final	$ 82,410

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies - Future Operating Lease Payments (Details) - USD ($)	Sep. 30, 2020	Apr. 01, 2019
2020 (remaining three months of the year)	$ 274,000
2021	1,123,000
2022	1,162,000
2023	1,203,000
2024	1,138,000
Lessee, Operating Lease, Liability, to be Paid, Total	4,900,000	$ 5,800,000
Less: Imputed interest	(630,000)
Leasehold liability as of September 30, 2020	$ 4,270,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Details Textual) - USD ($)						1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 19, 2019	Nov. 01, 2018	Jul. 13, 2018	Feb. 16, 2018	Feb. 14, 2018	Dec. 31, 2019	Jan. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Mar. 10, 2020	Aug. 28, 2019	Aug. 22, 2018	Jan. 31, 2015
Preferred Stock, Shares Authorized (in shares)						5,000,000		5,000,000		5,000,000		5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.001		$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total (in shares)						48,503		48,503		48,503		48,503
Preferred Stock, Shares Outstanding, Ending Balance (in shares)						48,503		48,503		48,503		48,503
Proceeds from Issuance or Sale of Equity, Net				$ 15,500,000
Common Stock, Shares Authorized (in shares)						100,000,000		100,000,000		100,000,000		100,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.001		$ 0.001		$ 0.001		$ 0.001
Common Stock, Shares, Issued, Total (in shares)						10,364,663		84,921,079		84,921,079		10,364,663
Common Stock, Shares, Outstanding, Ending Balance (in shares)						10,364,663		84,921,079		84,921,079		10,364,663
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						2,753,999		2,753,999		2,753,999		2,753,999
Proceeds from Warrant Exercises											$ 7,993,000
Class of Warrant or Right, Outstanding (in shares)								27,539,986		27,539,986
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)										4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)										0	0
Share-based Payment Arrangement, Expense, Tax Benefit								$ 0	$ 0	$ 0	$ 0
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								11,000		$ 11,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										146 days
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								$ 1,500,000		$ 1,500,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										1 year 73 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)						908,504		440,192		440,192		908,504
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value								$ 0.10		$ 0.10
Share Price (in dollars per share)								$ 0.32		$ 0.32
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value										$ 134,000	$ 110,000
Minimum [Member] \| Common Stock Options [ member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										100.00%
Minimum [Member] \| Common Stock Options [ member] \| Stockholder with More than 10% Voting Power [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										110.00%
Minimum [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)										3 years
Maximum [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)										4 years
The 2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)																	3,300
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Reserved for Issuance, Annual (in shares)																	4,225
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Reserved for Issuance, Percentage on Shares Outstanding																	5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	800,000												300,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)								202,544		202,544
Officer and Director Share Purchase Plan [Member]
Common Stock, Shares, Issued, Total (in shares)								53,034		53,034
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)														125,000	40,000	20,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)								92,170		92,170
Common Stock Warrants, Issued with Series E Convertible Preferred Stock [Member]
Class of Warrant or Right, Securities Called as Percentage of Convertible Preferred Stock Shares																	50.00%
Common Stock Warrants, Issued with Series B Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				1,797,900				1,768,850		1,768,850
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant One [Member]
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock (in shares)				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 20
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date (Year)				7 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				50
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant Two [Member]
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock (in shares)				1
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date (Year)				7 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				50
Class of Warrant or Right, Expiration Period Following FDA Clearance (Day)				60 days
Common Stock Warrants [Member] \| Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			108,309
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 15.80
Common Stock Warrants [Member] \| November Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,875,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercised (in shares)												1,998,079
Proceeds from Warrant Exercises												$ 8,000,000
Class of Warrant or Right, Outstanding (in shares)						876,840		876,840		876,840		876,840
Preferred Stock Warrants [Member] \| November Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		250
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		728,500							3,813,559
Common Stock [Member] \| Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member]
Stock Issued During Period, Shares, New Issues (in shares)			216,618
Common Stock [Member] \| November Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		728,500
Conversion of Series B Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)												1,523
Conversion of Stock, Shares Issued (in shares)												380,750
Conversion of Series C Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)											542,500
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								48,325		48,325
Dividends, Preferred Stock, Total								$ 967,000	$ 895,000	$ 2,900,000	$ 2,700,000
Series A Preferred Stock [Member] \| CRG [Member]
Preferred Stock Dividends, Shares (in shares)						3,580	2,945
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)						178		178		178		178
Stock Issued During Period, Shares, New Issues (in shares)				17,979
Preferred Stock, Convertible, Conversion Price (in dollars per share)										$ 0.25	$ 0.25
Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)									2,170		2,170
Stock Issued During Period, Shares, New Issues (in shares)		8,586
Proceeds from Issuance or Sale of Equity, Net		$ 10,200,000
Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] \| Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares of Common Stock Issuable on Conversion (in shares)					2,090,000
Preferred Stock, Dividend Rate, Percentage					8.00%
CRG [Member] \| Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member]
Debt Conversion, Original Debt, Amount					$ 38,000,000
Debt Conversion, Fees and Prepayment Premium Amount					3,800,000
Debt Conversion, Converted Instrument, Amount					$ 41,800,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholder's Equity - Outstanding Warrants (Details) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Total outstanding and exercisable (in shares)	27,539,986
Underlying shares of common stock (in shares)	2,753,999	2,753,999
Series 1 February 2018 Warrants [Member]
Total outstanding and exercisable (in shares)	8,979,000
Underlying shares of common stock (in shares)	897,900
Exercise price per share (in dollars per share)	$ 20
Series 2 February 2018 Warrants [Member]
Total outstanding and exercisable (in shares)	8,709,500
Underlying shares of common stock (in shares)	870,950
Exercise price per share (in dollars per share)	$ 20
November 2018 Warrants [Member]
Total outstanding and exercisable (in shares)	1,083,091
Underlying shares of common stock (in shares)	108,309
Exercise price per share (in dollars per share)	$ 15.80
July 2018 Warrants [Member]
Total outstanding and exercisable (in shares)	8,768,395
Underlying shares of common stock (in shares)	876,840
Exercise price per share (in dollars per share)	$ 4

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Stock Option Activity (Details) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Options (in shares)	7,401
Options, weighted average exercise price (in dollars per share)	$ 1,309.47
Balance, weighted average remaining contractual life (Year)	6 years 18 days	6 years 295 days
Expired (in shares)	(549)
Expired, weighted average exercise price (in dollars per share)	$ 2,138.72
Forfeited (in shares)	(26)
Forfeited, weighted average exercise price (in dollars per share)	$ 820
Options (in shares)	6,826	7,401
Options, weighted average exercise price (in dollars per share)	$ 1,241.89	$ 1,309.47
Exercisable (in shares)	6,781
Exercisable, weighted average exercise price (in dollars per share)	$ 1,244.72
Exercisable, weighted average remaining contractual life (Year)	6 years 18 days
Vested and expected to vest (in shares)	6,826
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 1,241.89
Vested and expected to vest, weighted average remaining contractual life (Year)	6 years 18 days

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Restricted Stock Units Award Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Awards outstanding, Shares (in shares)	908,504
Awards outstanding, Weighted grant date fair value (in dollars per share)	$ 4.09
Awards outstanding, Weighted average remaining contractual term (Year)	1 year 73 days	1 year 295 days
Awarded, Shares (in shares)	47,500
Awarded, Weighted grant date fair value (in dollars per share)	$ 0.58
Released, Shares (in shares)	(363,085)
Released, Weighted grant date fair value (in dollars per share)	$ 4.58
Forfeited, Shares (in shares)	(152,727)
Forfeited, Weighted grant date fair value (in dollars per share)	$ 3.04
Awards outstanding, Shares (in shares)	440,192	908,504
Awards outstanding, Weighted grant date fair value (in dollars per share)	$ 3.67	$ 4.09

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Allocated Share-based Compensation Expense	$ 384	$ 523	$ 1,160	$ 1,532
Cost of Sales [Member]
Allocated Share-based Compensation Expense	36	40	97	128
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	116	122	354	339
Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense	$ 232	$ 361	$ 709	$ 1,065

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

K3 7;!F1Q2GOO3 MDF'0QB;8OSJ" 7)>XV$/B_A4@B"A5<31: M,AW:C.FH#\\4V91Y X0](.8@0@(;JR(O*09M]OI(HVA-'590^;!"W&J\H\#Q M@>NXOGA-&9#K$L='OOC@ X*GI*,T#[JJ:F8SB!_V$:*.^*T)#!T1P)3 MQ]'T]MM,!#)Y(*Y-B.HMJ9) T!W?00&'98I 4/EVCC2]&?+5-V5H0 'VH("A MI Y43QVV>E-#;[-%;TGEGIO(ZP=P=4DZ]ZJQ5,U.V;M3?>]N@%CI/;0I65,- M/07ZZ\ 5MQ],N1O4N:M"4S;S5-_,MZ-5>F-M4##UUHPI0WT*G'Y0!XL;X+5B MU7<[2VKB;'7X44M3G&:''X"8GE0Y)25P&A]^U$=KZO##D0\_)%(%R("D"I"# M214@")&JWL9W2N7?+'@>)H\1;_3&[('KV1\\CD*R_+*^Y8VK/35:&/,[F(RT?F&;YG^+'>\@E]64FV9@5NU MGNB=XJRHE;;EA$RGV63+1#6ZOJR?/:GK2[DWI:CXDT)ZO]TR]?.6E_+U:H1' M;P^^BO7&V >3Z\L=6_-G;K[MGA3<3;I1"K'EE1:R0HJOKD8W^.(QJ15JB;\$ M?]4'U\B:LI3RN[WY4ER-IA81+WEN[! ,_KWP.UZ6=B3 \4\[Z*B;TRH>7K^- M_E@;#\8LF>9WLOQ;%&9S-9J/4,%7;%^:K_+U/[PU*+7CY;+4]5_TVLI.1RC? M:R.WK3(@V(JJ^<]^M(XX4(!Q_ JD52!#A22@0%L%>NX,2:N0G#M#VBJD0X4L MH)"U"EGM^\99M:?OF6'7ETJ^(F6E831[42]7K0T.%I6-K&>CX%N;Z3E8% MQ DOT+-AAD/,&(WD"MTQO4&/$'<:??A6L7TA#"\^HC'Z]GR//OSV$?V&1(7^ MW,B]9E6A+R<&P-@A)WD[\6TS,0E,3-'OLC(;C1X 0.'1OX_K+T[I/\;U,8D, M, $O=JXD;ZZ\)=$1G_GN,Z+33XA,R=0#Z.YL=;SP^>/79G_XM=D?X^KW/ =U M[%,_\B7MPI+6X]%06-KP6]7AMU)RBR"3*F9$M6Y2D3""Z\@T23=-4D^3!*;Y M U)W*;4W?!O-K-:T^?GE>IRD)+V%/^#/-+L;".!#G)9Y:+DJ&JMMT_M=6Z=OK>Y +:VS^,7$9=G M'9HLZO)[#@R8"];P2E4@MI7*B'_K![ZP;X9+#YR2.8[SR*2)WVNS#N&*:X/X M#PN4^T N/"#Q8@#2%5ID 8QXVE/D-(KR;L.J-;>;0MDZQ48#[!+$M.;>%6^' M"RUG@]0C-*;I+(#U@,YQ%.N3DB^B+ON@Z@1WYEPW<2J76I;<6#->(!5(Y630 M%CQV<-'%,!8\0O-I #KIH9,H]/^:#5>HDM6XCHD/:ZB+]<Q[#)XBLCAT]R*@VE)\QT3QEHG:S5.'9KY7"H"WR^>%[A+1 M&"]F0^@>J30$O.L9OM$L+DDDPZ!N2)CG 6 ]42$XTS41>2._0R&H\LN M8XJ'\#Q"),23N.<@'"'J*#,F@VCW"M'9S20=DE/1>1]/94M!/3Y/17I*8C$*>AI MK_(-LV$*E=).60>9GW7(\G_V8F<[$:^#HJ.^9^$]M#4/A7'/6B3.6E!9Y9P7 MK?,T@P;J?>:YA)4,ZRJ/# X![QF-Q!FMB]B=K0T+B-KE3_2A#=^/9X1!B]]E M+1>_A]EF@<*0],Q&9N\*W)6HH D[/W![IB)QICI>XJ54, ),XW>'2T:$4LO$+; =5OH$;1M$J%2+)F!:# 2O3*E6&7[,*YR MH0.1$)WY/1O5YQ@IT$]%$JS M9#Y8V:E9S+K89XZO==;U"YKDFR*AUV#1PSC>1K(L?3@N)*> MQMX=$]166+?7%Y857H N*G]=WHY\W(G1.1TB=\6@M0CU.[0G:QHGZ[L0UD]H MR=>BJJSO+='![I#>PAZ+'9L9T_?-$[?$3NY M+:8C%MZV0Q]B(BD=GN+=><1PDF2# N^>NB3O&>W!(^89[=$WZ9'WC_W55PTT MBY)N?S37E0?@)M]VC)U;T)[DZ8GS5FAQ^-MAZS.WAP/H!E(!A[2L(!E'BD:2MA) M7R,D\1KA2P7A9FG0OA%QT=='<_;WC2S[0SJH\I70-OIK$JX%$(."OP@5_7$4 M[UC,Q*TJDBQTYIKT5442KRK^A&I/KVR5L.3FE?.J.QYN.IKSVYMVHJ.75\.S M$8\,=6R8'+S,WG*UKC\[T*@^0VI>('9/NT\;;NH7^H/GM_CB#GN>W^.+A^;# MA7[XYCN*WYD"QM.PL"N8:OIY!NY6S:<)S8V1N_I5^E(:([?UY88SJ+:L /R^ MDM*\W=@)N@]$KO\/4$L#!!0 ( $B+:E&@Y U+K04 "\, 8 >&PO M=V]R:W-H965T&UL?5=M;]LV$/XK!\_;,D"3]6+93IL$L-.F M2]$V1IQN'X9]H"7*(BJ1*DG9S7[][J@7.VL:((E$\NZYN^=>Q%PY$I7S.)2[R:FUIQE3JDJ)U$0S"85$W)T M=>'VUOKJ0C6V%)*O-9BFJIA^7/%2'2Y'X:C?N!>[PM+&Y.JB9CN^X?9SO=:X MF@PHF:BX-$))T#R_'"W#5ZLIR3N!/P4_F)-WH$BV2GVAQ6UV.0K((5[RU!(" MP\>>7_.R)"!TXVN'.1I,DN+I>X]^XV+'6+;,\&M5_B4R6UR.%B/(>,Z:TMZK MPQ^\BR0-L:JJE-&#RHAVR?[UO%PHK (?J 0=0J1\[LU MY+Q\PRR[NM#J )JD$8U>7*A.&YT3DI*RL1I/!>K9JT_*<@CA=[C3.R;%OXRX MNIA8A":!2=K!K%J8Z "LSGCW5GZ!+@U]1[]A%PPVL?XL"# M*(B"%_#B(<[8X<4OQ&G *K@1DLE4L!(VEEF.]67-"_C3 7_J\*<_PF>VT1Q4 M#GMK5=5,/KI5^/HW#QB\X24[,$1( ME:Z5[E /S("0_1;/< $?F4X+S$Q.

RG7Y'DAT$L2X55=,I=U!,"!57:<$5=H@:-M)C-W:O# Y"SMCTO! MMJ(45G"BP8E(F@%DN]'&T;WMZ/9=G,>R6F+$#3FXHPJ3&=.9@97"!YQUM-TL M-ZN!MV?E/]<9NCXH+#>?!_E/RLK8%,A:RATZO=2TZO1YR_70^1Z,XUGDSV$<)7[\ MC #DZ+"ELHRP-<8+6-9:E%B"CT32.>G[N-GL<)2Z'=HXA_=,-O@-:B'&$4W M>NTZ]H,G.,Z/Q$_@?8-,O6_7C$,2;,%/_K6M@#+Y&)"A$>3JA+&16ZVHN, M:@I_;"^)W3/<S=K,7'913\3+_^T:K7"=[F3U(B##22;4M.0TXS@4ED&;8C MTDMERVIA\8G%;)H\%ZG R@!64>4A]1I+ +!GTHY):4'$O9IXBD:JA9R>SG MEX\>9(U3<-W4;+&_L:318:PUH!M\3YP"O0K&G(=]DA0T-W98U^GUK#\V MGVN"9ME>T[%FA8,YQVD)6MPU?7K!X5$+W>:NR; P8%%X7?6723V'-/03]/[=\=)2C;1D,!) MVM+J9H32^!W!(!#2/E>];WC:[81>6Y[$[+K9EMB==WF.@9+R73]]YUY?UDF M14KIH-_Q/'%IL87 ,=/5$RKU=3_KU6)O$<9>DF ;A'ZX:+OCAF]UUPVTY0Y0 MN>^1UC4JO)DWC19>,H]@'/CSH&VE_VF[ S+M^N?8QV'DS8+ "X 9+$M=:L MHR'T%N?=&?7>=Y H3@Y1]T6S'C%R&@/BO&V1\PXR/CV$0X.!-XH?P MW(5CN:NJ ?=Q:.]SP^YP&UZVE\"C>'N5QEK9"1RU)<]1%<-/1J#; MZVF[P.GOKH1;9?&"Z5X+O-%S30)XGBN\+G4+,C#\CW#U'U!+ P04 " !( MBVI1#83HPZ(/ #%0 & 'AL+W=O[4\J)NZJL[;.3G7/[)Z>G-M^I M2MI1LU7I=#P^.ZVDKD^>/^5[5^;YTZ9UI:[5 ME1&VK2II#B]4V=P^.YFGE36OY7W/JQ2TC,6^N:DS&[TK7_J^\"W;H33@?/S!A&B9,66\OB+5\ M9U\_M0TM\+0:Q&%[Q5G@WE=$V'BNNFE+G6MFGIPZ":?II'H2\\$F#PA9B5^:VNVL>%47 MJAC./X7"2>MIU/K%]),+7JO]2,S&F9B.I^-/K#=+5ICQ>K-/6,$UXC7NI9U MKF4IKIUT"M[G["?6GZ?UY[S^_('U7TBK+9GVRBB+-:7WR+KXGW%O]ZI.R=> ME$W^X=_'#/]IN=.1."[ZW4XA(/FVLOZ0 +;6K:%=JH0>8-#JBVN-LD8-AE# M[.2-$FNE:@$0V$N#<;KFM4R!T0K^ZW;B?7:3E#2NV>N:#@;:5[(&'-0C&"/\$O >$(6?P />&HF;GP;4TH56)WAI#&QM,J%6NK4(!Y(+392FTZ9:+5+;Y;O;$]C77OLAWK> M>G D8)[EA6B2VQFE1 W?$]=TNM5:F12=4,N)EQ#N[T[\W>S^K1[TS2='EO%>WVE76Z8N^D+?F# M]+&!AT>/"R<%!R%;:'<(;A[]%#;YL]4P3._TR$TK^4$)E421KTJ+!+CWONIV M$F>[V= 1L[=4%!1^7%M7C:VI46A76.<#S4:=TR_$4R51+<6LVP/6_YHBRT_ MN=W!;Z$6.4BGF%$('ZP/E37D(SHJ6 +9)_\@;F39=H 51_SQY006XJD 3+ M@S)6L)L3'&NPXJTT1K)7[DUSHRW;@KRI:-JUV[1EA =2+%?Z1JY+Q=+5'7DQ M7S9KVY0V4O7-]A88P"7F<@!@=AQ9PA\V =@_C# YJB>4&KS(WR\JPL>?.N M-;5?-:AV@,+VGDUIKY;7Z.R&+>VT)>$D4]WM@1J4) UK&$'HYL6XV #<^3H M#0%)J=6-M_V:@DO:IN8-MT C'V&Y-GE;X:RQM/46CD$(^WHL(,?D)QY_:'OA MF./98X=K\#_(O;)Z$"[Y5:KG6I'66@I"@%3R4/_/]K0H_?:"K- M[++F3[5UIO7"WG5X LB$U;Q3T$YW75 4'HENXEIDWS[V=.M)UO((PAR!@TMI M=[P3OGB%V(2 C[1".%L-&UO&UQT('&"TU!A=L%<%\/2Q+N'+1F^A6@D3P&,( M!=B["?V^1"V OM!^_+O[)'T6]_9.\QP3BP<#ZT MUTY!]?!($['MEW_$;$G&@5NF'MA!HM[&UE.$'DTE^HGE$9UXZ$;$C4 MH#"]'!-!#N/ &;KDN98E$P@FLW;4/RGDHSTQHH/03-/\X3 B/Z13%C4G)Z>L MVM2?-=\06S06AY"58]Y&WP^)TJ&7C:=(6848L-_ E1K(BX$I;@Y=SX<' M%3;,T&OWB=0CD;&/(RI2"VJ@\XW_6!YN%5.S8B"^P?H[V#]!)1@)@8R_#U M?FKHG79_-6P&;K+11-;<%[KM\,B.@CC,6B#2-Z:IP$(('Y6/HYV2I=OE- U MIJSU7X'0A9PWI)2T0U_;>:Y6\V .33IA'.[%ERG-03D9?_L9%C,8VC]WF+G= MH+;D/!USIS+L3SC;HLV9.CS>(0VH+# V\DG:TQ7LCS#6?C^_YJB1X9RRTN7! M!QR>8G/8S:4/[H]Y6I#!.1@^&:,1D?V8 +U:EX0'B 4$0JM"DNDI78@U< "9 M%%/V>PPVMJ]E,"[ 8B1>:FM:3E^>"P6!@A)I)^[@%SKX(W8<8CUY %N,YV?1 MG$/M/!MTR+FV LE..M64M$N-':;NP@4QTCJOK&ZQU%2;FR0D;T?#;R3<"2! M'P O6)=C8'A(\'TZU4+=Z)SIW8$3(3R!_KB=-H5X=1=Q!CMK:9=I//[B4/?> MS&[@-]W_;S&(#N1(/CP6D)% MG-7+],[ZU[JM7'2T/\30"0C6,M$V/\VJC-UX:WF=BG?[;2#,C1F3Y%=Q&3>683.Q":WF)E!A[+:AK!A#6+=31&R'B%6S9[PF:6Q,^H8TETL M0(=.NKYK1,$YU XU9DOXQ%CWLN<051J42MS'F"@6##?8N"5E(1:D2I MZ(&1]\?@4(CD1>ZJZ4^8ABRBQ1?(DB0UBIT,%+R45T-AIE;(RN2#O=L;A/> M668:@LVDG(ULRMV8[9GZZ#X7XH525)]!R'])56. ,ZF<.>T(,"EU.JU7<# M(\4ZP-O)F\#[TJ=TEUNL57W,-D,3PG;';7N%TQ94GGT!F^VUUT BZD:PDI M@D^29<5^T<5UZA>)\_DT$S\KKOW>-",B G,Q!A>(H,TH?)ED 6EFL.G\"@M+\;J];',+/R][C)U_'H M'@%C?W^3K('V7 +_P#)R3_D@=OW\Y\X7!ZIN?T@V_X"X#"$"@%EOZ'7(? MZX)UJM?A5DV[W1& PO?6 M+:#SZK53PMHY%IC:!!.M6XJA)/#SR88"?A?+X[%S-3H2K&B'O$ M8#/@/T/DIM9-S4TS2H@QH6/MHJ0?W VBC %J2,H4(=]S^Y4AOHIVIZ$DZ;Q MD?@])MXH#*Y??EH2<=)HPI%,GP:OS-K**RWOZ M19I!EL'!F%![=)2=B2W2+PJTPJM')\?DKXR&X7XET351RC7%R,6@Q3N9:\9 MV",P'RGCC[H\=&I]1IE8Q@_OIM9X_TA0'3/F,#$AG^AMA.@:P,NWW6-+\1 1 M(T-5EH>.6,9MAGUPVZ)78E#E0ZS!QDD<_#1QW8'VVXZ%PJPG[:)Z+@C:G# M'C.OBN#<9JNQ".TO0-NQG]NX#6Q#"C\%8N!XGCNU[JQ#I6ZLV5VPBCK) M&,(A>Q-[M^PY6YS?Z5OE M[?UHMA#?QW\G\S'_F9[C#W09BINL5BQH/KA^HYSXF0@VW$1<[RB&+YS'YM@O MN_2-\FMJE.^:DKN3] XO1S7L/#NGR98GRWN3^UWV.#G4'US9 )@+#1(9^P]I MR2]9%1$M_RBFT ' 0?KB+KEXZ$JA93B@!VT^YO6<>XBJ84/8\32.(]",H\O4H-[S!C\Z@0U'4-_50._B! QP;3-K%"FA>L M_%UO@5A4!5H5X "J/]3;3WVW-U]WPO<8J2"@4H@,'/.UTUK85#"]#LB"KW5 M407[Y]\#23=WX;_;R)6@^LW_TWL?2,>+;+Y:@JHX=LEW?5/7#H^L^'?%Q#OGN MYG[O_M5M@QP35F<)#Y'#DR MF\!-EMEB=49%, SGWTZ S""OF_BB6,S/LP4FS>?9:CI+OQ;9&"?^GM_F.[; MPIWR]'H99(<8^W^@L-/X8R3[&PQ$>?3,11&FIY 2?C)+%LLSK/59(FKR?D$ MVZ MG,% LSD]74X6V?)\ =MM$VG[45%;8;_C0N.G[@N'83N'F5WHIGDNYYL6 MZ];B9Q_)UG'+R >A_5_%NQ.OLV^\S;!1KV5E'3=? ID$'1TX)5^+-#Z#N M6M'<_Y+&IK;&3^%S""Q\QN\YSL!KL@=>U%O8S+Y(;YC_-F[Z48;$%;_U065 MB$&SH^+H.42FERM^/_ZKCFF&1P@YL#M)!#9T1):@3TG$)YPT6[;(#689GQ& MWXJL'2LY_8$N0X^%O2U1;?\^]-?@HH^NV[5C.?,EQ\4Y!\DTIM@YSOX="U!L.A8J2YY$-^W? MCY0<+\/:8B_6[?#HD"+IQ<[YN] @$CRTQH9EUA!U[_(\E VVDQ0M^VRC^NT;C=,IME M^XTO>MN0;.2K1:>V>(/TK;OVO,I'EDJW:(-V%CS6R^QL]FY](O@(N-6X"P=S M$$\VSMW)XF.US8B" V6) RAWL\1V.$B&7\&CBS\4HQ/)SOV2^C[^S+1@4\ M=^:[KJA99F\SJ+!6O:$O;O"5_I3(A?V"7L_'4&91_(M8,Q*VBU3:-Z M&.)P8/!V^HQ!,1@447>Z**J\416"^]VX 7-;#)KD9K%J>M/,H->3[5;$>K MSXX0YG ,ETI[N%6F1[A"%7J/''HBYSX%L'FY<"X3HS%,XRG<.4L-0'>VPJK MO^US5C=+/82U\6+A#?836 ^/8)B6DQ?X)N/+L\CW_P%EP.0@TMME2VU,G!# MBI[R]R_^DY'_)/?/,-_$,D+'4KC))@!?GS%!XU<>7=SZ>B^C+I? )?&X1S MUW;/D;GBA B9ZX]* >?5$A( 50M@CU48;39J!BJ 68?=1F-0#UU39>Z_M M5O):ATG@030P@#XH DZKTL\8C17?> 8B0&Q%M6ZWA)/F7KG>E/!!H43N$!>V5"C9PU[B8_ 3C#6^0J]>4P0E2IW@[1#M)SV_HZ) M.N5)EYKCP.T(S@(WE+(Y.O1.Q _H8RG9:A\O>>(D.#1[Q142>JXL1B6LBXK[ MMI/+0X(_D//+7W^6WFL-IL&;3Z>3-JPQ\:IEI0:Z+;6KCB)M> MG#;\ET$O #ZO'=?ML) +QO_6ZC=02P,$% @ 2(MJ4?+V/I2$ @ /P4 M !D !X;"]W;W)K&UL?53?3]LP$/Y73A$/FP1- MFH9"J[82A:'M@0E1-AZF/;C)M;%P[,R^4/CO=W;2K).@4A3[?GV^.]_GV<[8 M9U8F5< -3HV;+QMA$(MV&[O:HBA"47B-$G&<26D MCA:SH+NWBYEI2$F-]Q9<4U7"OBU1F=T\&D9[Q8/70VGR\S[!X>?$G?N8 ^^DK4QSU[X5LRCQ">$"G/R"(7 M%[Q&I3P0I_&GPXSZ(WW@X7Z/?AMJYUK6PN&U44^RH'(>7490X$8TBA[,[BMV M]9Q[O-PH%_ZP:WU'601YX\A473!G4$G=KNUZ\-!P&7R04#:!:0A[_:@D.6- M(+&86;,#Z[T9S6]"J2&:DY/:7\J+%LEQ]'BNR&$#,[@FWY!3<9=+.8&-G; MX[Q#6;8HZ0+W)'\+,>/POXV0?X^^Z]P8UTN3NL0B_ M'O&58E,_OS[O9X>A?1LG+I:Y#B/F&X.[0M&BVQP>%&0&V:'(RS ;(!A(U1 M3#.IM_!):M:8Q@E=N,]3X(YRN6NTH:TWF'?"T/>X_88P@0>QX_$BM-PB!R
32=:NPQ3>NX'X8@KM-M 75]RHZF=[U[;OPY7+2G^N;=/RYVP M6ZD=-QP:#X.(_ MG1M!3)UH,C:$!,N;$M^X=!Z![9O#,]/)_@#^C=S\1=0 M2P,$% @ 2(MJ4269O%1>!P P1$ !D !X;"]W;W)K&ULM5AMD]K($?XK7=SZ8E?I0!(Q=Z7JEWO^>+D[%!K7UI5#X, MT@"3E33;)KJ5T]4J:WLS6#NW M>3,:V7PMV&'>B-K["RUJ83#UQ&=F.D#Q158[2.)Z.J'JP>VU7YN;VVO= MN%+5EGI[,T@&W<C6JT=+XQNKS=B)3])]]MF;C ;]5P5%L/M+O^A"K>^&:EM M8R3]Z[/\XNB^U/G3OT^9\SRW;$AO'W^AO]4$.T#(A324IFR,)(OH(HOI@S#Y MFM+7?NUR2!?C^,19K"\H%S4"]$F2JITT MTCK:B)TW-%:Z,0^?%#B]_/&'69K&5_/W?_6CY.H5^\D+W09 R$X5#"O55!$)>+Z +&KIC^A%J5:"L?LO7!L]4(]JP(Q MKF !8:UT=E0JL5"E8,96P#'Y\XMU70=R') > A)XY@&J[E,9@ M"B8"URI3A$A!#!T%RJ37:06J7MY.2!X;ADG>T!LV#>R[:XW),;%=ZQ6,R%4 M3- 1M<0Z&(QMOS'P@]H@@46E&URA@[%_U9"243\[%$6LO+\:6Y4+EGAQ7]0 M"+Q_6X?G&BR]>X[=L16H$X=R_\FB_/S>./QPK/ !N3>K<^&XU>(#;/D'X# M- ;A!+@ )KW(=+8O1@>+',<#R=TD0XONWDV#('= M+XZ'1^F#Z><#'U0P=#:,7U#"7[C3LLR895CR&Y];<^YEZ]2WWV:[-;2!&SM M["J62\7UDJW(=JWEDSR+D4_1,_1V1A3] M9#ON"6H"@&L8^ M6N[\1?ORTM7EZ,S./QFR?@XI^R#S=CL)V_02'L"= 4LA+E6A?6CUV8'X%5T0 M%X0$@,V!3N-H$LFXUDGP G+&DS?-O5:.7XRC#SZOCVQ"[R )0L4X<5V4 M8IIK"U^]G$P34.W;K(@CXZ3YH'H21VD\9N\#I>JV@_5P4QBQ+?06"C4]HGR- M)(<.-C+7QD?!"@>0B3+(5Z!;8=&]# "5\2E!OG)=@H;C GI$,5QQDX_Q\\#9LI?"3TTLJM(@">T M+UQ%BF=I+)(J;KB6BL:R[E_PJ[!_NC,@H'9V5S5^W!;]XE)-D?L:;'^+G8 MX:65/Z%2H4O-VZE44 K+K)WJ'@EI>,NLX#RXQZB(Q1,A4J^%;:3F=]I'I,8 MV"IEK4:GAWM0 PM?TEN&?3P?+Z24O""KOOC,1W78EZTCF)K/YU';!W7UF D^ M:O_#XLWWM_LWAN3^)"1$RR"8%_'-^&/;QP[WI7TRA>8)2@K#[83B-HS3^!CW M41U1?W8;C].^6Q'>BH=59L^<"T$(^O;MANMX?/6Z8C=B5$'WR%/NT:O)0A0 ML@#^PV^>TU<"^_V]S%PM L.^M]O;\=AH53K_+#RP$9>YD.1V;^0?3$ MW9.8WK7-8)#^.R"!A)HRBIQZ!(X.GM65-"O_YP$"E94)+^Q^M?]_XBX\R_?' MPY\;>%2M.,A+N01I/+S,!J$3[B9.;_PC?:$= M4/UU(@]_@ ]I<:X=%.^(+^ M7YO;_P)02P,$% @ 2(MJ464>B_QZ!0 9@P !D !X;"]W;W)K&UL?5?O;]LV$/U7#H:'=8!C2[+B.$42H&E6+$-_!$V[ M81CV@99HBRU%JB05Q__]WE&RXZ2)/R0A=[CW;N[1^9L;=UW7TD9Z+[6QI\/ MJA":UY.)+RI9"S^VC33XLK2N%@%3MYKXQDE11J-:3[(DF4UJH3;NA9N7.>^/&_Y2KPV:[_D'T\ MQXQ76.WC;UIW>X_S 16M#[;NC>%!K4SW5]SW/.P9S),7#++>((M^=P=%+Z]$ M$!=GSJ[)\6Z@\2"&&JWAG##3B#<]$+BG8.F=,@)!"DVW0009&3B G^_P\XB?OX!_ MD$^Z4K[0UK=.TK]?Y'V@2VV+[_\]Q_/A8V9C>B]1E8_R]Z6\T:8S:^>T,!. M\-FDXTZ[T&HEN"<\-4ZA%Y7>4(&I\H'LLMM68K14A1R1%@L+ .LVHQA)+4R[ M1#>UCC%](PI)+;+L2)"QYJ@ G1)&6OYT=@$3G!J!49_(B(H4H^%,YGOP$_^F%Y"0%Y M.@K1O;RR56CVEX#(2]8+)\]-1G&!H;Z-HP]Z97J;45>GX/.]]/XU7==-&\O/!+0NY.+5;)K0;YT&55:7>\2\&,<0 MD-E)0C>MRJ.^-.>(NT6]V5J3YS$"I%UV0"3S7;WRMJRRX^7[@ZZY4E&'Z.O MEJ6%.; .W'&K%[9U?,B2%JU'C7D_WI=-JD3Y5,R/84%HF^;1BOI/$K[1SA M3T%HSH%H&F?OH:]!0NIB^3]7E-%(18(UBUEGTL.3[G+R1\N%"B#?PL-"X,)">8ZX M/M%YP.:"[BZPZ0:X:.]Q3JZSGP5!:HF-G(49XZ/7>LR%E,#";"NX4LR/C1A MM]@ H2\I)C>]J!ZDFPXH"R:1GC.FB=M.08,'V++USN MF-:$[AFX6]T]HM]T;\>'[=T+_(-PN)CAA%S"-!F?' ^Z.V8[";:)+\F%#7B7 MQF&%?P2DXPWXOK1X5/43/F#WK\7%_U!+ P04 " !(BVI1R9:2Q>$& #L M$0 &0 'AL+W=O5A.)NN15F/3H[WTL3TY&@C;N65M)\W%QJC:8^R->R-J6JF9;+X]%I].HL(7DG\646[/W MSLB2&Z6^T>#]XG@4$B%9R;DE!($_=_)<5A4!@<9?+>:HWY(4]]\[]'?.=MAR M(XP\5]77F\A3OS
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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 236 341 1 false 68 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.avinger.com/20200930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Balance Sheets (Current Period Unaudited) Sheet http://www.avinger.com/20200930/role/statement-condensed-balance-sheets-current-period-unaudited Condensed Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.avinger.com/20200930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.avinger.com/20200930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited Condensed Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) Sheet http://www.avinger.com/20200930/role/statement-condensed-statements-of-stockholders-equity-unaudited Condensed Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.avinger.com/20200930/role/statement-condensed-statements-of-cash-flows-unaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Organization Sheet http://www.avinger.com/20200930/role/statement-note-1-organization- Note 1 - Organization Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Fair Value Measurements Sheet http://www.avinger.com/20200930/role/statement-note-3-fair-value-measurements Note 3 - Fair Value Measurements Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Inventories Sheet http://www.avinger.com/20200930/role/statement-note-4-inventories Note 4 - Inventories Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Borrowings Sheet http://www.avinger.com/20200930/role/statement-note-5-borrowings Note 5 - Borrowings Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://www.avinger.com/20200930/role/statement-note-6-commitments-and-contingencies Note 6 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Stockholders' Equity Sheet http://www.avinger.com/20200930/role/statement-note-7-stockholders-equity Note 7 - Stockholders' Equity Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Stock-based Compensation Sheet http://www.avinger.com/20200930/role/statement-note-8-stockbased-compensation Note 8 - Stock-based Compensation Notes 14 false false R15.htm 014 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.avinger.com/20200930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies 15 false false R16.htm 015 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies 16 false false R17.htm 016 - Disclosure - Note 4 - Inventories (Tables) Sheet http://www.avinger.com/20200930/role/statement-note-4-inventories-tables Note 4 - Inventories (Tables) Tables http://www.avinger.com/20200930/role/statement-note-4-inventories 17 false false R18.htm 017 - Disclosure - Note 5 - Borrowings (Tables) Sheet http://www.avinger.com/20200930/role/statement-note-5-borrowings-tables Note 5 - Borrowings (Tables) Tables http://www.avinger.com/20200930/role/statement-note-5-borrowings 18 false false R19.htm 018 - Disclosure - Note 6 - Commitments and Contingencies (Tables) Sheet http://www.avinger.com/20200930/role/statement-note-6-commitments-and-contingencies-tables Note 6 - Commitments and Contingencies (Tables) Tables http://www.avinger.com/20200930/role/statement-note-6-commitments-and-contingencies 19 false false R20.htm 019 - Disclosure - Note 7 - Stockholders' Equity (Tables) Sheet http://www.avinger.com/20200930/role/statement-note-7-stockholders-equity-tables Note 7 - Stockholders' Equity (Tables) Tables http://www.avinger.com/20200930/role/statement-note-7-stockholders-equity 20 false false R21.htm 020 - Disclosure - Note 8 - Stock-based Compensation (Tables) Sheet http://www.avinger.com/20200930/role/statement-note-8-stockbased-compensation-tables Note 8 - Stock-based Compensation (Tables) Tables http://www.avinger.com/20200930/role/statement-note-8-stockbased-compensation 21 false false R22.htm 021 - Disclosure - Note 1 - Organization (Details Textual) Sheet http://www.avinger.com/20200930/role/statement-note-1-organization-details-textual Note 1 - Organization (Details Textual) Details http://www.avinger.com/20200930/role/statement-note-1-organization- 22 false false R23.htm 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-tables 23 false false R24.htm 023 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) Sheet http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) Details 24 false false R25.htm 024 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Sheet http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Details 25 false false R26.htm 025 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://www.avinger.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 26 false false R27.htm 026 - Disclosure - Note 3 - Fair Value Measurements (Details Textual) Sheet http://www.avinger.com/20200930/role/statement-note-3-fair-value-measurements-details-textual Note 3 - Fair Value Measurements (Details Textual) Details http://www.avinger.com/20200930/role/statement-note-3-fair-value-measurements 27 false false R28.htm 027 - Disclosure - Note 4 - Inventories - Schedule of Inventory (Details) Sheet http://www.avinger.com/20200930/role/statement-note-4-inventories-schedule-of-inventory-details Note 4 - Inventories - Schedule of Inventory (Details) Details 28 false false R29.htm 028 - Disclosure - Note 5 - Borrowings (Details Textual) Sheet http://www.avinger.com/20200930/role/statement-note-5-borrowings-details-textual Note 5 - Borrowings (Details Textual) Details http://www.avinger.com/20200930/role/statement-note-5-borrowings-tables 29 false false R30.htm 029 - Disclosure - Note 5 - Borrowings - Schedule of Debt (Details) Sheet http://www.avinger.com/20200930/role/statement-note-5-borrowings-schedule-of-debt-details Note 5 - Borrowings - Schedule of Debt (Details) Details 30 false false R31.htm 030 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) Sheet http://www.avinger.com/20200930/role/statement-note-6-commitments-and-contingencies-details-textual Note 6 - Commitments and Contingencies (Details Textual) Details http://www.avinger.com/20200930/role/statement-note-6-commitments-and-contingencies-tables 31 false false R32.htm 031 - Disclosure - Note 6 - Commitments and Contingencies - Future Operating Lease Payments (Details) Sheet http://www.avinger.com/20200930/role/statement-note-6-commitments-and-contingencies-future-operating-lease-payments-details Note 6 - Commitments and Contingencies - Future Operating Lease Payments (Details) Details 32 false false R33.htm 032 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) Sheet http://www.avinger.com/20200930/role/statement-note-7-stockholders-equity-details-textual Note 7 - Stockholders' Equity (Details Textual) Details http://www.avinger.com/20200930/role/statement-note-7-stockholders-equity-tables 33 false false R34.htm 033 - Disclosure - Note 7 - Stockholder's Equity - Outstanding Warrants (Details) Sheet http://www.avinger.com/20200930/role/statement-note-7-stockholders-equity-outstanding-warrants-details Note 7 - Stockholder's Equity - Outstanding Warrants (Details) Details 34 false false R35.htm 034 - Disclosure - Note 7 - Stockholders' Equity - Stock Option Activity (Details) Sheet http://www.avinger.com/20200930/role/statement-note-7-stockholders-equity-stock-option-activity-details Note 7 - Stockholders' Equity - Stock Option Activity (Details) Details 35 false false R36.htm 035 - Disclosure - Note 7 - Stockholders' Equity - Restricted Stock Units Award Activity (Details) Sheet http://www.avinger.com/20200930/role/statement-note-7-stockholders-equity-restricted-stock-units-award-activity-details Note 7 - Stockholders' Equity - Restricted Stock Units Award Activity (Details) Details 36 false false R37.htm 036 - Disclosure - Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) Sheet http://www.avinger.com/20200930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) Details 37 false false All Reports Book All Reports avgr-20200930.xml avgr-20200930.xsd avgr-20200930_cal.xml avgr-20200930_def.xml avgr-20200930_lab.xml avgr-20200930_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 53 0001437749-20-023413-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-20-023413-xbrl.zip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end